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"A country which contains more strange and new and beautiful objects than any
other part of the globe" Sir Alfred Russel Wallace on New Guinea, 1858.
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AIMS
The aims of the project were as follows.
1. To develop a screening methodology that would allow the efficient identification
of tropical rainforest plants with antibacterial activity.
2. To develop methods for purification of the active principles from the most
promising plants.
3. Using spectrometric techniques, to chemically characterise the active principles
4. To test the pure compounds on both sensitive and drug-resistant bacterial
pathogens along with human cell lines to determine their biological activities.
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ABSTRACT
Tropical rainforest plants represent a potential source of novel antimicrobial drugs since
they have adapted to their humid, septic environment by synthesising such compounds
as a means of self defence. Similarly, people who inhabit rainforests have adopted
certain species to treat infectious diseases, and by investigating such plant medicines it
may be possible to find novel compounds with therapeutic potential. With this is mind,
ethnobotanical fieldwork was carried out in New Guinea, an area of the world little
investigated for indigenous plant medicines and rich in endemic flora. An antibacterial
field assay kit was developed using freeze-dried strains of S. epidermidis and E. coli
which allowed plants used in traditional medicines to be screened in situ without having
to take them back to a laboratory. This approach identified Lunasia amara (Blanco) as a
candidate species; the use of its bark by tribes of the Whitman Range to treat tropical
ulcers, supported by clear zones of inhibition with S. aureus. Samples of the bark were
collected for analysis and through activity-guided fractionation, the anti- S. aureus
activity of the bark extract was pinned down to a single well resolved HPLC peak (MIC
S. aureus NCTC 6571 64pg/ml) which subsequent NMR analysis revealed to be the
quinoline alkaloid lunacridine; 2'-<9-trifluoroacetyl lunacridine was found to be a more
stable derivative however. Lunacridine's planar cationic structure suggested it might act
as a DNA intercalator; 220uM giving 50% binding in an ethidium bromide displacement
assay. This in turn suggested DNA topoisomerase II as a likely target for the compound
which was confirmed with a kDNA decatenation assay revealing complete inhibition of
the enzyme at 5pM. Cell viability assays with MRC-5, H226 and HELA cells showed
the compound to be cytotoxic in a time dependent manner producing non-linear dose
response curves indicative of a topoisomerase poison mode of action. Activation of the
apoptosis pathway enzymes caspase 3/7 was also detected, reaching maximal activity
between 24 and 48 hours for the H226 cell line. Thus, lunacridine does not represent a






1.1 Tropical rainforest plants as a source of antimicrobial agents
The defining features of a tropical rainforest climate are high annual rainfall of at least
250cm, temperatures which do not fall below 18°C as the monthly mean and humidity at
ground level not far below 100% (Whitmore, 1990). In such conditions bacteria and
fungi flourish; so for rainforest plants, adaptation to their environment requires an
effective means of self defence from microbial plant pathogens. The synthesis of
antimicrobial secondary metabolites represents one method by which plants defend
themselves from infection and it is this that has prompted numerous efforts to screen
rainforest plants in the hope of discovering novel antibiotics (Florey, 1949; Newton et
al„ 2000).
A second feature of rainforests that makes them conducive to drug discovery is their
biodiversity. It is estimated that there are 250,000-500,000 species of flowering plants
on earth and that approximately half of these are found in rainforests (Borris, 1996;
Cowan, 1999; Mendelsohn, 1995); one single hectare of tropical rainforest may contain
over 100 tree species, more than the total for all of northern Europe (Whitmore, 1990).
Thus whilst the British Isles have approximately 1,800 native plant species Peru has
closer to 18,000 (Macilwain, 1998). It is reasonable to assume that the floristic
biodiversity of tropical rainforests is reflected in the chemical diversity of their
constituent plants. Currently the number of structurally elucidated secondary metabolites
in the world stands at more than 20,000 and is rapidly increasing (Harborne, 1988)
whilst estimates for the total number of secondary metabolites present in plants suggest
figures as high as 500,000 (Firn, 1996).
In addition to this only 5-15% of the worlds higher plants have been systematically
investigated for pharmacologically active compounds (Balandrin, 1993). Altogether
there are 47 clinically used drugs on the market that owe their origins to tropical
rainforests. Based on the number of pharmacologically un-evaluated plants and the
number of potential screening methods available it has been estimated that at least 300
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potential clinically viable drugs remain to be discovered in tropical forests around the
world (Mendelsohn, 1995).
Rather than representing a set of random structures the great chemical diversity present
in rainforest plants has in fact been honed through many millennia of evolution so that
each secondary metabolite may provide a range of functions to a plant such as defence
against herbivores, microbes, viruses and competing plants or signals to attract
pollinating or seed dispersing animals (Dixon, 2001; Wink, 2003). Thus secondary
metabolite structures are crafted through evolution to interact with specific receptors in
the target organism (Onaga, 2001). For example certain species of Solanaceae synthesize
alkaloids with the same quaternary nitrogen configuration that is present in most
neurotransmitters and only this precise configuration allows the alkaloids to interact with
its receptor (Wink, 2003). This process has been termed "evolutionary molecular
modelling" in analogy to the molecular modelling applied in structure-based drug design
(Wink, 2003). The highly specific interactions of some plant-derived antimicrobial
compounds suggest they too have been tailored to dock with specific target receptors
through years of evolution. Such specific interactions can easily be interrupted however,
(Duffy et al., 2003) and since the lifecycle of a microbe is vastly shorter than the plant it
infects there is ample opportunity for the microbe to evolve resistance to the compound
and a lot less time for the plant to respond. Evidence suggests that plants overcome this
problem by synthesising more than one active compound and by keeping a wide range
of molecules as stock to synthesise new antimicrobials should the need arise (Firn,
1996). The synthesis of secondary metabolites requires a significant expenditure of raw
materials, energy as well as genetic space to code for their biosynthesis, but this effort is
more than paid off by the survival advantage such compounds offer to plants under
attack (Attardo and Sartori, 2003).
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1.2 Ethnopharmacology
The title of this study namely "the isolation of antimicrobial compounds from tropical
rainforest plants" gives rise to the obvious question of which tropical rainforest plants to
screen for antimicrobial activity. If purely random sampling techniques are used then
one could spend an inordinate amount of time assaying plants with no guarantee of
finding an active species to work on (Shultes, 1994). Indeed, results of screening natural
product-based libraries for antibiotics have yielded hit rates as low as one in 30,000 to
40,000 (Onaga, 2001). What is needed is a way of narrowing down the extensive plant
biodiversity of the tropical rainforests to a range of identified plant species associated
with a particular antimicrobial activity. One way of doing this is to use local knowledge
of rainforest tribes who use plants to treat infections that are common ailments of
rainforest life (Xue and Zhang, 1998). For example, a study by (Brandao et al., 1992) of
plants used to treat malaria in the Brazilian Amazon found 18% of the 22 plants
recorded showed activity whereas a mere 0.7% were active in a study carried out by
Carvalho et al in which 273 plants were randomly selected for screening (Elisabetsky
and Shanley, 1994). In a second study, plants selected for antiviral screening on the basis
of their folklore use were five times more likely to be active than those selected
randomly (Vlietinck and Vanden Berghe, 1991). Not only is there an increased chance
of finding active compounds with the ethnopharmacological approach but it is said that
compounds isolated using this approach are less likely to be toxic since they have
already been exposed to humans and have therefore in effect already undergone a very
basic form of clinical trial. Caution must be applied to this rationale however since
certain toxic effects of plant may only become apparent years after the dose has been
taken (de Smet and Rivier, 1989).
In the search for novel antimicrobial compounds the use of such indigenous knowledge
may be particularly poignant since the humid rainforest environment not only poses a
problem for its constituent plants but for its human inhabitants too. For rainforest
dwelling people the slightest cut or graze is a potential hazard since it may rapidly
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become infected and if left untreated may develop into a more serious infection
(Adriaans and Drasar, 1987). Therefore, just as rainforest plants have adapted to their
habitat by evolving biosynthetic pathways that produce secondary metabolites to defend
themselves, people have adapted to life in rainforests by discovering which plants
possess antimicrobial properties and using them to treat infections.
The study of such native medicines is termed ethnopharmacology, the term was first
used as the title of a book by Efron et al (Efron, 1970) and was later defined by Bruhn
and Holmstedt (1981) as the interdisciplinary scientific exploration of biologically active
agents traditionally employed or observed by man (Bruhn, 1981). The primary goal of
an ethnopharmacological investigation is to verify the pharmacological activity of an
ethnomedical treatment (Waller, 1993) and broadly speaking such an investigation
should proceed in a three step process (de Smet and Rivier, 1989):
1. Botanical or zoological identification of the source material
2. Chemical isolation and identification of the active principles
3. Pharmacological testing of the active principles
Ethnopharmacology is a highly interdisciplinary subject encompassing diverse areas of
study such as ethnobotany, chromatography, analytical chemistry and various
biomedical disciplines such as pharmacology, microbiology, immunology etc (Waller,
1993; Wickberg, 1993). By using such a broad interdisciplinary approach it is possible
to identify plants that are used traditionally to treat specific diseases and then determine
if they contain bio-active compounds to provide an explanation of the plants use. It is
not possible for a single researcher to master all of these specialities but it is none the
less important for each member of an ethnopharmacological research team to have an
understanding of each others disciplines.
The first step in any ethnopharmacological investigation is the gathering of field data
(Wickberg, 1993) and where the source material is of plant origin the science of
28
ethnobotany possesses the relevant techniques to allow the acquisition of reliable
information.
1.2.1 Ethnobotany
The term ethnobotany was first coined by the Botanist Dr. John Harshberger at a
conference in 1895 which he defined as "the study of plants used by primitive and
aboriginal people" (Harshberger, 1895; Heinrich, 2001). Thus ethnobotany could be said
to be a fusion of botany and anthropology where anthropological techniques are used to
gather information on the uses of plants and taxonomic botany is then used to identify
the plants (Wickberg, 1993).
Ethnobotany provides the source material along with descriptive information of the
medicinal uses of the plant from which all further work in an ethnopharmacological
investigation depends, so it is vital that accurate information is obtained (de Smet and
Rivier, 1989). The taxonomic identification of plants is important since active
compounds may have already been identified from a related species or from members of
the same genus since particular types of secondary metabolites tend to predominate
within a single taxon (Waller, 1993; Wink, 2003). Misidentification of a plant or
insufficiently detailed field observations could severely hamper the chances of verifying
the use of the plant later in the investigation.
Understanding the cultural context in which plants are employed is often central to
gaining meaningful information on their medicinal use and this is why anthropological
skills are required (de Smet and Rivier, 1989). For example, a botanist enquiring about
the source material used to prepare a concoction used in rituals may be deliberately
supplied with the wrong plants if members of that tribe do not wish to disclose the
source of their sacred plant (de Smet and Rivier, 1989). Highly detailed descriptions of
the way plants are employed as medicines are vital since the smallest detail may provide
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clues as to the disease the plants are intended to treat. For example, plants used to treat
weight loss may in fact be intended to treat diabetes since obesity is a symptom of
certain types of diabetes (de Smet and Rivier, 1989).
Thus developing a good rapport with members of local communities is vital to gaining
reliable ethnobotanical information (Etkin, 1993) and this is most effectively achieved
by participating in activities such as collecting plants observing rituals and general
situations in which plants are discussed, prepared or used (Etkin, 1993). Such participant
observation helps establish rapport with native communities and enables a more precise
understanding of the ways in which plants are used. Ethnobotanical information may
come from key figures within a native community who are especially involved with
administering plant medicines or perhaps more reliably from a number of sources within
a community taking only that information which is corroborated by a second source.
Despite the purely qualitative nature of such work, ethnobotany is nonetheless the
starting point for most ethnopharmacological investigations and is capable of providing
meaningful information relating to a specific pharmacological activity. For example,
when inhabitants of the Sibundoy Valley in Columbia were asked to rank cultivars of
Brugmansia according to their toxicity the five cultivars named were found to contain
increasing concentrations of the toxic alkaloid scopolamine (de Smet and Rivier, 1989).
1.2.2 Chemical isolation of compounds
The isolation of pure compounds from plant material is one of the most technologically
challenges steps in the ethnopharmacological process and is a pre-requisite for structural
determination by methods such as nuclear magnetic resonance spectroscopy (NMR)
(Wickberg, 1993). Since plants synthesise compounds in quite convoluted pathways a
single extract may contain several active principles of similar structure along with
inactive but highly related compounds. This means that as the purification process
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proceeds it becomes increasingly difficult to separate the active constituents since each
chromatography step produces a mixture of increasingly related compounds.
Before separation of the plant analytes can begin it is necessary to determine the
optimum extraction solvent in which to solublize the active principles. For plants with
antimicrobial activity, ethanol and methanol are popular solvents since the majority of
plant antimicrobial compounds are organic heterocycles and are readily soluble in these
alcohols (Cowan, 1999). An optimum solvent is one that completely extracts all the
active principles but leaves as much of the inactive material behind. Where active
principles exhibit a broad range of hydrophobicities more than one extraction solvent
may be needed. At the same time a convenient biological assay for the activity in
question is needed to determine which solvents extract the most activity and to test
active fractions during the purification process.
In order to isolate pure compounds, chromatography techniques are required that
provide excellent separating power, are non-destructive, preparative rather than purely
analytical and allow at least mg quantities of sample to be run at a time since a minimum
of 5mg are needed for NMR and active principles may form only a small proportion by
weight of the total material in a plant extract. A variety of techniques fit this description
such as thin layer chromatography (TLC), supercritical fluid chromatography (SCFC),
counter current chromatography (CCC) and high performance liquid chromatography
(HPLC) (Phillipson, 2003).
Each technique offers different advantages, TLC is relatively cheap compared to the
other techniques but does not give as good separation. CCC is able to handle gram
quantities of sample on relatively cheap apparatus but does not offer as good a
separation of some analytes as HPLC (Wickberg, 1993). Overall the choice of technique
depends very much on the type of active compounds in the plant and for this reason an
accurate identification of the voucher specimen collected in the fieldwork period is vital
since a literature search may inform the chromatographer of the classes of compounds
present in the sample and direct his choice of technique accordingly (Waller, 1993).
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In addition to the techniques described above there are a variety of older techniques that
use the traditional open column format that are of use as preliminary steps in a
purification process and in some circumstances may be able to replace the more
sophisticated high cost techniques. A variety of separation media are available such as
silica and charcoal for adsorption chromatography, various cyclodextrans for gel
filtration and cellulose based media for ion-exchange. Again the choice of media
depends entirely on the analytes in the sample mixture. Care must be taken however
since even with standard media such as silica and aluminia it is rare to have 100%
recovery of active principles (Wickberg, 1993). Despite this, such techniques are
cheaper than their modern counterparts such as HPLC and offer the possibility of scaling
up to the gram level without a significant increase in cost.
1.2.3 Identification of compounds
The structural characterisation of active compounds has advanced dramatically in recent
years due to the advent of technologies such as NMR and mass spectroscopy which
allow structures to be unequivocally solved in a matter of days where they would have
once taken years (Wolfender et al., 2003). The development of soft ionisation techniques
and instrumental configurations in which HPLC and gas chromatography (GC) are
connected directly to mass spectroscopy has increased the ease with which individual
molecules can be purified and provided a means by which previously isolated
compounds may be identified provided authentic samples are available for comparison
(Wolfender et al., 2003). One of the advantages of tandem techniques such as GC-MS
and LC-MS is the small quantities required to identify the presence of particular
metabolite. The ability to detect sub-microgram quantities is well suited to
ethnopharmacological research where an active substance may form only a tiny fraction
of the total material in a crude extract.
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NMR is a technique that has revolutionised natural product research perhaps more than
any other and has therefore impacted greatly on ethnopharmacology too (Phillipson,
2003). With as little as 5mg of a 90% pure compound it is possible to run a proton
spectra in a matter ofminutes and when combined with C13-spectra and molecular
formulae obtained with mass spectrometry a complete characterisation of an active
principle is possible. NMR has improved dramatically since its conception; where once
100MHz machines were state of the art 600MHz apparatus with a concomitantly
improved resolution are increasingly commonplace and more recently LC-NMR has
become available making de-replication of complex samples (distinguishing between
already known and novel compounds) a far more efficient process (Wolfender et al.,
2003)
1.2.4 Biological activities and testing
The purification and testing of compounds is dependent on a functional assay that is
both simple and convenient enough to allow large numbers of semi-pure fractions to be
tested (Wickberg, 1993). The choice of assay must be informed by the traditional use of
the plant as recorded in the original field observations and must be sufficiently broad so
as to encompass the greatest possible number of modes of action within the suspected
disease state. A great strength of ethnopharmacology is its potential to deliver
compounds with entirely novel modes of action and so inform the wider biomedical
community of new drug targets. Thus the microbiologist in an ethnopharmacological
investigation must be open to the possibility that the active principles are acting by an
entirely new mode of action (Waller, 1993). If the choice of assay is too focussed,
compounds with novel modes of action will display no activity at all but if too all
encompassing such as in vivo animal models, will not be sufficiently convenient for
activity-guided purification of active principles. In practice several assays must be used
starting with a simple reproducible test in the purification and finishing with more
sophisticated assays once pure compounds have been isolated.
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One of the advantages ofmicrobiology based ethnopharmacology i.e. investigations into
antibacterial type uses of plants is that rapid and convenient methods for detecting
antibacterial activity such as the Kirby Bauer disc diffusion assay already exist and are
ideally suited to assaying large numbers of semi-pure fractions. Once pure compounds
are available more detailed assays such as minimal inhibitory concentrations (MIC) and
time kill assays may be used. Where the ethnobotanical use of a plant suggests an
antiviral activity the available methods are not so straight forward since they require the
culture of mammalian cell lines.
Viral inhibition may be detected by reduced plaque formation, transformation of cell
lines with a colour linked gene or detection of viral products such as surface
glycoproteins or reverse transcriptase activity (Cowan, 1999). Because of the
requirement to use mammalian cells to culture viruses there is less scope for testing
crude plant extracts since compounds in the mixture may have effects on the cells and
produce false results. With bacteria and fungi the testing of crude plant extracts is
common place and in some cases may be preferable since some plant metabolites work
synergistically and show little activity when assayed individually (Cowan, 1999). The
types of assays used to test anti-viral activity are sufficiently broad that they routinely
detect compounds that act as inhibitors of viral attachment and not just compounds that
attack the virus directly; this is a limitation ofmany studies with antibacterial/fungal
plant extracts in that most look only at the growth inhibitory activity (Cowan, 1999).
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1.3 A history of plant derived antimicrobial compounds
By identifying plants used by native rainforest populations a variety of useful
compounds have been identified some of which have become adopted as clinical
treatments for certain infectious diseases. The best known examples are the antimalarial
drugs quinine and artemisinin along with the anti-amoebal compound emetine. But
whilst there are many noteworthy examples of plant derived anti-protozoal compounds
and a plethora of anti-tumour compounds of plant origin there are far fewer examples of
antibacterial or antiviral plant derived compounds that have been developed as
successful pharmaceutical agents (Cowan, 1999). This section briefly details the history
of the development of the better known antimicrobial drugs derived from rainforest
plants along with some of the more promising plant-derived drug leads currently
undergoing development.
1.3.1 Plant derived anti-protozoal compounds
Plants have proved an excellent source of anti-protozoal drugs; quinine, emetine and the
artemisinins all owe their origins to plants and this has resulted in enormous health
benefits throughout the world in the treatment of malaria and amoebic dysentery.
Among the most remarkable of the three compounds is quinine whose isolation and
discovery could be considered one of the first examples of ethnopharmacological drug
discovery.
1.3.1.1 Cinchona and the isolation of quinine
Quinine is a quinoline alkaloid found in the bark of Cinchona spp. (Rubiaceae) and has
potent activity against blood stage malarial parasites (Jaramillo-Arango, 1950).
Crucially, it is sufficiently non-toxic to be taken orally and can therefore be considered
one of the first systemic antimicrobial compounds. Cinchona species originate in the
cloud forests of the Andes from where the bark was brought to Europe once its
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antimalarial properties were discovered (Jaramillo-Arango, 1950). The first reference to
the cinchona tree comes from Antonio de Calancha who writing in Lima, Peru in 1633
states 'There is a tree of fevers in the land of Loja, with cinnamon coloured bark of
which the Lojans cast powders which are drunk in the weight of two small coins, and
thereby cure fevers and tertians; these powders have had miraculous effects in
Lima"(Honigsbaum, 2001).
Figure 1.1 Quinine from Cinchona spp.
It is not certain that malaria existed in pre-Columbian South America so there is some
debate as to whether the discovery of Cinchona's anti-malarial properties should be
attributed to the Native American inhabitants or the Jesuits who themselves had a
significant interest in medicinal plants. Perhaps the most reliable account of the early use
of cinchona bark comes from de Jussieu who writing in 1771 states "it is certain that the
discovery is owed to the Malacatos Indians", a tribe from the malarious coastal region of
Ecuador who had settled in the valley of Vilcabamba (Honigsbaum, 2001). Since
quinine has mild antipyretic properties(Rang, 2003) it seems probable Cinchona bark
might have been used by local Indians as a febrifuge and then later adapted as a
treatment for malaria.
In 1820 the French chemists Pelletier and Caventou became the first scientists to isolate
the active principle quinine from Cinchona bark (Jaramillo-Arango, 1950). From the
yellow and red barks they obtained a yellow, transparent non-crystalline substance,
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which proved to be therapeutically the most active substance present. This substance
proved to be a mixture of two alkaloids Cinchonine and Quinine. By removing the acidic
fraction from the bark they were able to fractionate the basic portion through partition
between immiscible solvents leading to the isolation of pure quinine (Jaramillo-Arango,
1950). After the isolation of quinine there were numerous attempts at a chemical
synthesis. The German chemist Runge succeeded in isolating quinoline from coal tar but
it was not until 1944 that Woodward and Doering achieved a total synthesis (Woodward,
1944) but by this time several synthetic antimalarials had already been developed.
Since the discovery of several species of plasmodia as the causative agents of malaria,
various suggestions have been made for quinines mode of action. Blood stage parasites
inhabiting erythrocytes are known to digest haemoglobin and sequester the toxic haem
moiety to form haemozoin crystals to prevent the accumulation of free iron which is
toxic to the parasite. The most recent studies suggest a mode of action in which
antimalarial quinolines bind to the growing crystals either by a surface binding or
substrate sequestration mechanism thereby acting as crystallisation inhibitors (Chong
and Sullivan, 2003). The resulting build up of toxic haem proves fatal to the parasite.
This is backed up by intracellular evidence that shows that quinolines concentrate to
millimolar levels in the digestive vacuole, despite circulating in the plasma at nanomolar
concentrations (Yayon et al., 1985).
1.3.1.2 Artemisinin from Artemisia annua
Artemisinin is an antimalarial compound from the plant Artemisia annua (Asteraceae),
an annual herb native to Asia, most probably China, where it is known as Qinghao
(Balint, 2001). A. annua has a long history of use as a medicinal plant in the Far East,
the anti-fever properties of Qinghao were first described in 340 A. D by Ge Hong of the
East Yin Dynasty in the Zhou Hou Bei Ji Fang (Handbook of Prescriptions for
Emergency Treatments). In 1979 reports appeared in the Chinese Medical Journal of a
compound isolated from the plant with exquisite activity against blood stage malarial
parasites. The active principal artemisinin was revealed to be effective against
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chloroquine-resistant strains of Plasmodium falciparum which are a factor in the high
morbidity rate ofmalaria world-wide (Balint, 2001).
Figure 1.2 Artemisinin from Artemisia annua
Artemisinin was isolated using ethyl acetate extraction of the aerial parts of the plant
followed by a combination of classical silica column chromatography and
crystallisation. Spectroscopic analysis revealed the compound to be a 1, 2, 4-trioxane
sesquiterpene lactone (Klayman, 1985) containing an endoperoxide bridge.
The artemisinins are the only class of anti-malarials that remain effective against the
drug resistant malarial strains that have emerged since the introduction of chloroquine
and artemisinin-based combinations therefore offer a potentially effective way to
counter malarial drug resistance. Clinical trials conducted in African children have
attested to the good tolerability of oral artesunate when combined with standard
antimalarial drugs (Clifford et al., 2003). The clinical efficacy of the drug is
characterized by an almost immediate rapid reduction of parasitaemia, and it is an
effective stand alone treatment in areas where multidrug-resistance is rampant (Jung et
al., 2004).
The mode of action of artemisinin and its derivatives is believed to involve an initial
interaction of the endoperoxide moiety with plasmodium sequestered haemozoin,





are highly destructive to a variety of protozoal proteins (Singh and Lai, 2001). By
targeting haemozoin the drug offers good selectivity for the parasite since there is no
comparable target in human cells, and because its cytotoxic effect occur so swiftly it is
claimed there is little opportunity for the parasite to develop resistance.
1.3.1.3 Emetine from Cephaelis ipecacuanha
Emetine is an anti-amoebal compound derived from the roots of the South American
straggling bush Cephaelis ipecacuanha (Rubiaceae) but has been isolated from other
species as well (Shamma, 1972). It was used as a treatment for amoebic dysentery by
South American Indians (Shamma, 1972) and became widely used as a treatment for
dysentery in 18th century Europe. Its close relative dehydroemetine is still used today for
the treatment of complicated intestinal amoebiasis and liver abscess caused by
Entamoeba histolytica (Verhoef, 1986). The name of the plant is derived from an
Amerindian word i-pe-kaa-guene, which is said to mean 'road-side sick-making plant'
(emetine has emetic properties).
Figure 1.3 Emetine from Cephaelis ipecacuanha
M.M Pelletier whose previous work included the isolation of strychnine and quinine
applied similar techniques of acidic and basic extraction to partially isolate emetine and
Me OM
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demonstrate it to be responsible for the medicinal properties of Ipecac (Magendie,
1828). Emetine was precipitated from an aqueous extract by the addition ofmagnesium
oxide and then extracted into alcohol before taking up in dilute acid to which purified
animal charcoal was added. Trace impurities were then removed by the addition of a
salifiable base (Magendie, 1828). The presence of contaminants however meant that the
correct empirical formula was not established until 1914 (Shamma, 1972) and the
correct structure was not determined until 1948 (Robinson, 1948).
Emetine has been shown to bind reversibly to the amoebic ribosome and therefore act as
a protein synthesis inhibitor (Entner and Grollman, 1973). In cell free lysates protein
synthesis is inhibited in a dose dependent manner whilst experiments with [3H] emetine
revealed an irreversible interaction with free ribosomes which is thought to involve
hydrogen bonding via its two nitrogen atoms and a third contact made between the C-l'
carbon atom and the ribosomal chain elongation active site (Entner, 1979).
1.3.2 Plant derived antiviral compounds
Since the onset of the HIV pandemic there have been several programs dedicated to
screening plant extracts for anti-HIV activity. There has also been a concomitant need to
find new agents effective against secondary viral infections such as herpes simplex virus
(HSV) and cytomegalovirus (CMV). A wide array of active compounds have been
reported and of these a few have provoked interest as leads compounds for the
development of new viral inhibitors.
1.3.2.1 Provir and Virend/SP-303
Virend and Provir are the product names given by Shaman Pharmaceuticals to SP-303,
an extract of the sap of Croton lechleri (Euphorbiaceae). The tree is a native of the
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eastern slopes of the Ecuadorian and Peruvian Andes where it is known locally as
Sangre de Grado (Jones, 2003). The sap is used to treat a variety of complaints including
HSV infections (Jones, 2003). Provir is indicated for AIDS related diarrhoea whilst
Virend which was withdrawn from clinical trials in 1998 due to financial problems was
intended for topical treatment of HSV infections. SP-303 is rich in proanthocyanidins
such as (-)-galloepicatechin and (+)-gallocatechin with lesser amounts of (+)-epicatechin
and catechin (Jones, 2003; Ubillas, 1994). The average molecular weight of the
proanthocyanidins in the mixture is approximately 2100Da, each being composed of
between 4 and 11 flavanoid units (Jones, 2003).
Figure 1.4. Proanthocyanidins (SP-303) from Croton lechleri
SP-303 displays activity against a variety of HSV isolates including both HSV-1 and
HSV-2 acyclovir resistant strains. It is also inhibitory to respiratory syncytial virus
(RSV). In plaque reduction assays, inhibitory concentrations ranged from 0.9 and
2.1[xg/ml for various isolates of HSV-2 and 2-10 pM for RSV (Barnard et al., 1993;
Jones, 2003). SP-303 was entered into a double-blind, placebo-controlled Phase II
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clinical trial for safety and effectiveness against recurrent genital herpes lesions in
patients with AIDS. The primary endpoints of the study were complete healing of
lesions and time to healing. 41% of patients treated with a topical solution of P-303
experienced complete healing of their lesions compared with 14% in the placebo group
(Orozco-Topete et al., 1997). The mode of action of the proanthocyanidins for both
viruses is thought to involve inhibition of adsorption early on in the viral life cycle
(Barnard et al., 1993; Jones, 2003).
1.3.2.2 Dicafeoylquinic acids
Dicafeoylquinic acids are a group of plant metabolites that include curcumin the
compound responsible for the yellow colour of tumeric, Curcuma longa (Zingiberaceae)
(De Clercq, 2000). Dicafeoylquinic acids have in vitro activity against HIV-1 in the sub
micromolar range and low toxicity against human cell lines with LD50 values above
700pM (Zhu et al., 1999). The mode of action appears to be inhibition of the virally
encoded enzyme integrase which mediates the integration of viral cDNA into the host
cell. A single amino acid substitution (G140S) decreased the susceptibility of virus to
another dicafeoylquinic acid derivative L-chicoric acid (King and Robinson, 1998) and
molecular modelling of dicafeoylquinic acids with the core catalytic domain of integrase
suggests an energetically favourable interaction in which the most potent inhibitors
occupy a groove within the predicted catalytic site of the enzyme (Robinson et al.,
1996). Integrase represents a novel HIV target and as such inhibitors based on the
dicafeoylquinic acid structure could be of benefit if used in combination with existing
anti-retroviral drugs.
Figure 1.5 L-Chicoric acid from Echinacea purpurea
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1.3.2.3 Betulinic acid
Betulinic acid is a triterpenoid isolated from Syzigium claviflorum (Myrtaceae) and
displays HIV-1 inhibitory activity in H9 lymphotic cells with an IC50 of 1.4pM.
Synthetic structural improvements have produced derivatives of the compound with
exquisite activity (inhibition occurring in the sub-nanomolar range) and selectivity index
values in excess of 20,000 (Hashimoto et al., 1997). Resistance to betulinic acid
derivatives has been mapped to amino acid substitutions at positions 22 and 84 of the
HIV antigen gp41. If gp41 is the target then betulinic acid derivatives are the only drug¬
like small molecules to act as virus-cell fusion inhibitors via gp41and are therefore an
ideal template from which to develop new fusion inhibitors (De Clercq, 2000).
Figure 1.6 Betulinic acid from Syzigium claviflorum.
1.3.2.4 Calanolides and inophyllums
Calanolides and inophyllums are related coumarin HIV-1 reverse transcriptase inhibitors
that have been isolated from the South East Asian rainforest trees Calophyllum
inopyllum and Calophyllum lanigerum (Clusiaceae) (Kashman et al., 1992) (Patil et al.,
1993). The two coumarins have IC50 values for reverse transcriptase inhibition of 0.1 p
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and 1 pM and unlike existing RT inhibitors calanolide analogues have been found to
increase their antiviral activity in mutants with the common reverse transcriptase amino
acid substitution (Y181C). It therefore seems likely that calanolides and inophyllums
bind to HIV-1 reverse transcriptase in a different manner to existing non-nucleoside
reverse transcriptase inhibitors which makes them an attractive structural motif from
which to develop new leads. The calanolide isomer (+)-calanolide A, is currently being
evaluated in clinical trials in the USA (Buckheit et al., 2000).
Figure 1.7 Calanolide A from Calophyllum lanigerum
1.3.2.5 The camptothecins
Camptothecin, a pentacyclic alkaloid is a topoisomerase 1 inhibitor isolated from the
Chinese tree Camptotheca acuminata (Nyssaceae). Camptothecin and its analogues have
been extensively investigated as potential anti-tumour agents and in 1996 the water
soluble variant topotecan was licensed for the treatment of refractory ovarian cancer
(Sadaie et al., 2004). Since a number of viruses including HIV and human
cytomegalovirus (HCMV) depend upon topoisomerase 1 for DNA replication there has
been a certain amount of interest in developing the compounds as viral inhibitors
(Bailly, 2000) although concerns over toxicity have so far prevented these compounds
from reaching the clinic. One possible advantage of camptothecin based topoisomerase 1
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inhibitors is that since the drug target is not virally encoded resistance is expected to
develop more slowly than with conventional viral inhibitors. In a single treatment in
vitro assay a 30nM dose of 9-nitrocamptothecin gave 95% inhibition of HIV-1
replication with minimal cell toxicity suggesting inhibition of topoisomerase I has a
greater effect on viral replication than cellular mitosis so providing some degree of
selectivity (Balint, 2001).
Figure 1.8. (S)~(+)-Camptothecin from Camptotheca acuminate.
1.3.3 Plant derived antibacterial and antifungal compounds
Unlike microorganisms, plants have proved a disappointing source of potent, selective
antibacterial and antifungal agents (Newton et al., 2000). Whilst many species produce
compounds with some degree of antibacterial or antifungal activity very few are both
sufficiently active and non-toxic to be considered leads for the development of new
antibiotics. For example, in a review of over 350 plants cited over the last 30 years as
having antimycobacterial activity only 7 species yielded pure compounds with MIC
values of 8pg/ml or less (Newton et al., 2000). Two examples of plant derived
antibacterial compounds that have found clinical use are the alkaloid berberine and the
simple phenolic eugenol.
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1.3.3.1 Berberine from Berberis Spp.
Species of the genus Berberis (Berberidaceae) have been used traditionally in a variety
of antimicrobial type roles and the alkaloid berberine present in Berberis Spp. has been
administered for the treatment of bacillary dysentery (Rabbani et al., 1987) and has a
wide range of antimicrobial activities. Although it readily intercalates with DNA and
inserts into lipid bilayers it is relatively non-toxic and can be taken orally (Sun et al.,
1988). Despite berberine's broad spectrum antibacterial activity it is not clear whether
the therapeutic effect of the compound arises from its antibacterial activity or from
secondary effects. When used in the treatment of enterotoxigenic E. coli and Vibrio
cholerae it appears that its primary mode of action is antisecretory agent rather than
antibacterial (Rabbani et al., 1987). Berberine also interferes with bacterial cell
adhesion; experiments with Streptococcus pyogenes showed that at concentrations below
its MIC, berberine caused an 8 fold increase in the release of the adhesin lipoteichoic
acid from the cell surface (Sun et al., 1988) and that this could act to inhibit colonisation
during the infection process. There is some interest in using berberine as a starting point
for creating analogues with improved activity.
Me
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Figure 1.9. Berberine from Berberis Spp.
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1.3.3.2 Eugenol
Eugenol is a simple phenolic derived from the clove tree Eugenia caryophyllata
(Myrtaceae) which is indigenous to the spice islands of Indonesia, and Cloves have a
long tradition of use as a treatment for toothache in both India and China (Curtis, 1990;
Meeker and Linke, 1988). Reacting eugenol with zinc oxide produces zinc eugenolate
chelate which has been used as a component of dental capping agents for many years
due to its antibacterial and analgesic properties (Curtis, 1990; Meeker and Linke, 1988).
Eugenol has broad spectrum antibacterial activity with a MIC of less than lpg/ml for
strains of E. coli and S. aureus and is effective at inhibiting the facultative anaerobes
commonly isolated from infected root canals as well as certain moulds such as
Penicillium citrinium (Walsh et al., 2003). The mode of action of eugenol remains
unclear but experiments measuring ion flux suggest the bacterial membrane as a likely
target. When susceptible strains of E. coli and S. aureus were exposed to eugenol rapid
potassium loss indicative of membrane damage was observed (Walsh et ah, 2003).




2.1 Acquisition of plant material
Plant material for laboratory analysis was gathered through a process of ethnobotanical
survey and "in the field" screening of plant material. For a more detailed account see the
Chapter 3 (Fieldwork).
2.1.1 Gathering of ethnobotanical data and samples for screening
Information was gathered largely according to the "rapid ethnographic assessment"
approach outlined by Etkin 1993 (Etkin, 1993). Three field work sites were selected on
the basis of their differing ecologies and contacts were made in nearby villages with
locals recommended by other villagers for their knowledge of plant medicines.
Interviews were carried out in the local Neo Melanesian dialect with key informants to
establish a range of candidate plants for screening, taking detailed notes on the use,
preparation and local names of each species. Where possible, information was cross
checked with secondary sources and where such information could not be corroborated
it was discounted. An effort was made to focus on plants used to treat illnesses such as
tropical ulcers that were likely to constitute some sort of microbial infection.
Once an exhaustive list of medicinal plants had been obtained, samples of each plant
were collected for "in the field screening". This was done in conjunction with
informants who had provided the source information. Samples were collected from the
surrounding forest by informants themselves to prevent anomalies in the method of
preparation occurring. Samples for initial screening were typically less than a gram of
material and were collected into freezer bags labelled with the local name used for the
plant.
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2.1.2 In the field screening of plant material
Plants were screened in the field to avoid the need for a return to the fieldwork location
at a later date. The field assay was based around the filter paper disk diffusion assay and
the well diffusion assay in which samples are placed into pre-cut wells or disks in an
agar plate. A strain of Staphylococcus epidermidis and Escherichia coli were stored as
freeze-dried stocks in glass vials and opened when required. Bacteriological media was
autoclaved in a miniature pressure vessel specifically designed for the purpose, (see
Chapter 3 for more details) and bacterial cultures were grown in the ambient tropical
temperature (approximately 30°C) and seeded onto sterile glass agar plates prepared
with the pressure vessel. Ethanolic or aqueous plant extracts of each sample were made
using a mortar and pestle and approximately 20ql or 5ul respectively were added to
wells or disks on the plate and incubated over night. Active extracts were revealed by
zones of inhibition of bacterial growth, small zones l-2mm around the rim of the well
were discounted.
2.1.3 Collection of botanical voucher specimens
Botanical voucher specimens were collected into 70% ethanol and sent for identification
to the Papua New Guinea Forest Research Institute, Lae. Samples were prepared so as to
show the overall morphology of the plant and its range of vegetative features. For
smaller plants (shrubs) this meant collecting the whole plant including roots but for large
tree species sections of branches showing the leaf arrangement along with sections of
fruit and where possible flowers were all collected. Each voucher specimen was
labelled with a number written in pencil on a jeweller's tag which was attached to each
piece of the specimen. Each number was cross referenced to collection data which
included a description of the location the plant was collected in, colours of fruit/flowers,
the local name for the plant along with the ethnobotanical use and preparation.
Specimens were placed into folded newsprint sheets and sealed in polythene before
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adding alcohol. Where the water content of the plant material was high the water content
of the alcohol was lowered accordingly. Export licences for voucher specimens were
issued by the Papua New Guinea Department of Forestry after taxonomic identification
had taken place.
2.1.4 Collection of insect specimens
A similar approach was taken for insect specimens recording location, local name and
descriptions of use. Photographs were also taken to aid identification. Specimens were
collected into 100% ethanol to reduce the likelihood of decomposition.
2.1.5 Collection of samples for laboratory analysis
After active species were identified with the field assay, bulk samples of more than 1kg
were collected for lab testing. Where possible, specimens were collected from the
original plant the initial screening sample was taken from. Specimens were dried in the
shade on sheets of newspaper to avoid deactivation of chemical constituents by sunlight.
For insect specimens the voucher specimen doubled as the sample for lab analysis.
2.2 Extraction of plant material
Plant material was extracted with a variety of different solvents to determine the
optimum extraction conditions. For initial open column chromatography testing, bark
was ground in a mortar and pestle whereas for later experiments the bark was ground in
a coffee grinder and filtered in a Buchner funnel.
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2.2.1 Small volume extracts for initial experiments
Extracts of each of the plants were made by grinding up 50mg of the dried plant material
in the presence of 1ml of the solvent used (water or ethanol) with a mortar and pestle.
The sediment was allowed to settle and the extract was filtered through Whatman No 1
paper. In some cases a cellulose acetate 0.2 pm disposable syringe filter was used to
clarify the extract.
2.2.2 Large volume extracts for purification of active compounds
Larger volume extracts were made by grinding the bark in a coffee grinder to form a fine
powder taking care to insure the raw material did not become over heated. The resulting
powder was then transferred to a 500ml flask and 500ml of the solvent was added. The
resulting solution was then stirred magnetically for at least 10 minutes to form a crude
extract before being filtered through Whatman No 1 filter paper in a Buchner funnel
using a water pump for suction. In some cases the crude extract was centrifuged at 3000
rpm for 1 minute to sediment out particles before filtration took place.
2.3 Concentration of fractions
Chromatography experiments tended to produce fractions more dilute than the sample
mixture and so to maintain samples at a workable volume they were concentrated in a
centrifugal evaporator, rotary evaporator or a lyophiliser (freeze-dryer).
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2.3.1 GyroVap evaporator
A GyroVap evaporator connected to an Aquavac pump was used to concentrate
chromatography fractions from so they could be easily assayed. The fractions were
loaded into Ependorf tubes and these were spun at lOOOrpm with the internal oven
temperature set at 40°C.
2.3.2 Rotary evaporator
A Buchi Rotavapor rotary evaporator was used to concentrate samples where the sample
volume was too large for the GyroVap. The rotary evaporator was connected to a water
pump to provide negative pressure and was used in conjunction with a water bath set at
40°C.
2.3.3 Freeze-drying
Freeze-drying was carried out with an Edwards Muduylo system and used to concentrate
aqueous samples where temperature and oxidation were a concern or before weighing
pure compounds where traces of solvents would effect the accuracy of the reading.
Samples containing small quantities of organic solvents were first treated in the rotary
evaporator to remove traces of solvents that would prevent freezing. Samples were
placed in a round-bottomed flask and frozen in a Cryobath CB-60 oil bath, spinning the
flask by hand to ensure an even build up of ice on the inside of the flask. For small
samples, (less than 1ml) the solution was frozen in an Eppendorf tube and a small hole
pierced in the lid to allow equalisation of pressure. The Eppendorf tube was then placed
in a round-bottomed flask that was connected to the freeze-dryer. In this way small
volumes could be easily concentrated, weighed and then re-dissolved in small volumes
of solvent.
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2.4 Open column chromatography
A variety of chromatography separation media were trialled in open column format
using gravity to feed the mobile phase through the column. In each case the separation
media was swelled before pouring into a solvent resistant plastic column and allowing to
bed out.
2.4.1 Gel filtration chromatography
Gel filtration was carried out using Pharmacia Sephadex LH-20 which was swelled in
water for one hour allowing the fines to collect on the surface before decanting them.
Water was replaced with the solvent of choice (normally ethanol) by filtering the
Sephadex slurry through Whatman No 1 filter paper to remove water and then adding
back the minimal amount of solvent required to produce a mixture sufficiently fluid to
be poured into the column. The Sephadex was gently stirred so as to provide an even
mixture which was then poured into a column held in a clamp at a 45° angle so the
Sephadex ran down the sides of the column thereby displacing air bubbles. Once poured
the column was allowed to stand upright to allow the Sephadex to form a bed before
washing the column with several column volumes of solvent to clean it. Loading was
achieved by running out excess solvent to a centimetre above the bed and then pipetting
the sample into the column so that it ran down the side of the column and did not stir up
the bedded Sephadex. The end cap and tubing were secured to the top of the column and
the solvent reservoir placed high enough to produce the desired flow. The out flow line
of the column was always connected to a Gilson FC 203B fraction collector and the
drops/tube function used to programme it to collect 3ml or 5ml fractions.
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2.4.2 Ion exchange chromatography
The cation exchange resin Whatman Microgranular CM52 or anion exchange resin
Sigma Dowex-1 were first swelled with an equal volume of water for 10 minutes and
then poured into a column using the same technique used for pouring Sephadex taking
care not to introduce air bubbles into the resin. The resin was allowed to bed out before
running the column first with aminimum of 10 column volumes of 1M pH 7.0 HC1 Tris
buffer and then a similar amount of lOmM pH 7.0 HC1 Tris. Samples of the outflow
were taken periodically and the pH taken to monitor the progress of the equilibration.
Once the column was equilibrated the sample was loaded by pipetting the sample onto
the inside surface of the column just above the resin bed, the end cap attached and the
column run with the lOmM pH 7.0 HC1 Tris solution for 10 fractions as a flow through
to elute unbound material. The outflow line was connected to the fraction collector
programmed with the drop/tube function to collect 3ml or 5ml fractions depending on
the size of the loading sample. When elution proceeded very slowly an electrical pump
was used to increase the flow rate.
After the flow through a salt gradient was then set up using a gradient maker, each
chamber filled with 80ml lOmM Tris with varying amount of salt (NaCl, KC1 or
MgCk). The low salt chamber (connected to the inflow to the column) was stirred with a
magnetic flea to insure constant mixing of the solutions and therefore a linear salt
gradient but care was taken not to over stir as this caused a back pressure and uneven
flow from the high salt to the low salt chamber. The salt gradient was normally run for
sixty 5ml fractions and collected automatically as before. In some experiments a pH
gradient was run by replacing the salt solutions for Tris buffer adjusted to different pH's.
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2.4.3 Chromatography elution profile graphs
For each liquid chromatography experiment an elution profile graph was created of
elution volume versus optical absorbance by taking spectrophotometer readings of each
fraction at 280nm wavelength. Where small quantities of material were loaded onto
columns, 1ml of each fraction was pipetted directly into a clean quartz quvette but where
more concentrated extracts were used, fractions were diluted so as to keep the
absorbance readings below 3.0. The dilution was carried out in an Eppendorf tube that
was vortexed to ensure thorough mixing.
2.5 High Performance Liquid Chromatography
High Performance Liquid Chromatography (HPLC) was carried out initially on an
Applied Biosystems 130A machine and later on a Gilson system consisting of four 306
pumps and a 115 UV detector.
2.5.1 Set up and use of Applied Biosystems 130A and Gilson systems
For the applied Biosystems machine sample injection was carried out using a lOOpl
Hamilton Bonaduz Schweiz glass syringe with a 200pl loop fitted to the machine.
Before injecting the sample the loop was cleaned by flushing through with 1ml distilled
water. Flow rates ranging from 200 to lOOOul/min were programmed into the machine
before starting each run. For flow rates above 500pl/min a gradient could not be
sustained for long due to the low capacity of the solvent chambers in the machine.
Instead, isocratic elutions were used where both chambers contained the same solvents
so allowing the run to continue for longer without re-filling. This was achieved by
selecting the free-run mode on the machine which allows changes in flow rate, %
solvent B and duration of run to be altered during the course of the experiment.
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At the end of each run the column was washed with a buffer rich in solvent B to elute
any remaining material. Detection was set at UV 280nm in order to have the greatest
chance of detecting material eluted from the column. This was recorded with a Kip and
Zonen BD51 chart plotter run at 2mm/min with the variation set at 50mv. Samples were
either collected manually as peaks appeared on the trace or over time using the fraction
collector.
For the Gilson system different solvent gradients and flow rates of up to 1.5 ml/min
were used. Injection was carried out automatically using a model 231 sample injector
fitted with a 200pl loop. Integration was carried out by the Unipoint Software used to
control the system.
2.5.2 Solvent preparation
Solvents were all HPLC grade unless stated and were filtered though Millipore 0.45p
filters to remove particles that would damage column packings if not removed. Filtering
in this way also helped to degas solvents although in general the 75psi backpressure
regulator fitted to the Gilson system prevented problems of out-gassing. Where solvent
A alone contained salts care was taken to ensure that the salts would remain in solution
at the full range of concentrations of solvent B during the gradient run. If when mixing
the two solvents a precipitate was observed then a lower salt concentration was used.
2.5.3 HPLC experimental conditions
A wide variety of stationary and mobile phases were tried during the optimisation of the
purification procedure. Listed below are the stationary phases, mobile phases and flow
rates used. Unless stated otherwise the temperature was ambient. For each run numerous
different gradient systems were tried.
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Solvent B 0.08% TFA 70% MeCN
2.5.3.2 Supelcosil LC-Si 5 micron 250 x 4.6mm normal phase column
Flow rate 1ml/minute run isocratically
0.5% ammonia in methanol
0.1% TFA 70% MeCN
0.28% acetic acid 30% methanol
0.32% acetic acid 20% methanol
0.0425M pH 2.5 phosphate buffer 15% MeCN
0.003M pH 5.0 EDTA 70% Methanol
40% Methanol 0.05mM Heptane sulfonic acid adjusted to pH 3.5 with NaOH
70% Methanol 3mM pH 9.0 Tris HC1 0.09M KC1
70% MeCN 0.024% TFA 0.0015M Heptane sulfonic acid
2.5.3.3 Supelco supelcosil C-18 5 micron 250 x 4.6mm reverse phase column
Flow rate 1 ml/minute run isocratically
0.28% acetic acid 9% methanol
80% methanol 20% 0.002M phosphate buffer pH 7.0
75% MeCN 1.25mM lauryl sulphate 0.0025% HCIO4
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0.0425M pH 2.5 phosphate buffer 15% MeCN
0.007M EDTA pH 5.0 30% Methanol
0.003M pH 5.0 EDTA 70% Methanol
40% Methanol 0.05mM Heptane sulfonic acid adjusted to
60% Methanol 0.05mM Heptane sulfonic acid adjusted to
70% MeCN 0.024% TFA 0.0015M Heptane sulfonic acid
70% MeCN 0.024% TFA 3mM EDTA
Gradient runs
Solvent A lOmM pH 8 Tris 20% MeCN
Solvent B lOOmM pH 8 Tris 20% MeCN 1.0M KC1
Solvent A lOmM pH 8 Tris HC1 1% Triethylamine
Solvent B 70% MeCN lOmM pH 8 Tris HC1 1% Triethylamine
Solvent A H2O
Solvent B MeCN
2.5.3.4 Supelcogel TPR 100 Polymeric column reverse phase column
Flow rate 0.5ml/minute
Solvent A lOmM pH 9 Tris HC1
Solvent B lOmM pH 9 Tris HC1 70% Methanol
Solvent A H2O
Solvent B MeOH
pH 3.5 with NaOH
pH 3.5 with NaOH
Solvent A lOmM HC1 KC1 buffer pH 1
Solvent B MeOH
Solvent A lOmM Citrate pH 3
Solvent B MeOH
Solvent A lOmM Citrate pH 5
Solvent B MeOH
Solvent A Tris HC1 pH 7
Solvent B MeOH
Solvent A Tris HC1 pH 9
Solvent B MeOH
Solvent A lOmM Na2C03/NaHC03 pH 10.6
Solvent B MeOH




Solvent A H20 5mM B-mercaptoethanol
Solvent B MeCN B-mercaptoethanol
Solvent A H2O 5mM B-mercaptoethanol
Solvent B methanol 5mM B-mercaptoethanol
Solvent A H2O 5mM B-mercaptoethanol
Solvent B acetone 5mM B-mercaptoethanol
Solvent A H2O 5mM B-mercaptoethanol
Solvent B tetrahydrofuran (THF) 5mM B-mercaptoethanol
Solvent A 5mM heptane sulfonic acid
Solvent B 5mM heptane sulfonic acid 90% MeCN
Solvent A lOmM pH 9 phosphate buffer
Solvent B lOmM pH 9 phosphate buffer 70% MeOH
Solvent A lOmM pH 8 phosphate buffer
Solvent B lOmM pH 8 phosphate buffer 70% MeOH
Solvent A 0.1% Triethylamine 5mM 6-mercaptoethanol
Solvent B 0.1% Triethylamine 5mM B-mercaptoethanol MeCN
Solvent A 0.2% ammonia 5mM B-mercaptoethanol (pH 10)
Solvent B 0.2% ammonia 5mM B-mercaptoethanol MeCN
Solvent A lOmM pH 8 Tris HC1
Solvent B lOmM pH 8 Tris HC1 70% MeCN
Solvent A 0.05M phosphate buffer pH 8
Solvent B 0.05M phosphate buffer pH 8 70% Methanol
Solvent A 0.1% phosphoric acid
Solvent B 0.1% phosphoric acid 70% methanol
Solvent A 0.2% phosphoric acid
Solvent B 0.2% phosphoric acid 70% methanol
Solvent A 300mM KC1
Solvent B MeOH
2.5.3.6 Thermohypersil Hypercarb 4.6 x 50mm normal/reverse phase column
Flow rate 1.5ml/minute
Initial gradient of 0 to 100% MeOH followed by 100% THF followed by a second
gradient of 50% THF 0.05% TFA going to 100% THF.
Solvent A 0.1% TFA
Solvent B 1:1 Isopropanol/MeCN 0.1% TFA
Solvent A 0.1% TFA





Solvent A 0.1% diethylamine
Solvent B 1:1 MeCN/IPA 0.1% DEA
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2.5.3.7 Thermohypersil phenyl/hexyl betabasicl50 x 4.6mm reverse phase column
Flow rate 1.5ml/minute
Solvent A 0.1% TFA
Solvent B 1:1 Isopropanol/MeCN 0.1% TFA
Solvent A 0.1% TFA
Solvent B 1:1 Isopropanol/MeCN 0.1% TFA
Column temperature 50°C
Solvent A 5mM B-mercaptoethanol 0.1% TFA
Solvent B 5mM B-mercaptoethanol 1:1 Isopropanol/MeCN 0.1% TFA
Solvent A H2O
Solvent B 1:1 Isopropanol/MeCN
Solvent A H2O
Solvent B 1:1 Isopropanol/MeCN
Solvent C 0.1% TFA
Solvent A 0.1% ethanolic acid
Solvent B 0.1% ethanolic acid 1:1 isopropanol/methylcyanide
Solvent A 0.1% phosphoric acid
Solvent B Methyl cyanide: isopropanol 1:1
Solvent A lOmM KH2P04
Solvent B 1:1 MeCN/IP
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Solvent C 0.1% TFA
















Solvent A 0.1% Methanoic acid
Solvent B Isopropanol
Solvent C MeCN
Solvent A 0.5% Methanoic acid
Solvent B Isopropanol
Solvent C MeCN
2.6 Nuclear Magnetic Resonance Spectroscopy
The initial TFA lunacridine derivative was identified using both carbon-13 and proton
NMR and allowed later samples to be identified using proton NMR alone. A variety of
NMR techniques were used which are briefly outlined below.
2.6.1 Instrumentation
Nuclear magnetic resonance (NMR) spectroscopy was carried out by Dr Ian Sadler at
the Ultra-High Field NMR Centre, Department of Chemistry, University of Edinburgh
using a Varian INOVA 600MHz spectrophotometer.
2.6.2 Standard single pulse spectra
A short (microsecond) long radiofrequency pulse was applied to the sample and the
resulting emission signal (Free Induction Decay - FID) collected. This signal was
converted into a conventional spectrum by Fourier transformation used for a basic
proton spectrum. A basic carbon-13 spectrum was similarly obtained except that broad¬
band proton decoupling was applied throughout the experiment to remove all proton
couplings thus giving a single line for each carbon nucleus present.
2.6.3 Carbon-13 DEPT spectra
By a specially designed rapid sequence of pulses, rather than a single pulse it is possible
to obtain selected parts of a spectrum only, thus simplifying the spectrum. The DEPT
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sequence enabled us to obtain (a) a spectrum showing signals only from carbons bearing
one hydrogen (b) a spectrum in which signals from CH and CH3 carbons are positive
and those from CH2 carbons are negative.
2.6.4 HMQC Heteronuclear Multiple Quantum Coherence spectroscopy
This method was used to correlate proton resonances with those of directly bonded
carbon-13 (or other) nuclei. The axes of the contour plot represent the proton and other
nucleus chemical shift ranges. Signals occur at co-ordinates corresponding to the shifts
of the bonded pairs of nuclei.
2.6.5 HMBC Heteronuclear Multiple Bond Correlation spectroscopy
HMBC is essentially the same as HMQC and was used for correlating proton and
carbon-13 (or other) resonances showing mutual coupling through two or three bonds
(occasionally more). This is usually optimised for couplings around 8 Hz and so only
signals from those nuclei whose couplings lie in the 6-10 Hz range were likely to be
observed.
2.7 Bacterial cultures
Cell cultures were made according to standard methods by inoculating autoclaved broth
with cells from a single colony removed from a plate on which the stock culture had
been streaked out. For assaying semi pure fractions, cultures grown in LB broth were
used and these were made by autoclaving 2.5g of LB powder (Oxoid) in 100ml water.


















For MIC experiments Isosensitest agar was used and made up according to the
manufacturers instructions, (11.7g isosensitest broth (Oxoid) autoclaved in 0.5L distilled
water).
Once inoculated the nutrient broth was incubated at 37C° overnight to produce log phase
cells. Strains of bacteria used included E. coli (E. coli) ATCC 10536 and S. aureus
NCTC 6571 as well as NCTC 12493 (methicilin resistant S. aureus). Agar plates for
assaying semi-pure fractions were made by autoclaving LB medium containing 25g LB
powder, 15g bacteriological agar and 1 litre de-ionised water in a 1 litre Gibco bottle,
allowing to cool until hand hot before pouring into 14.5cm x 2.1cm sized plates. Plates
were generally poured to a thickness of 1.2cm for the well assay and 0.7cm for the paper
disk assay. For MIC experiments 15.7g isosensitest agar and 11.7g isosensitest broth
(Oxoid) were autoclaved in 0.5L distilled water and 20ml poured into plates. All
autoclaving was run on a cycle at 15 pounds per square inch for 20 minutes.
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2.8 Bacterial inhibition assays
To assay fractions the well method or Kirby/Bauer filter paper disk diffusion assay were
used depending on the activity of the sample. More quantitative information was
obtained using the agar and broth dilution assay.
2.8.1 Well method
Plates were poured to a thickness of approximately 1.2cm and allowed to harden. The
agar was then seeded with the appropriate cells by pouring 5 to 10ml of the broth cell
culture directly on to the agar making sure to cover the whole plate, excess culture was
then removed with a sterile pipette. A glass pipette with an open end 6mm in diameter
was then sterilised by flaming it with ethanol. Once cool, the sterile pipette was used to
cut holes in the agar, (one for each sample to be tested). The resulting plugs of agar were
then removed with sharp tweezers which were also sterilised by flaming with ethanol.
The wells were injected with samples ranging in volumes from 10 to lOOpl depending
on the size of the sample being assayed. One of the wells was always loaded with the
solvent the samples were prepared with to act as a negative control. The plate was then
placed in an incubator overnight at 37°C. Zones of inhibition surrounding active samples
were measured by their diameter from underneath the plate. Solvent controls rarely
produced significant zones of inhibition.
2.8.2 Filter Paper disk method
This assay was used where samples had high enough activity to show up with small
volumes. Plates were poured to a thickness of approximately 0.7cm, allowed to solidify
before being inoculated with cell culture as above. Excess cell culture was removed and
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the plates left to dry with the lids partially removed. Filter paper disks 6mm in diameter
were made by cutting holes in blotting paper with a hole punch. Autoclaved disks were
impregnated with the test samples by pipetting 3-5pl of sample onto each disk. The
disks were then placed onto the agar with sterile tweezers and their positions recorded
with marker pen on the lid of the dish. As with the well assay the plate was then placed
in an incubator overnight at 37°C and zones of inhibition surrounding active samples
were measured by their diameter from underneath the plate.
2.8.3 MIC by agar dilution
MIC experiments were carried out using the agar dilution method according to the
protocol stipulated by the Journal of Antimicrobial Chemotherapy (2001) (Andrews,
2001). Drugs were added to 20ml molten agar from stocks of specified concentrations
(10, 1 and O.lmg/ml). For example, for 128ug/ml 256pl of a lOmg/ml stock were used
or for 1 |ig/ml 200pl of a O.lmg/ml stock were used. In each case the drug volumes were
aliquoted into sterile autoclaved flasks and 20ml hand hot molten agar (approximately
50°C) made from 15.7g isosensitest agar and 11.7g isosensitest broth (Oxoid) autoclaved
in 0.5L distilled water.
For each concentration the molten agar was added to the flask, mixed by swirling once
before pouring directly into 90mm Petri dishes. Molten agar was added to each drug
concentration in turn and poured straight into the Petri dish so as to minimize the amount
of time the drugs were exposed to 50°C temperatures. The plates were allowed to cool
and once solidified were dried for 10 minutes in an incubator with the lids partially
removed resting on the rims of the plate. An overnight culture of cells was prepared as
described above and adjusted to the same opacity as a 0.5 McFarland standard
(purchased from BioMeriux Basingstoke UK) with sterile isosensitest broth and then
diluted ten fold in sterile distilled water, lpl of the diluted culture was added to the
surface of each plate and allowed to stand with the lid partially removed in the incubator
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until the inoculum had been visibly seen to be absorbed into the agar. A no inoculum
control was generally included to check for contamination as well as a no drug control to
ensure the cell culture was viable. The plates were incubated for 18 hours at 37°C and
then inspected visually for signs of growth. The MIC was defined as the lowest
concentration of drug at which there was no visible growth of the organism. The
presence of one or two colonies or a thin film of growth was disregarded as stipulated by
the Journal of Antimicrobial Chemotherapy (2001) method (Andrews, 2001).
2.8.4 MIC by broth microdilution
The broth microdilution method described by Andrews et al (Andrews, 2001) was used
for isolated plant compounds since the amounts of material available were insufficient to
be used with the agar dilution method. Briefly, 75pl of each drug concentration were
added to a sterile Nunclon (Nunc) 96 well plate using the same antibiotic solutions as for
the agar dilution method. The bacterial cultures were prepared as described above and
adjusted to the same opacity as the 0.5 McFarland standard before diluting 100 fold with
isosensitest broth to produce a final concentration of 105 CFU/ml. 75ul of diluted broth
was then added to each well and the plate incubated for 18 hours. On each plate a no
drug control and uninoculated well was included to allow comparison of both full and no
growth. The MIC was defined as the lowest drug concentration in which there was no
visible growth.
2..8.5 Streptococcus pneumoniae disk diffusion assay
The S. pneumoniae disk diffusion assay was carried out by Professor S. Amyes
(Department ofMedical Microbiology, University of Edinburgh). Lunacridine
impregnated disks were screened against S. pneumonia strains using the Kirby/ Bauer
filter paper disk diffusion assay. Bacterial cultures were
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prepared according to NCCLS guidelines and seeded onto Mueller-Hinton agar plates
supplemented with 5% defibrinated horse blood. Sterile filter paper disks 6mm in
diameter each containing 200|ig TFA lunacridine were added to plates inoculated with
each strain. The plates were cultured for 24 hours at 37°C in 5% C02 and then inspected
for zones of inhibition which were measured from the front of the plate.
2.9 HSV-1 virus yield reduction assay
The assay required specialised lab conditions and so was carried out by Dr M. Ogilvie,
at the specialist virology centre at the Edinburgh Royal Infirmary
2.9.1 Cell culture
Briefly, the virus yield reduction assay was carried out using a known HSV-1 reference
strain SCI6 using the nucleoside analogue acyclovir as a positive control. SCI6 was
grown on confluent monolayers of both MRC-5 fibroblasts and African green monkey
kidney (Vero) cells which were cultured as follows:
2.9.1.1 MRC-5 cell line
10% minimal essential medium (MEM) supplemented with 10% heat inactivated foetal
calf serum, 1% sodium bicarbonate (7.5%), 1ml L-glutamine and 1ml penicillin and
streptomycin (100 units/ml penicillin, 100pg/ml streptomycin). Maintenance medium
containing 2% foetal calf serum was added once cell were confluent.
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2.9.1.2 Vero cells
10% minimal essential medium (MEM) supplemented with 2% heat inactivated foetal
calf serum, 1.5% sodium bicarbonate (7.5%), 1ml L-glutamine and 1ml penicillin and
streptomycin (100 units/ml penicillin, 1 OOug/ml streptomycin). Maintenance medium
containing 1% foetal calf serum and 2.4% sodium bicarbonate (7.5%) was added once
cells became confluent.
2.9.1.3 HSV-1 SC16
HSV-1 SC16 from stocks was added to a 75cm2 flask of confluent MRC-5 cells and
once 100% infected the contents were centrifuged briefly and the supernatant removed
and stored as frozen 2.5ml aliquots at -20°C.
2.9.2 Yield reduction assay
MRC-5 cells or Vero cells were seeded into a 24 well microtitre plate at 2 xlO and 1
xlO5 cells/ml respectively. Once confluent, the culture was inoculated with 200ul HSV-1
SCI6 supernatant at a multiplicity of infection of 5 plaque forming units per cell. The
plate was then incubated at 36°C for 1 hour to allow virus adsorption whereupon the
inoculum was replaced with 1ml aliquots of TFA lunacridine or acyclovir at varying
drug concentrations.
The plate was incubated at 36°C overnight after which the cells were lysed by freeze-
thaw at -80°C. lOOul aliquots were then taken from the infected wells and transferred to
a fresh plate and serially diluted 1:3 across the next five columns of the plate. The plates
were incubated at 36°C for one hour to permit virus adsorption whereupon virus
inoculum (containing test compounds) was replaced with 0.2ml fresh medium. The
plates were then incubated for a further 2 days after which medium was removed, and
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the cell sheets fixed with methanol. The medium was then removed from each well and
the cells stained with Wrights stain for 10 minutes, rinsed with PBS and allowed to dry.
Viral plaques were counted visually.
2.10 Human cell cytotoxicity assays
Cytotoxicity assays were performed using the Cell Titer 96 Aqueous One solution cell
proliferation reagent (Promega) which contains the tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS(a)] and an electron coupling reagent (phenazine ethosulfate; PES).
Reduction of the reagent as a result of cellular metabolic activity results in the
production of a coloured formazan product whose absorption at 490nm is directly
proportional to the number of living cells.
MRC-5, H226 and HELA cells were grown in tissue culture flasks in a Sanyo CO2
incubator set at 37°C and 5% CO2, plated into 384 well tissue culture plates and allowed
to attach overnight before adding drugs and then reagents. Throughout the assay sterile
techniques were observed and all liquid handling and cell culture was carried out in a
class II microbiological safety cabinet which was swabbed down with 70% IMS before
use. Care was taken to avoid contact between skin and lab materials and latex gloves
were worn at all times. Pipetting of liquids was done using an electric pipettor
(Finnpipette) using sterile 10ml disposable pipette tips. Cells suspensions were added to
plates using a 16-channel pipette (Finnpipette).
2.10.1 Cell culture
MRC-5, H226 and HELA cells were obtained as frozen stocks maintained in liquid
nitrogen and were rapidly thawed out by placing in a water bath at 37°C before adding
to 2-3ml pre-warmed culture medium in a 75cm2 tissue culture treated flask with a filter
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cap lid (filter cap lids were used with all tissue cultures to reduce the risk of
contamination). The cells were allowed to grow to near confluency before splitting and
transferring to a larger 175 cm2 flask. Splitting of cells was carried out for a 175cm flask
as follows, and varied according to the size of the flask.
Cell culture medium was removed from the culture flask which was then washed out
with phosphate buffered saline (PBS) to remove traces of culture medium which would
inhibit the trypsin solution. IX Trypsin solution (Gibco) was then added in sufficient
quantity to just cover the surface of the culture flask but no more and swirled slightly to
ensure it was evenly distributed. The flask was then placed back in the incubator where
it was left for 2-3 minutes to allow cells to detach after which the flask was removed
from the incubator and tapped on each side several times to help fully detach cells. To
achieve an even suspension the detached cells were pipetted up and down ten times,
each time allowing the cells to run down the bottom of the flask. Between a half to two
thirds of the detached cells were discarded (depending on the cell type) and 15ml culture
medium was added back to the flask, which was then returned to the incubator. Media
for each of the cell lines was as follows:
2.10.1.1 MRC-5 cells
• 500ml minimal essential medium (MEM) + Earle's - L-glutamine (Gibco)
• 50ml foetal bovine serum (heat inactivated) (Gibco)
• 5ml L-glutamine pen/strep solution (200 mM L-glutamine10,000 units/ml
penicillin, and 10 mg/ml streptomycin in 0.9 % sodium chloride) (Sigma).
• 5ml MEM lOOx non-essential amino acids (Gibco)
• 5ml 100 mM Na Pyruvate (Sigma)
2.10.1.2 H226 cells
• 500ml RPMI 1640- L-glutamine (Gibco)
• 50ml foetal bovine serum (heat inactivated) (Gibco)
• 5ml L-glutamine pen/strep solution (200 mM L-glutamine10,000 units/ml
penicillin, and 10 mg/ml streptomycin in 0.9 % sodium chloride) (Sigma).
• 5ml 100 mM Na Pyruvate (Sigma)
2.10.1.2 HELA cells
• 500ml minimal essential medium (MEM) + Earle's - L-glutamine (Gibco)
• 50ml foetal bovine serum (heat inactivated) (Gibco)
• 5ml L-glutamine pen/strep solution (200 mM L-glutamine 10,000 units/ml
penicillin, and 10 mg/ml streptomycin in 0.9 % sodium chloride) (Sigma).
• 5ml 100 mM Na Pyruvate (Sigma)
To harvest the cells for the assay the same procedure outlined for splitting the cells was
followed. Cells were split before they approached confluency and culture media changed
24 hours prior to splitting to ensure cells were log phase.
2.10.2 Plating out of cells
After trypsinisation of the cells with 3ml pre-warmed trypsin solution, a 20ql aliquot of
the cell suspension was removed and placed adjacent to the cover slip of a 0.1mm3
haemocytometer and the number of cells counted and converted into a per ml figure. The
trypsinised cells were then diluted to 2.5 xlO5 cells per ml with pre-warmed culture
medium and pipetted up and down twenty times to ensure any cell clumps had been
removed since a single cell clump would greatly increase the number of cells in a given
well and so result in an erroneously high reading of cell viability. 25pl aliquots of the
resulting cell culture were then added to sterile transparent optical 384 well plates
(Nunc) in columns of 8 or 16 wells at a time using the 16 channel Finnpipette to produce
a final count of 6,250 cells/well in accordance with Nuncs recommendation of 5000 to
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20 000 cells per well in 384 well plates. Care was taken to ensure the culture was
delivered to the bottom of each well and all the tips of the pipette were attached
securely. Plates were then placed in the incubator overnight for the cells to attach.
2.10.3 Incubation with drugs and Cell Titer reagent
Drug solutions were made up by diluting 5mg/ml aqueous drug solutions with the
appropriate cell culture medium to make 200pM solutions. A range of concentrations
were achieved by serial dilution along the columns of wells removing and discarding
25pl of media from the penultimate column. The last column was left as a no drug
control so that each cell line/drug had its own no drug control. Further control wells of
25pi uninoculated culture medium were included to control for background absorbance.
Plates were incubated for 4, 12, 24, 48 or 72 hours after which 5pl of the Cell Titer dye
compound (pre-warmed to 37°C) was added to each well including all the control wells
and the plate incubated for a further 2 hours. The plate was removed from the incubator
and 5pl isopropanol added to each well to remove air bubbles which would affect the
reading. The plate was then read in a Wallac Victor 1420 multi label counter which was
set to shake the plate for 1minute before reading the optical absorbance of each well at
490nm. Controls of the drugs at their highest concentrations were also included but were
found not to absorb at 490nm. Graphs were then plotted with the cell viability expressed
as % of the no drug control subtracting background absorbance.
2.11 Caspase-3/7 assay
The caspase-3/7 assay was carried out as for the cell viability assay with minor
modifications and replacing the Cell Titer reagent with the Apo-1 caspase-3/7 reagent
(Promega) using white non-transparent fluorescence plates. The Apo-1 reagent consists
of a lysis buffer which allows release of cellular caspases and a profluorescent caspase-
76
3/7 consensus substrate, bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-aspartic acid
amide) rhodamine 110 (Z-DEVD-R110). Upon cleavage on the C-terminal side of the
aspartate residue in the DEVD peptide substrate sequence by caspases-3 or 7, the
rhodamine 110 is free to fluoresce at 521nm when exited at 498nm. The reagent was
made up according to manufacturer's instructions by diluting the rhodamine substrate
1:100 with the lysis buffer and warmed to 37C° in a water bath.
After addition of the Apo-1 reagent the plates were shaken using the Wallac Victor 1420
multi label counter and then incubated for 7 hours on a bench top with the lid on before
reading fluorimetrically at 498nm excitation and 521nm emission using the same Wallac
Victor 1420 multi label counter. No drug controls were included on each plate along
with wells containing each drug at its highest used concentration which was not found to
have an effect on fluorescence. Graphs were then plotted as % increase in fluorescence
over the no drug controls.
2.12 DNA intercalation assays
DNA intercalation assays were carried out according to the method described by Cain et




• 1.26fxM ethidium bromide
The pH was then adjusted to 7.0 with NaOH as described. To carry out the assay, 3ml of
the SHE buffer was placed in a plastic cuvette with the corrugated side facing the
excitation beam of a Hitachi F-2000 fluorescence spectrophotometer. Excitation
wavelength was set at 546nm and emission at 595nm. 2pl of 1 mg/ml solution of calf
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thymus DNA (Invitrogen) was then added to the SHE buffer and stirred vigorously with
a blue tip to ensure thorough mixing. Drugs were then added in a stepwise fashion and
readings taken making sure that the contents of the cuvette were properly mixed after
each drug addition.
2.13 Reverse transcriptase assays
Reverse transcriptase assays were carried out using the reverse transcriptase assay
colorimetric kit (Roche Diagnostics) in which HIV-1 reverse transcriptase activity is
detected with an ELISA type protocol.
Digoxigenin and biotin-labelled nucleotides are included in the kits reaction mixture in
an optimised ratio and once incorporated into the DNA reaction product they allow
binding of the DNA to the surface of the streptavidin-coated microplate wells the
reaction is carried out in. This allows unincorporated labelled nucleotides to be washed
away so that in the next step which involves addition of an anti-digoxigenin peroxidase
antibody conjugate (anti-DIG-POD), only synthesised DNA is bound by the antibody. In
the final step, the peroxidase substrate ABTS is added and converted to a coloured
reaction product thereby giving a quantitative reading of DNA reaction product and
therefore RT activity.
2.13.1 Procedure
To carry out the assay drugs were first dissolved in lysis buffer (50mM Tris, 80mM KC1,
2.5mM DTT, 0.75mM EDTA and 0.5% Triton X-100 pH 7.8). Next 20pl aliquots of
reconstituted enzyme (2ng/pl corresponding to 10 mU/pl) were placed in sterile reaction
tubes and 20ul aliquots of the drugs at the desired concentrations were added. A further
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20[a,l of the reaction mixture (46mM Tris-HCl, 266mM KC1, 27.5mM MgCl2, 9.2mM
DDT, lOpM dUTP/dTTP, template/ primer hybrid, 750mA260nm/ml) were added last.
The tubes were then incubated at 37°C for one hour. Controls of lysis buffer only and
lysis buffer with the highest concentration of each inhibitor were included. Each of the
60pl reaction samples were transferred to the streptavidin-coated microplate wells and
the whole 96 well plate covered with a plastic film to prevent evaporation and incubated
for 1 hour at 37°C. The solution was then removed from each well and washed five
times with 250pl washing buffer (supplied with the kit) allowing the washing buffer to
sit in each well for at least 30 seconds before removal.
200(il of anti-digoxigenin-peroxidase polyclonal solution (200mU/ml) were added to
each well, covered as before and incubated for 1 hour at 37°C. The antibody solution
was removed by inverting the microtitre plate before rinsing each well with washing
buffer as before. 200pi ABTS solution (supplied with kit) were then added to each well
and incubated at room temperature for 20 minutes after which time a dark green colour
developed in the no-drug control and other wells with low RT activity. The absorbance
of each well was then read at 405nm (reference wavelength 490nm) using a Wallac
Victor 1420 multi label counter. Graphs of RT activity were plotted as % of the no drug
control subtracting background absorbance. None of the drugs used in the experiment
were found to absorb at 405nm at the highest concentrations used.
2.14 Topoisomerase II decatenation assays
Topoisomerase assays were carried out using a kit supplied by Topogen Inc. The kit
used a kinetoplast (kDNA) substrate which when decatenated by topoisomerase II alpha
(supplied with the kit) displayed a clear increase in mobility when run on an agarose gel.
The large size of the kDNA relative to its monomeric reaction product ensured a
significant difference in mobility between the two.
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Reaction mixtures generally contained in order of addition; sterile water to 20pl, 2\il
10X reaction buffer (50mM Tris-HCL pH 8, 120mM KC1, lOmM MgCl2, 0.5mM ATP,
0.5mM DTT and 30gg BSA/ml),lpl kDNA substrate, drugs in dH20 and lgl
topoisomerase II enzyme supplied with the kit. The reactants were always added in that
order to prevent initiation of the reaction before all the reactants were added or
denaturation of the enzyme due to addition of undiluted reaction buffer. The final
volume of each reaction was 20pl and the reaction mixture was incubated for 1 hour at
37°C after which the reaction was halted by addition of one fifth volume of stop buffer
loading/dye supplied with the kit.
The contents of each reaction tube were then run on a 1% agarose gel at 90V using TAE
as running buffer(40mM Tris buffer 20mM glacial acetic acid ImM EDTA). Gels were
made by heating 200mg of electrophoresis grade agarose with 20ml TAE buffer in a
microwave until the resulting solution began to boil. A lid was used when preparing the
gel mixture to prevent evaporation changing the gel concentration. Once cool enough to
handle, the molten gel was poured into its mould and allowed to harden before being
placed inside a gel tank and filled with TAE running buffer. In each experiment a
positive (no drug control) was included and in the earlier experiments a marker of
decatenated kDNA to indicate the position of reaction product. A linear kDNA marker
was also used to check for degraded kDNA substrate. DNA was visualised by staining
the gel in 50ml of a 1 ug/ml solution of ethidium bromide, rocking gently for 10 minutes





3.1 The ethnobotanical approach
Conventional ethnopharmacological studies are multidisciplinary and usually require
several participants from different fields (Malone, 1983). There is normally an
ethnobotanist who provides candidate species for screening based on their use in folk
medicines, a chemist to isolate and identify the structures of chemical constituents
(Malone, 1983) and in the case of antimicrobial plants a microbiologist to assay
fractions and gather data on the activity of purified compounds. Plants samples are
normally collected by the ethnobotanist and sent back to a laboratory where testing
begins; about a kilogram of material is generally required to allow purification of active
compounds without having to return to the field to re-supply (Macilwain, 1998). This
presents a problem in that such large quantities of plants are difficult to transport and
collecting them would be inefficient since only a small number could be expected to
posses any sort of antimicrobial activity.
To increase the chances of finding active plant species it was decided to develop an
antibacterial field assay kit which would allow detection of plants with antibacterial
activity in the field. Such an approach would allow one to assay fresh plant preparations
before activity is lost during transportation. It would also eliminate the need to export
large quantities of plant material which based on the premise that at least a kilogram of
material is needed to give a reasonable chance of isolating mg quantities of pure
compounds could be expected to run into hundreds of kilograms.
3.2 The development of the antibacterial assay kit
It was reasoned that a field kit based on the paper disc diffusion assay could be simple
enough to allow reliable screening of plant extracts in the field provided methods for
sterilising glassware and maintaining viable bacterial cultures could be established. To
this end a lightweight pressure vessel was made that would allow glassware and culture
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media to be heated above 100°C for sterilisation. A small stainless steal container was
fitted with a rubber pressure seal and a pressure release valve and a methanol burner
used as the heat source. After safety testing to ensure the pressure release valve
functioned properly the system was tested by heating a culture of Staphylococcus aureus
mixed with soil for 15 minutes. The culture was subsequently plated out and incubated
overnight before inspecting for colonies. The plate was devoid of signs of microbial
growth indicating complete sterilisation of the culture and soil sample.
The second part of the problem was to find a way of producing bacterial cultures in the
field. It was speculated that freeze-dried samples of a gram positive and gram negative
species could be kept at ambient temperature over the course of the field work period
and revived in culture medium when required. Furthermore there would be no need for
an incubator since the daily temperatures in a tropical rainforest range from 20°C to
30°C. The kit contained the following items.
• Light weight pressure vessel.
• Alcohol burner (Trangia).
• Glassware (Petri dishes, bottles etc).
• Freeze-dried cultures of S. epidermidis and E. coli (Selectrol).
• LB media as powder (Oxoid).
• Agar as powder (Oxoid).
The kit was highly portable and lightweight, and so ideally suited to be taken to the
remote locations selected as fieldwork sites (Fig. 3.1). To produce bacterial cultures, a
Selectrol disk containing freeze-dried bacteria (S. epidermidis and E. coli) was placed
into sterile LB broth and incubated overnight or until a the culture medium became
translucent. The agar and LB media were kept in numerous screw cap vials with silica
gel desiccant to reduce exposure to humidity.
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Figure 3.1 The field assay kit in use in the Whiteman range, Papua New Guinea.
To assay plants, aqueous and ethanolic extracts were made by grinding up plant material
in a mortar and pestle in the presence of solvent. Where possible the preparation
methods described in the ethnobotanical survey such as the addition of slaked lime
(CaOH2) made from burning local limestone deposits were used. Extracts were then
applied to paper disks or wells cut into a Petri dish and left overnight at ambient
temperature (typically 20-30°C) after which the plate was examined for zones of
inhibition. Control wells or disks containing extraction solvents were used as controls.
During the course of the fieldwork it was found that adding the extracts to wells cut into
the agar rather than to paper disks allowed for greater sensitivity in detecting
antibacterial activity.
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3.3 Selection of field work sites
New Guinea has been described a biodiversity "hotspot" since it contains one of the
largest undisturbed areas of rainforest in the world and at least 6,500 species of plants
found nowhere else on earth. An estimated two-thirds to three-quarters of the land area
is highly species diverse undisturbed tropical moist forest containing some 11,000 plant
species, of which as many as 90 percent may be endemic (Myers, 1988). In addition to
this New Guinea possesses some of the longest human inhabited rainforest in the world
so providing the greatest possible length of time for local populations to develop a
knowledge of medicinal plants through trial and error. Excavations carried out in the
Whiteman Range of New Britain have provided evidence of inhabitation dating back
over 35 000 years (Pavlides, 1994).
A wide variety forest types are represented ranging from the mangroves and swamp
forests through to upper montane forests which in some cases continue up to 4000m
above sea level (Whitmore, 1984). The ecological diversity is matched by ethnographic
and linguistic diversity; estimates for distinct ethno-linguistic groups within Papua New
Guinea range from 700 to 850 (Wurm, 1981). Since each group has their own
knowledge of medicinal plants which differ according to ecological habitat it is not
surprising that an estimated 1,035 different plant species are known to be used for
specific purposes e.g. medicinal, agricultural, structural, decorative etc (Powell, 1982).
3.3.1 Location of fieldwork sites
With this is mind three fieldwork locations were selected on the island of New Britain
covering the entire altitudinal range of inhabited rainforest on the island (Fig. 3.2).
These were as follows:
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1. The tip of the Williamez Peninsula (Bulu ethnolinguistic group).
2. The foothills of the Whiteman Range (inland Kaulong ethnolinguistic group)
3. The Nakanai Mountains (Mamusi ethnolinguistic group)
Each location represented a distinct population group and different rainforest type so as
to minimise the likely overlap in plant species revealed by any subsequent
ethnobotanical survey.
New Britain is Papua New Guinea's largest offshore island comprising 36,520 sq km of
land area, almost all of which is forest covered; the climate is described as tropical-wet
receiving between 3000mm to 6000mm of rain per annum (Lamoreux, 2001). The island
was never attached to mainland New Guinea but instead emerged from the ocean floor
as a result of volcanic activity during the late Miocene period (8-10 million years ago)
and as a result most of the soil is either acidic volcanic or limestone (Mueller-Dombois,
1998).
The forest is predominantly lowland in type but the backbone of the island is punctuated
by several mountain ranges providing extensive areas of terrain between 1000m and
2000m isolated from each other by lowland forest (Lamoreux, 2001). The boundary
between lowland and montane forest is set at 1000m at which point the forest height,
leaf and crown size diminishes, the temperature drops and the humidity increases
(Mueller-Dombois, 1998). There are currently no comprehensive modern botanical
datasets for New Britain, and much of the area is unknown in terms of biodiversity for
any taxa (Sekhran, 1994).
In each fieldwork location, several informants were independently interviewed in the
local Neo Melanesian dialect about the uses of medicinal plants and an extensive list of
local plant names, uses and mode of preparation were recorded. Voucher specimens of
each plant were collected and sent to the Papua New Guinea Forest Research Institute
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for taxonomic identification. In many cases specimens were not fertile and so
identification to the species level was not possible. Care was taken to only include plants
whose uses could be independently verified by at least two separate sources. In the Bulu
language group area (Williamez Peninsula) this was done by carrying out the study in
two separate villages but in the Whiteman Range and Nakanai Mountains this was not
possible.
A limitation of the ethnobotanical methodology was the lack of first hand evidence for
the use of individual species. The number of times the author was able to observe plants
being prepared and used to treat specific ailments was very limited indeed. This may be
due in part to the rarity with which plants are used or to the increasing availability of
commercially produced medicines available in towns on the edge of the forest. Some
informants described the use of amoxicillin capsules which could be broken open and
the contents applied directly to tropical ulcers so as to avoid the expense of a full course
of treatment.
Despite this, in each location the respondents were able to name and describe a wide
variety of species used for a range of medicinal purposes, many of these consistent with
an antibacterial type role. These included the treatment of infected cuts, eye infections
similar to conjunctivitis, dysentery, respiratory infections and tropical ulcers. Amongst
the coastal populations (Williamez Peninsula) dysentery was the most common
microbial-associated use for plants whereas in the Whiteman and Nakanai mountain
ranges, tropical ulcers represented the most frequent condition plants were used to treat.
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Figure 3.2 Location of field work sites on the island ofNew Britain, Papua New Guinea. Adapted from
tactical pilotage chart M-14D produced by the RAAF, Victoria Barracks, Melbourne, Australia.
3.3.1.1 Location 1. The tip of the Williamez Peninsula
The Williamez peninsula is a remarkable physiographic feature, (Swartzendruber, 1993)
and includes a very diverse area of lowland rain-forest on rich volcanic soils
(Swartzendruber, 1993). The forest is almost entirely lowland although there are several
volcanoes approximately 1000m in height. The climate is monsoonal giving rise to a
distinct dry season. The local population forms a distinct ethno-linguistic group called
the Bulu and number approximately 600 (Johnston, 1980). Their villages and hamlets
are distributed exclusively along the coastal shoreline and in the centre of the peninsular
is a large caldera lake but it supports little aquatic life.
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Amongst the plants used by the villagers was Derris alata whose roots were employed
as a fish stun poison. The roots are first pounded to release the sap and then packed into
crevices in the surrounding coral reef. This caused the fish to become paralysed so
allowing them to be easily taken from the water. Derris spp. are known to contain
rotenoids that bind NADH:ubiquinone reductase (complex I) of the respiratory electron
transport chain (Crombie and Whiting, 1998) thereby inhibiting mitochondrial
respiration.
Of the 59 plants recorded in the ethnobotanical survey only 9 were used as topical
antiseptics whereas 16 were used as either emetics, stomachics or to treat dysentery. The
remaining plants were used in variety of roles including poisons, asthma type use and as
analgesic/anti-inflammatory agents. It was claimed by the villagers that the water from
the caldera lake in the centre of the peninsula was useful in treating tropical ulcers which
are a common infective lesion in Papua New Guinea. It is conceivable that the extremes
of pH found in such lakes could have produced an antibacterial effect thereby decreasing
the emphasis on antiseptic plants that is found in other parts of Papua New Guinea.
Many of the 59 plants assayed with the field kit gave rise to faint l-2mm zones of
inhibition but these were not considered sufficiently active to merit collection of
samples.
3.3.1.2 Location 2. The foothills of the Whiteman Range
The second fieldwork site was centred on the village ofUmbi in the foothills of the
Whiteman Range at an altitude of approximately 500m. The local population who are an
inland subgroup of the Kaulong linguistic group farm and hunt in forest up to
approximately 1000m above sea level and so inhabit the ecotone between lowland forest
and the lowermargins of lower montane forest (Whitmore, 1984). The inland Kaulong
are a small group numbering only a few hundred who practice a form of swidden
agriculture made necessary by the poor soil quality which is a feature of the
mountainous limestone karst terrain.
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The Whiteman Range and its foothills are said to support an important tract of limestone
flora and forest developed on sedimentary materials (Swartzendruber, 1993). The area is
little explored botanically, but large tracts ofNothofagus forest are thought to occur on
the higher plateaus (Swartzendruber, 1993).
46 plant species were recoded in the ethnobotanical field work and of these 19 were used
to treat tropical ulcers, in each case either the sap from the relevant part of the plant or a
mulch made from the plant was applied directly to the ulcer. In four cases plants were
mixed with CaOH made by heating limestone from local deposits to form CaO and then
adding water. Little mention was made by informants of non-plant derived medicines
although the fat from a species of eel was reputedly used to treat Tinea imbricata skin
infections. The most active plant species revealed with the field assay were a species of
Garcinia (tentatively identified as Garcinia dulcis (Roxb. Kurz) known in the local
Kaulong dialect as Kap and a bitter bark tree identified as Lunasia amara (Blanco)
known locally as Avyai. Both trees were identified from infertile voucher specimens
collected in forest within a 15km radius of the village of Umbi; the collection locations
are shown below.
Lunasia amara (Blanco) Garcinia dulcis (Roxb.) Kurz
Bark extracts of both trees provided clear zones of inhibition against S. epidermidis but
not against E. coli. Informants had described the use of shavings from the bark of
Lunasia amara and the yellow sap from the bark of Garcinia dulcis which were applied









3.3.1.3 Location 3. The Nakanai Mountains
The third location was centred on the mountainous region immediately east of the
Nakanai plateau which provided extensive montane forest terrain above 1000m. The
Nakanai Plateau is an uplifted limestone-capped formation reaching above 2000m at its
highest point. It is the largest high altitude area in New Britain and is little surveyed and
apparently biotically rich (Swartzendruber, 1993). The area is dominated by Lithocarpus
and Nothofagus forest developed on the limestone substrate (Swartzendruber, 1993).
The local population form part of the Mamusi ethno-linguistic group which extend from
the south coast up in to the central mountains.
Respondents provided 19 species of plants and three species of insects that were used
medicinally, of which 14 were used for the treatment of tropical ulcers. In the assay all
but 6 preparations failed to give some sort of zone of inhibition with the field assay. One
single preparation stood out amongst the other in terms of its activity which was a
defensive secretion produced by a brightly coloured species of stick insect later
identified as Megacrania nigrosulfurea (Redtenbacher).
When the insect is approached it fires either a fine spray or a stream of pungent smelling
white fluid from glands located dorsally on the second segment of its body. 20pl of the
secretion were assayed in wells giving zones of inhibition 22mm and 20mm in diameter
with S. epidermidis and E. coli respectively. The local name in the Mamusi dialect for
the insect is Kain tagho which translates literally as "eats Pandanus sp." (specimens of
the insect that were caught in the field were generally found feeding on the leaves of a
spiny bush tentatively identified as Pandanus tectorius). To gain sufficient quantities of
the insect a specimen of Pandanus tectorius was uprooted and placed in an area of open
cleared ground. Insects collected from the surrounding forest (see below for precise
location) were then placed on the plant and were found not to stray from its shade.
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Megacrania nigrosulfurea (Redtenbacher). 05° 40.004S
151° 05.551E
Alt 847m
Collecting the defensive secretion proved too difficult so when approximately 100
insects had been collected they were placed directly into ethanol for shipping to the UK.
3.4 The phagedenic ulcer
The tropical or phagedenic ulcer (Fig. 3.3) is a common infection amongst forest
dwelling populations of Papua New Guinea and so featured occurred frequently in the
ethnobotanical survey. The ulcer forms a distinct circular lesion of the skin causing
necrosis of the dermal and epidermal layers that rapidly develops into a lesion a few
centimetres in diameter within a few days (Adriaans and Drasar, 1987). The ulcer
commonly affects lower parts of the leg which are particularly prone to infection after
minor trauma such as a scratch or insect bite in the hot, humid tropical conditions;
malnutrition is also thought to be a contributing factor (Braun-Falco, 1991).
The aetiology of the ulcer is not entirely clear although it is thought the ulceration may
be preceded by a banal Streptococcal or Staphylococcal infection (Braun-Falco, 1991).
The term tropical ulcer has been used to describe ulcerating infections caused by a
variety of different organisms which in fact represent distinct diseases. These include the
Buruli ulcer whose causative agentMycobacterium ulcerans gives rise to sporadic
outbreaks of infection as well as the rapidly developing frambesia ulcer associated with
Treponema pertenue (Andrews, 1990).
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Amongst the natives ofNew Guinea the terms used to describe tropical ulcers are no
more discriminatory and as such it must be inferred that plants used to treat tropical
ulcers are in fact used in the treatment of several distinct ulcerative infections.
Figure 3.3. Application ofLunasia amara bark to a tropical ulcer. Fresh bark scrapings were placed in a
leaf and applied directly to the eye of the ulcer.
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The phagedenic tropical ulcer is thought to be caused by a polymicrobial infection with
fusobacteria, aerobic microorganisms and spirochaetes each playing a role (Adriaans and
Drasar, 1987). Adriaans et al (1987) isolated fusobacteria from samples taken from
patients in Papua New Guinea, India, Zambia and Gambia revealed the presence of a
species of Fusobacterium distinct from known members of the genus in terms of
morphology, biochemistry and cell wall composition (Adriaans and Drasar, 1987).
Spirochaete isolates have also been identified by electron microscopy as belonging to
the genus treponemes (Adriaans and Drasar, 1987).
3.5 The active species
In total over 200 species of plants and 3 species of insects were screened using the field
assay kit. Many of these gave small zones of inhibition (8-10mm including the well) but
three in particular stood out as having clear antibacterial activity against one of the two
test species; these were:
1. Garcinia dulcis (tentative identification)
2. Megacrania nigrosulfurea (Redtenbacher)
3. Lunasia amara (Blanco)
Garcinia dulcis and Lunasia amara were identified by Robert Kiapranis of the Forest
Research Institute Papua New Guinea from infertile voucher specimens whilst the
phasmid insectMegacrania nigrosulfurea was identified by Dr Oliver Zompro of the
Max Planck Institute for Limnology, Germany from specimens collected into 100%
methanol and colour photographs.
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3.5.1 Garcinia dulcis
Garcinia dulcis (Roxb.) Kurz is a medium sized tree with smooth evergreen leaves
which produces an edible fruit a few inches in diameter. The Garcinia genus falls within
the Guttiferae and consists of 180 species ofmostly evergreen trees distributed
throughout tropical Asia, Africa and Polynesia (Ansari et al., 1976).
Figure 3.4. Garcinia dulcis. Taken from the internet site
http://www.tradewindsfruit.com/order_fruit_f_o.htm
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The genus has attracted considerable attention in recent years as a source of novel
flavanoids, benzophenones and xanthones (Harrison, 1994). The bark is known in
Thailand for its antiseptic properties and in Indonesia its leaves are used in the treatment
of various disorders including lymphatitis, parotitis and struma (Likhitwitayawuid et al.,
1998). Xanthones, a type of flavanoid are widely distributed in the genus and have been
associated with a variety of pharmacological activities including antibacterial, antifungal
and antimalarial activity (Kosela et al., 2000). Rubraxanthone isolated from Garcinia
dioica has what is thought to be the lowestMIC for MRSA strains (0.31-1,25pg/ml)
recorded for a plant derived compound (Iinuma et al., 1996).
A number of compounds have been isolated from G. dulcis (Fig. 3.5); Ansari et al
(1976) isolated a series of biflavanoids and a flavanone-chromone from the leaves
(Ansari et al., 1976) whilst extraction of the branches yielded a novel xanthone, the
triterpenoid friedelin and three flavanoids 3'-(3-methylbut-2-enyl)naringenin, 13,118-
biapigenin and podocarpusflavoneA (Harrison, 1994). Five further xanthones were
isolated from the bark all of which displayed inhibitory activity towards the malarial
parasite Plasmodiumfalciparum, with IC50 values of between 0.96 and 3.88pg/ml
(Likhitwitayawuid et al., 1998). A further four dulxanthones were isolated from the
leaves by Kosela et al (Kosela, 1999), (Kosela et al., 2000).
A quantity of the bark was collected for laboratory analysis and once in the lab it was
apparent the active principles were extremely hydrophobic since they readily extracted
into hexane but not at all into water. A hexane extract of the bark re-suspended in
methanol gave MICs of lpg/ml against both sensitive and drug resistant (MRSA) strains
of S. aureus (NCTC 6751 and NCTC 12493) using the standard agar dilution method
for sensitivity testing stipulated by the British Society for Antimicrobial Chemotherapy
(Andrews, 2001). A variety of extraction and separation schemes were applied to the
bark including normal phase HPLC using hexane and ethylacetate as eluents but none of
these afforded fractions of sufficient purity to allow structural characterisation of active
principles. Thus despite the promising antibacterial activity of the bark extracts the
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inherent limitations of normal phase HPLC meant that isolation of pure compounds
would prove unlikely and further work with the plant was not carried out.
Ri R2 R3 R4 Rs R6 R7 Rs
HHHHHHHH
H H OH OH H H H
Me OH H X^- OH OH H H
H OH H X^ OH OH H H
H H OH H OH OH
Figure 3.5 Xanthones isolated from the bark of G. dulcis by Harrison et al (Harrison, 1994). Complete side
chains including the -R stem are shown for clarity.
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3.5.2 Megacrania nigrosulfurea
Megacrania nigrosulfurea (Redtenbacher) belongs to the order Phasmatodea which
includes both the leaf and stick insects (Redtenbacher, 1908). There are at least 3,000
described species of phasmid the majority ofwhich occur in the tropics; they are
predominantly arboreal and nocturnal (Whiting et al., 2003).
Figure 3.6. Megacrania nigrosulfurea (Redtenbacher) adult and nymph on a Pandanus sp. leaf.
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The name phasmid is derived from their ability to camouflage themselves with their
surroundings and as such they are characterised by the use of morphological and
behavioural crypsis to mimic sticks and leaves (Whiting et al., 2003). In the case ofM.
nigrosulfurea however the black and orange and black and yellow stripes seem to
indicate an aposematic colouring scheme. A second morphological characteristic of the
Phasmatodea is the presence of prothoracic repellent glands (Whiting et al., 2003) which
can be used in one of two ways, either to spray a narrow jet of fluid at the predator itself
or to spray a fine mist of the defensive secretion so as to cover the body of the insect and
make it unpalatable to the predator (Bouchard, 1997).
M. nigrosulfurea is only known from the type material collected by Redtenbacher in
1908 and therefore until rediscovered during this fieldwork project had not been
recorded in almost 100 years (personal communication Dr Oliver Zompro). As such
there is no information on compounds derived from the species but analysis of the
defensive secretions of other insects in the order have been carried out. Chow et al
(1986) isolated five odour compounds from the secretions of the related species
Megacrania alpheus and identified the major component as the monoterpene alkaloid
actinidine (Fig. 3.7) which has also been isolated from the rove beetle, dolichoderine
ants and the Argentine ant (Chow, 1986). They also determined that insects deprived of
the secretion stood a greatly reduced chance of surviving to maturity indicating an
adaptive role for the secretion.
CH3
Figure 3.7 Actinidine isolated from the defensive secretions ofMegacrania alpheus.
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More recently, eight constituents were isolated two of which were revealed to be
stereoisomers of l-acetyl-3-methylcyclopentane and the remaining six were tentatively
assigned as derivatives of actinidine by comparison with authentic samples on GC-MS
(Ho, 1993). Intriguingly, actinidine was also found in the leaves of the insect's dietary
plant Pandanus tectorius suggesting the phasmid not only concentrates the alkaloid to
form its secretion but chemically modifies it as well (Ho, 1993). Other constituents
isolated from insects within the order include the monoterpenes iridodial and
nepetalactone along with benzaldehyde, benzothiazole, limonene, diethyl ether and
acetic acid (Bouchard, 1997).
A number of the insects were collected for analysis rather than the defensive secretion
itself which proved too problematic to collect and these were later tested along with the
methanol the insects were collected into but the antibacterial activity could no longer be
detected.
2.5.3 Lunasia amara
The genus Lunasia (Blanco) is almost exclusively Malesian; specimens described by
Hartely in his revision of the genus have been found throughout the Philippines, Borneo
and Java through to Papua New Guinea as well as the Cape York Peninsula of Australia
(Hartley, 1967). Members of the genus are typically dioecious, evergreen erect shrubs or
small trees and are distinguished by their trimerous flowers arranged in small head like
clusters which do not occur in other genera of the Rutaceae. Although Lunasia is
extremely variable in certain vegetative features these do not correlate to specific
ecological habitats and as such, variant sub-types to do not represent distinct species
(Hartley, 1967). Thus various members of the genus such as L. costulata and L.
quercifolia are in fact all the same species Lunasia amara. Hartly recognises two
varieties; L. amara. Var. amara occurs throughout Malesia whereas var. babuyanica is
restricted to the Philippines. Hartley states that the genus is confined entirely to
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lowlands (up to 900m) and grows in habitats ranging from well drained rain forests to
secondary re-growth and dry thickets. In contrast to this, samples of Lunasia collected
for this project were all observed to be found growing next to or partly submerged in
fast flowing water (Fig. 3.8).
Figure 3.8 Lunasia amara (Rutaceae) is a small tree up to approximately 5m in height with variable
vegetative features. The wood is very hard and the bark extremely bitter tasting.
Lunasia spp. are reported to be used in native medicines of the Philippines and Indonesia
for the treatment of snake bite, skin diseases, swollen limbs, inflamed eyes as well as
digestive disorders for which it is taken internally but only in small quantities otherwise
side effects such as cramps and vomiting are said to occur (Hartley, 1967). There are
several reports of Lunasia barks being used as arrow poisons (Hartley, 1967) but later
investigations by Brill and Wells (1917) were unable find any evidence to support this
(Wells, 1917). The story is thought to have emerged as a result of shipments of
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Lophopetalum toxicum mis-labelled as Lunasia amara being sent to European
laboratories at the beginning of the 20th century (Wirth, 1931). This taxanomic error
seems to have been compounded by Blanco's original description of the species in
which he states "The grain is very fine and close, and the wood is so hard that the
Negritos use it instead of iron for the points of their arrows."
Father Juan J. Delgado a catholic missionary writing on the indigenous uses of
Philippino plants in 1892 describes the use of certain Lunasia spp. referred to locally as
Paetan, in treating infected wounds. He states, "it is admirable for infected wounds, for it
will clean and cure them in a short time" (Delgado, 1892). He also describes how
"merely chewing a small bit of its bark, I was hardly able to that day to remove the
bitterness from the tongue, experiencing some sort of convulsions for three days"
(Delgado, 1892). Delgado translates Paetan to mean "bitterness itself', perhaps a
reflection on the high alkaloid content of the bark.
Various studies have been carried out into the phytochemical constituents of different
Lunasia spp. and a number of compounds have been isolated and their structures
determined. Of all the plant families the Rutaceae is the most prolific in terms of the
structural variety of alkaloids it produces which include acridines, furoquinolines,
quinolines, quinazolines, indoquinazolines, canthinones, imadazoles, benzoisoquinolines
and aromatic amines and amides (Price, 1963). From the bark and leaves of L. amara 13
quinoline type alkaloids have been isolated (Fig. 3.9) starting as far back as 1899. The
bark is particularly rich in alkaloids with an alkaloid content reported to range from 4 to
4.5 % for Australian samples (Johnstone, 1958).
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2.5.3.1 Compounds isolated from the bark of Lunasia amara
The stem bark contains the alkaloid lunasine as the principal alkaloid (Collins, 1990)
together with 12 other structurally related quinoline type alkaloids. Boorsma isolated
lunasine, lunacrine and lunacridine (Henry, 1939) whilst Steldt and Chen (1943) isolated
lunacrine, lunacridine, lunamarine, lunamaridine by sequential extraction with a range of
solvents followed by crystallisation but lunasine was not isolated which the author states
may be due to its decomposition to lunacridine upon reaction with NaOH in the
extraction solvents (Steldt, 1943). Johnstone et al (1958) isolated lunacrine, lunine, and a
new alkaloid eduleine from the Australian variety L. quercifolia now recognised as the
same species as L. amara by filtering a benzene extract though aluminia followed by
numerous rounds of acid/base extraction and crystallisation (Johnstone, 1958). In their
samples lunacrine was the major alkaloidal component. Price (1959) isolated lunasine by
reaction of the water soluble bases with picric acid followed by several rounds of
crystallisation and using UV and IR spectroscopy was able to determine the structures of
lunasine and lunacridine (Price, 1959). Ruegger and Stauffacher (1963) isolated
hydroxylunidine, hydroxylunacridine, lunacridine, lunacrine as well as two new
alkaloids lunidine and lunidonine by alumnia chromatography eluting with increasingly



















Figure 3.9 Compounds isolated from the bark of Lunasia amara
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2.5.3.2 Compounds isolated from the leaves of Lunasia amara
Goodwin and Horning (1957) isolated a number of alkaloids from the leaves. 7
compounds were eluted from aluminia but only one 4 methoxy 2 phenyl quinoline was
described (Goodwin, 1957). More recently, steam distillation of the leaves by Brophy et
al produced an oil which when analysed by gas GC-MS was revealed to be almost
entirely composed of sesquiterpenoids, the principle components being y-elemene,
germacrine-D and bicyclogermacrine (Brophy, 1997).
Figure 3.10 4-methoxy-2-phenyl-quinoline
2.5.3.3 Biological activities of L. amara alkaloids
In a 1955 survey of 150 flowering plants collected in Queensland, Australia and New
Guinea and tested for antibacterial activity, L. amara bark appears as one of the two
most active species producing 3-5mm zone of inhibition for Salmonella typhi S76 and >
7mm for S. aureus B313 and Mycobacterium phlei CSL (Atkinson, 1956). Indeed, of the
18 species of Rutaceae tested, only one failed to show any antibacterial activity. The
methods used however included applying dried plant material in unspecified amounts
directly to agar plates so cannot be considered in any way quantitative.
105
The alkaloids lunacrine and lunasine were studied by Wirth in 1931 for their
pharmacological activity. Both alkaloids show a similar profile in terms of their action
on various muscle tissues but lunasine is the more potent of the two (Wirth, 1931). The
two alkaloids were found to have a stimulatory effect on voluntary and smooth muscle
as well as stimulating the contraction of blood vessel walls and decreasing cardiac
output but no anaesthetic action on sensory or motor nerves and or the sympathetic
ganglion was found (Wirth, 1931). Wirth also indicates the two alkaloids have an
inhibitory effect on certain protozoa but from the 1931 text it is not clear what species or
at what concentration the stated antimicrobial effects occur.
Steldt and Chen (1943) investigated the cardiac effects of lunacrine, lunacridine,
lunamarine and lunamaridine and found none of the four alkaloids to cause systolic
standstill when injected into the ventral lymph sac of a frogs heart thereby disproving
the notion of Lunasia alkaloids being cardiac poisons with a digitalis like actions as had
been indicated by some authors (Steldt, 1943). In etherised cats intravenous injections of
lunacrine hydrochloride 15mg or lunacridine lOmg caused a moderate fall in blood
pressure with recovery occurring within 2 minutes and a reduction in the amplitude of
respiration. Injection of lunamarine resulted in an initial drop in carotid pressure
followed by a secondary increase (Steldt, 1943). Lunamarine was also found to stimulate
isolated rabbits intestine and uterus at a concentration of 1:200 000. No significant
changes in blood sugar concentration were found to occur when three of the alkaloids
lunacrine 50mg/kg, lunacridine 5mg/kg lunamarine 0.4mg/kg were injected into rabbits
(Steldt, 1943).
Toxicity experiments were also carried out to determine the median lethal dose in albino
mice of each compound. The median lethal dose of lunacrine hydrochloride by IV
injection was 78.7mg/kg whilst the median lethal dose of lunacridine by mouth was
1097mg/kg. Doses as high as lOOOmg/kg lunamarine were not fatal (Steldt, 1943).
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When a fraction of L. amara water soluble bases was tested on mice, doses of 50 to 100
mg/kg produced ledge unsteadiness and ataxia whilst 500mg/kg resulted in death in 1 to
5 hours (Collins, 1990). In anaesthetised cats, doses of 20 or 40mg/kg induced
cardiovascular depression for 10-20 minutes whilst in isolated rabbit ileum 0.001-
O.Olmg/ml antagonised furmethide-induced spasm. The fraction displayed weak
antimicrobial activity againstMicrococcus pyrogenes, Diplococcus pneumoniae,
Klebsiela pneumoniae and Trichophyton mentagrophytes at 120pg/ml but was inactive
against Newcastle disease virus and adenovirus type 4 (Collins, 1990). Furoquinolines
similar to those found in Lunasia Spp. have been associated with phototoxicity towards
bacteria, viruses, yeasts and CHO cells. Their mechanism of action is thought to involve
the formation of photoadducts with DNA (Paulini et al., 1989).
Several kilograms of Lunasia amara bark were collected for laboratory testing and due
to the general paucity of information concerning the antimicrobial activity of Lunasia







4.1 Purification by open column chromatography
Open column or low pressure chromatography are terms used to describe all forms of
chromatography in which the movement of the mobile phase though the stationary phase
is gravity fed (Robards, 1994). It is the oldest from of chromatography and one of the
cheapest to perform since it does not require the highly engineered parts found in closed
systems such as HPLC and GC. Since different analytes in the sample mixture have
varying affinities for the mobile and stationary phases they separate out as they pass
through the column and are eluted at different time intervals.
The role for medium pressure chromatography in natural product separations should be
considered an initial cleanup step before more powerful separation methods such as
HPLC are applied. By reducing the amount of material loaded onto HPLC columns,
more efficient separations can be achieved. Samples chromatographed through open
column media have the added advantage that fine particles as well as high molecular
weight compounds such as tannins and proteins have been removed. Where the
composition of the sample mixture is not known or in this case the compound of interest
is unknown, it is impossible to accurately predict which conditions will favour a good
separation so this must be determined through trial and error followed by successive
rounds of optimisation.
Various chromatographies were trailed in a search for methods that could be combined
to form a protocol for the activity-guided purification of the active principle(s). In each
case, fractions were collected and assayed to check if the activity had been released from
the column and elution profile graphs were produced to determine the quality of the
separation. For convenience only a fraction of all the separations carried out are depicted
in this section.
The separation techniques employed generated a large number of pure or partly pure
fractions and so a simple easily reproducible assay was therefore needed to detect the
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activity in each fraction. The well method in which up to lOOpl of each fraction is
injected into pre-cut wells 6mm in diameter on plates inoculated with a bacterial culture
(S. aureus NCTC 6571) was found to work well with un-concentrated fractions whilst
fractions with higher activity were assayed using the disk diffusion method.
4.2 Optimising the extraction protocol
Before starting the purification of the active principle(s) it was necessary to optimise the
extraction of the bark to form a crude extract that contained the all the antibacterial
activity of the bark in the smallest possible volume of solvent. Solvents of increasing
hydrophobicity were tried revealing ethanol and water as possible candidates (Fig. 4.1).
These were then used at a range of proportions of solvent to bark (ground to a fine
powder) and after each extraction the extracted bark was re-extracted and assayed to
determine how much residual activity remained (Fig. 4.2). The minimal volume of
solvent that left no residual activity in the bark was then adopted for all future
experiments.
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Figure 4.1 Aqueous, ethanolic, acetone and chloroform extracts made by extracting lOOmg of powdered L.
amara bark with 1 ml of water, ethanol, acetone and chloroform were applied to a plate inoculated with S.
aureus NCTC 6571. 50|xl of each extract and solvent alone as controls were injected into wells and the
plate incubated overnight.
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Figure 4.2 Determining the optimal extraction conditions. Ethanolic and aqueous extracts were made with
varying ratios of bark powder to solvent. After vortexing thoroughly the extract was centrifuged and the
extract removed. The extracted bark powder was then re-extracted with 1ml solvent and 50pl assayed in
wells to detect residual activity left behind from the first extraction.
The plates suggest water and ethanol as suitable extraction solvents and in each case
50mg bark powder per 1ml solvent is the highest extraction ratio that can be used
without leaving behind residual activity in the bark.
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4.3 Trialling different open column techniques
A variety of separation techniques were applied to the L. amara bark crude extract
including adsorption chromatography on silica, gel filtration with Sephadex LH-20, and
ion exchange using DEAE and CM52 resins. The most effective chromatographies were
then combined to attempt the complete purification of the active principle(s). In the
following experiments dried L. amara bark was ground in a mortar and pestle in the
proportion 1ml of water/50mg dried bark. This produced a dark coloured liquid which
was filtered though Whatman No 1 filter paper to remove fine particles. Elution profile
graphs were produced by recording UV absorption (optical density) for each fraction at
280nm.
4.3.1 Silica adsorption chromatography
Classical silica column chromatography has been used with some success in the
isolation of plant alkaloids so it was decided to begin with this approach. The separation
mode is by adsorption chromatography in which solute molecules compete for active
sites on the stationary phase which is coated in a layer of mobile phase molecules
(Snyder, 1968). Solute retention occurs by either association with or displacement of the
adsorbed mobile phase molecules. As can be seen from the elution profile graph below
however, elution with ethanol/water 4:1 afforded very minimal separation of the bark
extract.
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Figure 4.3 Silica Gel was swelled in ethanol/water 4:1 and then poured into a plastic column and allowed
to bed out (bed size 2.4cm x 11.3cm) before running with more solvent to wash away impurities. 4ml of
the aqueous bark extract were then loaded into the column and eluted with 80ml ethanol/water 4:1
collecting fractions automatically every 2ml and recording UV absorbance (optical density) at 280nm.
Each fraction was concentrated to approximately 300pl volume and 80pl of each
assayed in wells but none of the fractions contained any activity.
The experiment was repeated eluting with methanol/water 4:1 to see if this would
improve the separation but after assaying each fraction in wells there was still no
detectible activity.
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Elution profile of aqueous extract run on a silica column and
























Figure 4.4 Separation of crude extract on silica. Bed size of column was 2.7cm x 3.8cm and eighty 5ml
fractions were collected.
Next, to try and reduce the strong adsorption seen with standard silica gel, a column was
set up using Florisil (activated Magnesium Silicate) and ran as before collecting fifty
3ml fractions. lOOpl of each fraction were assayed in wells but as before none of the
fractions contained any activity.
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Elution profile of aqueous extract run on a florisil column
eluting with ethanol/water 4:1
| 1.2
O
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Elution volume (ml)
Figure 4.5 Florisil powder was swelled in methanol/water 4:1 and then poured into a plastic column and
allowed to bed out (bed volume 1,6cm x 7.5cm) before running with more solvent to wash away
impurities. 2ml of the aqueous bark extract were then loaded into the column and eluted with 150ml
methanol/water 4:1 collecting fractions automatically every 3ml and recording UV absorbance at 280nm.
4.3.2 Sephadex LH-20 gel filtration chromatography
Sephadex LH-20 is a dextran-based gel that separates compounds according to size (gel
filtration) and is ideally suited to the separation of small molecule natural products such
as steroids, terpenoids, lipids and low molecular weight peptides (Pharmacia, 1987). LH-
20 is manufactured by hydroxyl propylation of cross linked dextrans which are formed
into beads 23-163 microns in diameter when swelled in methanol (Pharmacia, 1987).
The dextran beads contain numerous pores which small molecules may permeate into
with varying ease depending on their size. Large molecules do not enter the pore at all
and are eluted at the volume of solvent equivalent to the interstitial column volume
whereas intermediate sized molecules are able to permeate into the pores and are eluted
at varying intervals depending on their size. Thus LH-20 acts as a kind of reverse sieve
in which larger compounds may elute before smaller ones.
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A Sephadex LH-20 column was tried next to see if it would give some degree of
separation without the strong adsorption seen with silica.
Elution profile of aqueous extract run on a Sephadex LH-20
column eluting with ethanol
0 50 100 150 200
Elution volume (ml)
Figure 4.6 Sephadex LH-20 was swelled in ethanol and poured into a plastic column to form a bed size of
2.5cm x 40cm. 2ml ethanolic bark extract pre-filtered through a 0.20pm disposable syringe filter were
loaded into the column which was then eluted with ethanol collecting eighty 3ml fractions. UV absorbance
at 280nm was recorded for each fraction.
lml of each fraction were evaporated to dryness and taken up in 50pl water which was
then assayed in wells. Two fractions corresponding to 105-108ml elution volumes gave
zones of inhibition indicating the active principles were eluted from the column in the
first of the two large peaks.





Table 4.1 Zones of inhibition from LH-20 gel filtration fractions.
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Thus activity was released from the column which afforded some separation of the bark
extract suggesting LH-20 gel filtration as a potential step in the purification of the active
principles.
4.3.3 Diethylaminoethyl-cellulose anion exchange chromatography
Diethylaminoethyl-cellulose (DEAE-cellulose) is an anion exchange media useful in the
separation of sample analytes containing negatively charged compounds which may
bind to its positively charged amide group. A Dowex anion exchange column (bed
volume 19cm x 1.7cm) was set up and equilibrated in lOmM pH 7.0 HC1 Tris buffer.
The column was loaded with 2ml of the aqueous bark extract and eluted with a flow-
through of 50ml lOmM Tris buffer collecting fiftylml fractions. The column was then
eluted with a salt gradient to wash off bound material. A gradient maker was set up with
25ml 1M NaCl lOmM pH 7.0 Tris in the high salt chamber and 25ml lOmM pH 7.0 Tris
in the low salt chamber. The column was eluted with the resulting salt gradient until
eighty 1ml fractions had been collected. A dark band was still visible at the top of the
column so a further elution was carried out with 25ml 3.0M MgCl2 lOmM pH 7.0 Tris.
Each fraction was concentrated to 300pl and 80pl from each, assayed in wells.
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Figure 4.7 Anion exchange chromatography of aqueous bark extract eluted with a pH 7.0 flow through
followed by a 0 to 1M KC1 salt gradient and a 3.0M MgCl2 salt wash.







Table 4.2 Zones of inhibition ffom dowex anion exchange fractions.
The assay reveals the active principle(s) to be eluted in the first peak of the flow
through; therefore they do not bind to the column. There is however some degree of
separation as three distinct peaks are present.
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4.3.4 CM52 cation exchange chromatography
Since anion exchange chromatography failed to bind the active principles the ion
exchange procedure was repeated using a carboxy methyl cellulose based resin (CM52)
which binds positively charged species.
Elution profile of aqueous extract run through a CM52
cation exchange column
1 21 41 61 81 101 121
Elution Volume (ml)
Figure 4.8 A CM52 column (bed size 2.7 x 7cm) was set up and equilibrated with 200ml 1M pH 7.0 Tris
followed by 500ml lOmM pH 7.0 Tris. 2ml of the aqueous bark extract was loaded into the column and a
flow through carried out in which the column was eluted with lOmM Tris collecting fifteen 3ml fractions.
A salt gradient was then set up in which the low salt chamber contained 10 mM Tris and the high salt
chamber 1.0 M NaCl lOmM Tris. The salt gradient was run for seventy 1ml fractions whereupon the
column was eluted with 3.0 M MgCl2 to elute any remaining bound material.
Elution volume Zones of Inhibition
Flow through 1 -45 0
Salt gradient 46-115 0
High salt elution 116-125 0
Table 4.3 Zones of inhibition from CM52 ion exchange fractions.
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The results show the active principle(s) were not released from the column even after
elution with 3.0M MgC^ suggesting a strong interaction with the column media and the
presence of a positive charge. The experiment was therefore repeated with increasing
salt concentrations during equilibration to try and decrease the binding capacity of the
column. The column bed size was kept the same throughout.
Elution profile of aqueous extract run on a CM52 column
























Figure 4.9 Elution profile of2ml aqueous extract run on a CM52 with a 200mM NaCI equilibration
followed by 3.0M MgCl2 elution.
No activity was recovered so the experiment was repeated equilibrating the column with
2.0M NaCI lOmM pH 7.0 Tris.
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Elution profile of aqueous extract run on a CM52 column


































Figure 4.10 Elution profile of 2ml aqueous extract run on CM52 with a 2.0M NaCI equilibration followed
by 3.0M MgCl2 elution.
As with previous experiments no activity was released from the column demonstrating
that even high salt equilibrations are unable to remove enough binding capacity from the
column to allow elution of the active principle(s). An alternative approach was needed
so the experiment was repeated at a range ofpH levels to see if this would weaken the
interaction through ion-suppression.
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Elution profile of aqueous extract run on a CM52 column
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Figure 4.11 A CM52 column was equilibrated with 1.0M pH 6.0 Tris followed by lOmM pH6.0 Tris. Fifty
3ml fractions were collected eluting with lOmM pH 6.0 Tris 2.0M NaCl and a further 30 fractions were
collected eluting with 3.0M MgCl2 lOmM pH 6.0 Tris.
The lowered pH failed to release the active principles from the column so the
experiment was repeated at pH 2.0 using citric acid HC1 as the elution buffer. The buffer
was made by dissolving sodium citrate powder in water and adjusting the pH with HC1.
After equilibrating the column with pH 2 2.0M NaCl it was eluted with 150ml of the
same buffer collecting fifty 3ml fractions.
123
(0
Elution profile of aqueous extract run on a CM52 column




































Figure 4.12 Elution profile of 2ml aqueous extract run on CM52 with a 2.0M NaCI pH 6.0 equilibration
followed by 3.0M MgCl2 pH 6.0 elution.
Further lowering the pH failed to release the active principles so a higher pH elution was
carried out to see if this would suppress some of the positive charge associated with the
active principles.
The experiment was repeated with a pH 7 and pH 9 elution using a smaller bed volume
of 2.8cm x 3.6cm and equilibrated inl.OM pH 7 Tris followed by 10 mM Tris. 2ml
aqueous extract was loaded onto the column, which was eluted with lOmM pH 7 Tris
collecting fifty 3ml fractions (elution volume 0-150ml) followed by a pH 9 Tris elution
(elution volume 151-510ml) and then a high salt elution with 3.0M MgCl2 pH 9.0 Tris
(elution volume 513-630). Fractions corresponding to each of the two peaks were pooled
and assayed by the well method.
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Elution profile of 2ml aqueous extract run on a CM52
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Figure 4.13 Elution profile of2ml aqueous extract run on a CM52 column with a 2.0M NaCl pH 6.0
equilibration followed by 3.0M MgCl2 pH 9.0 elution.
Elution volume Zones of Inhibition
PH 7 elution (first peak) 0mm
3.0M MgCl2 elution (second peak) 16mm
Control, equal volume of elution 0mm
buffer concentrated in the same
way
Table 4.4 Active fractions from CM52 chromatography
The results show a combination of salt elution and pH 9 running buffer is necessary to
elute the active principle(s) from the column. The experiment was repeated with a salt
gradient to allow a more gradual elution of active principle(s) and all at pH 9.0 to see if
the method could be simplified.
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Elution profile of 2ml aqueous extract run on a CM52 column



























Figure 4.14 Elution profile of 2ml aqueous extract run on CM52 column with a 2.0M NaCl pH 6.0













Table 4.5 Active fractions from CM52 chromatography
Two main peaks were resolved and activity was released from the column suggesting
CM52 ion exchange as another potential step in the purification of the active principles.
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4.4 Activity-guided fractionation of the aqueous bark extract
The three successful chromatography methods (gel filtration, anion and cation exchange)
were then put together to see if they could be used to isolate the active principle(s) from
the crude extract. A larger volume of the extract was used to ensure a high yield of
active compound(s).
4.4.1 Extraction and phase separation
25g dried Lunasia bark was ground to a fine powder in a coffee grinder and then
extracted with 500ml ethanol stirring magnetically for 30 minutes. The extract was then
filtered through Whatman No 1 filter paper and dried down in a rotary evaporator. The
resulting residue was taken up in 100ml water and defatted with 300ml chloroform
stirring thoroughly for 10 minutes. The aqueous phase was then freeze-dried and taken
up in 5ml water to form a highly concentrated extract.
4.4.2 Anion exchange chromatography
A Dowex column (bed size 3cm x 2.4cm) was set up and equilibrated with lOmM pH
7.0 Tris. The extract was eluted through the column with the same buffer collecting
twenty 5ml fractions. Each fraction was then assayed by the disk method.




Table 4.6 Active fractions from dowex column.
Fractions 1 and 2 were combined, freeze-dried and taken up in 5ml ethanol.
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4.4.3 LH-20 Gel filtration
A Sephadex LH-20 column(bed size 60cm x 3.2cm) was set up and equilibrated in
ethanol. The 5ml sample was loaded into the column and eluted with ethanol collecting
eighty 5ml fractions. Absorbance readings were taken by diluting 5pi of each fraction in
950pl water and vortexing thoroughly. Fractions were assayed by the disk method.
Elution profile of 5ml sample run on a Sephadex LH-20 column
eluting with ethanol
Elution Volume (ml)
Figure 4.15 Separation of the dowex anion exchange fractions on Sephadex LH-20








Table 4.7 Active fractions from the Sephadex LH-20 column.
Fractions 41-45 were dried down with a rotary evaporator and taken up in 5ml water.
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4.4.4. Cation exchange chromatography
A CM52 column was set up (bed size 9.5cm x 2.8cm) and equilibrated in pH 7.0 lOmM
Tris. The 5ml sample was loaded into the column and eluted on a flow-through with
lOmM pH 7.0 Tris for twenty 5ml fractions. The column was then eluted with a lOmM
pH 9.0 Tris 0.0M KC1 to 3.0M KC1 salt gradient collecting sixty 3ml fractions.
Elution profile of 5ml sample run of a CM52 column with a























Figure 4.16 Separation of the gel filtration active fractions on a CM52 column










Table 4.8 Active fractions from the CM-52 column
129
Fractions 59-63 were freeze-dried and taken up in 30ml ethanol/water 1:1 as the sample
would not dissolve in pure ethanol and would not dissolve at all in 5ml water or ethanol
due to the salt.
4.4.5. Desalting
The LH-20 column was washed through with 500ml ethanol and the 30ml sample loaded
into the column and eluted as before collecting eighty 5ml fractions.
Desalting of 30ml CM52 sample on a Sephadex LH-20





Figure 4.17 Desalting of the CM52 active fractions on Sephadex LH-20.







Table 4.9 Active fractions from desalting step.
Fractions 37-40 were combined, dried down and taken up in 1ml water.
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4.4.6. High performance liquid chromatography
200pl of the sample were run on an Applied Biosystems 130A HPLC using a 5p 4.6mm
x 250mm C-18 column and eluting on a half hour gradient from 20-100% solvent B
where solvent A was 0.1% TFA and solvent B 70% MeCN 0.08% TFA. The flow rate


















Optical density % solvent B
Figure 4.18 Separation of pooled active fractions from open column purification steps using HPLC.
The trace shows the presence of several different compounds so the remainder of
medium pressure chromatography sample was run under the same conditions 200pi at a
time collecting 10 fractions per run using the collect by time function on the fraction
collector. Each run gave a trace identical to that above. 50pl of each fraction was
assayed in wells as the disk method using 5pi gave no zones of inhibition.
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Fraction Zones of inhibition (mm)
1-3 0
4 (24 mins) 21
5-10 0
Table 4.10 Active fractions from HPLC separation.
Fraction 4 which corresponded to an elution time of 24 minutes was freeze-dried and
taken up in 2ml water but would not dissolve fully. The sample was freeze-dried a
second time and then taken up in 950pl water to which concentrated ammonia was
added 5pi at a time to see if raising the pH which would have been lowered due to
concentration of TFA in the sample would help increase solubility. After adding 30pl
ammonia, the insoluble material had completely dissolved and the final volume was
adjusted to 1ml with water.
The 1ml sample was then run on the HPLC 200pl per run, eluting isocratically at 30, 40,
50 and 100% B respectively using the same C-18 column and solvents as before.
However, it was found that the excessive tailing on peak 1 could be significantly
reduced by temporarily increasing the % solvent B up to 50 and then back down to 30
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Figure 4.19 HPLC active fractions re-separated on a C-18 column.
Each of the four peaks were freeze-dried and taken up in 5ml distilled water. 5pi of each
peak was assayed by the disk method. Only peak 1 was active and this was freeze-dried











Table 4.11 Active fractions from second HPLC separation.
4.5 Structure determination of sample
The sample was sent to Dr I. Sadler at the Ultra-High Field NMR Centre, Department of
Chemistry, University ofEdinburgh who used a combination ofH1, C13 NMR and mass
spectroscopy to gain an unequivocal characterisation of the highly pure single compound
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present in the sample. NMR spectra were recorded using a Varian INOVA 600MHz
spectrophotometer.
Analysis of the NMR and mass spectra of the sample showed it to be a 2'-0-
trifluoroacetyl derivative of lunacridine (MW = 401) (Fig.4.20). The mass spectrum
shows a molecular ion at 401 (exact measurement 401.145) and fragment ions at 304
(loss of CF3CO), 273 (loss of CF3CO and CH3O) and 69 (CF3) consistent with the
molecular formula C19H23F3NO5 (410.145). The ID proton spectrum obtained at 360
MHz using d4-methanol as solvent was well resolved and showed the presence of the
following fragments: a 1,2,3-trisubstituted benzene ring, a 3-methylbutyl group with a
single bonded oxygen at C-2 and three methyl groups directly bonded to oxygen or
nitrogen.
The carbon 13 NMR spectrum showed 19 signals: 2 CH3 groups attached to carbon, 2
CH3 attached to oxygen, 1 CH3 attached to nitrogen, one aliphatic CH2 group, one
aliphatic CH bonded to oxygen, one aliphatic CH bonded to oxygen, three aromatic CH
groups, 6 aromatic/carbonyl quaternary carbons and two signals from a CF3CO group
showing coupling to fluorine (the weak signal from the CF3 group was only visible in a
spectrum from a more concentrated solution).
Given the source of the material and its molecular formula, a lunacridine derivative
seemed likely and analysis of the 2-dimensional 1-bond (HMBC) and multiple-bond
(HMBC) proton-carbon correlation spectra confirmed this, and allowed unambiguous
assignment of all the proton and carbon signals. The 1-bond (HMBC) correlation
spectrum allowed the assignment of the protonated carbons except that distinction
between the two methoxy signals and the H/C-5 and H/C-7 signals was not possible at
this stage. The multiple bond (HMBC) spectrum resolved these assignments and also
allowed assignment of the non protonated carbons.
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The carbonyl group (C-2) was assigned by correlation with the N-methyl protons (the
carbon shifts of the other correlations being too low). The methoxy proton signals at
4.14d and 4.58d correlate respectively with the carbon signals at 150.4d and 162.4d.
The latter proton signal, but not the former, also correlates with C-2'. Thus the latter
corresponds to the 4-methoxy group and thus C-4 and C-8 are both assigned. This is
confirmed by the correlation of C-4 (but not C-8) with both H-l' signals and by the
correlation of C-8 (but not C-4) with the H-6 and the signal at 7.63d, which must
therefore be H-7 (and not H-5). C-8a is identified by correlation with the N-methyl
protons, not shown by the remaining quaternary at 126.7d which must therefore be C-4a.
C-4a assignment is confirmed by its correlation with H-5 and H-6. Other 2- and 3- bond
correlations are listed in the table and all are consistent with the proposed structure.
The trifluoroacetyl resonance assignments follow from the magnitude of the C-F
couplings. Since the parent molecule has a hydroxyl group at C-2' this must be the site
of trifluoroacetylation. For comparison purposes, literature values for the carbon-13
chemical shifts (obtained using CDCI3 as solvent) (Brown, 1980) of the non-
trifluoroacetylated lunacridine are given in parentheses in the table. Except for C-2', the
agreement is excellent. The 15 ppm increase in chemical shift of C-2' is expected for O-
trifluoroactylation.
Site 8C 8c SH proton Jhh (Hz) Proton - Carbon
Lit* multiplicity long-range correlations







5 115.2 (116.1) 7.98 (dd)
C-7, C-8a
6 127.4 (123.0) 7.70 (t) 8.1
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[^cf = 284 Hz]
[2Jcf= 37 Hz]
d = doublet, dd = doublet of doublets, dt = doublet of triplets, q = quartet, oc = octet, s =
singlet, t = triplet
§ = signal not reported w = weak signal








Figure 4.20 Structure of 2'-0-Trifluoroacetyl-lunacridine.
The compound is therefore the trifluoroacetyl derivative of lunacridine,
trifiuoroacetylation most likely having occurred during or after the HPLC step since
TFA was used as a mobile phase modifier.
4.6 Purification by HPLC
The isolation of Lunacridine by open column chromatography used numerous steps each
of which increased the chances of active principles undergoing chemical changes and
despite the range of separation media used HPLC was still required as a final step in the
purification. A second disadvantage of using a multistep protocol is an increased chance
of loosing active principles which may not be noticed if the lost compound is one of
several that contribute towards the total activity of the crude extract. Thus it was not
known whether the Lunacridine was the sole antibacterial ingredient in the crude extract
or if there were others that had been lost or degraded during one of the purification steps
and further more a trifluoroacetyl derivative rather than native lunacridine had been
isolated. It was therefore decided to develop a simplified two-stage protocol based on an
initial cleanup step such as phase extraction followed by a single well resolved HPLC
separation.
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4.6.1 Developing an initial cleanup step
A variety of phase extraction systems were trialled to see if the activity of the crude
extract could be partitioned into chloroform. 5g Lunasia bark was extracted with 100ml
ethanol and filtered through Whatman No.l paper. The ethanolic extract was evaporated
to dryness and the residue taken up in 50 ml water to make a standardised extract. 0.1ml
of various solvents, acids and bases then were added to 0.9 ml aliquots of the extract and
the mixture vortexed thoroughly with 2 ml chloroform to allow partition of the active
principles. In each case the optical absorbance at 280nm for the two different phases was
recorded and lOOpl samples of each assayed in wells.
Tube Extract Additives CHC13 Abs Abs ZOI ZOI
volume (0.1ml) volume 280nm 280nm Aq Organic
(ml) organic aqueous layer layer
layer layer
1 0.9 Water 2 0.402 0.540 14 0
2 0.9 Methanol 2 0.399 0.503 14 0
3 0.9 Ethanol 2 0.437 0.506 15 0
4 0.9 Butanol 2 0.531 0.531 16 0
5 0.9 Butan-2-one 2 0.517 0.517 15 0
6 0.9 Acetonitrile 2 0.495 0.575 16 0
7 0.9 Methanal 2 0.463 0.563 16 0
8 0.9 10%HC1 2 0.651 0.483 14 13
9 0.9 10% nh3 2 0.556 0.728 11 0
10 1.0 Made to 1M 2x3 0.113 0.669 0 15.5
KC1
Table 4.13 Phase extraction methods applied to the bark extract. In each case, UV absorbance at 280nm
were recorded for both the organic and aqueous layers along with zones of inhibition produced by
assaying lOOpl of each layer.
Table 4.13 shows KC1 to be the most effective additive since it partitions all the activity
of the bark extract into the chloroform layer and the absorbance readings suggest a large
amount of impurities are left behind in the aqueous layer. The method was further
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improved by back extracting the active principles into water as follows. At each stage
lOOpl of the aqueous sample were assayed in wells to check for loss of activity.
Step Sample/Purification step ZOI (mm)
1 5g finely ground Lunasia bark extracted with 100ml water
and filtered through Whatman No 1 paper.
18
2 Extract made to 1M KC1 17
3 Aqueous phase extracted thoroughly with 100ml chloroform
and the chloroform layer removed with a separating funnel
13
4 Aqueous layer re-extracted with a further 100ml chloroform 9
5 Aqueous layer re-extracted a third time with 100ml
chloroform
0
6 Chloroform layers combined and back extracted with 100ml
water vortexing thoroughly.
15
7 Aqueous layer removed and freeze-dried; the resulting
powder was then taken up in 5ml water.
N.A.
Re-extracted bark 8
Table 4.14 Optimised phase extraction method for L. amara bark extract. At each step 1 OOpil samples were
assayed in wells to check for loss of activity.
Comparison of the phase extracted sample with an aqueous extract reveals 79% of the
bark material (by mass) had been removed through the phase extraction process (Table
4.15). Although water is a less selective extraction solvent than ethanol it was included
in the extraction method to avoid an extra concentration step since ethanol is miscible
with chloroform.
Sample Solids present after freeze-dying or rotary
evaporation (grams)
5g bark extracted with 100ml water 0.72
5g bark extracted with 100ml ethanol 0.55
Phase extracted sample 0.15
Table 4.15 Comparison of the amounts of dried solids present in ethanolic, aqueous and phase extracted L.
amara bark extracts after concentration to dryness.
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4.6.2 HPLC optimisation
HPLC is a technique that has developed from classical silica column chromatography to
meet the demands ofmore difficult separations in which analytes may differ by only one
functional group (Robards, 1994). The increased performance over open column
techniques is achieved through the use of column packings with reduced particle size (3-
5 microns in diameter) which allow increased mass transfer between mobile and
stationary phases. The small particle size also minimizes the effect of eddy diffusion that
arises as a result of the differing flow paths an analyte molecule may take to pass around
stationary phase particles. By reducing flow multipaths, zone broadening (the widening
of analyte bands in the column due to diffusion) is minimised and the separation
efficiency improved (Robards, 1994).
Initial separation of the L. amara bark extract was carried out on a C-18 column using a
mobile phase containing trifluoroacetic acid which is commonly used in the analysis of
peptides. The resulting peak shape was very poor (Figure 4.19) displaying a high degree
of peak tailing. Such distortion of the ideal Gaussian-shaped peak towards a Langmuir
isotherm is common in systems where secondary interaction sites are present or where
the interaction between analyte molecules is weak relative to their interaction with the
stationary phase (Robards, 1994). In such systems the areas of highest analyte
concentration in the centre of the band have least opportunity of interaction with the
stationary phase and so migrate fastest, yielding a tailed peak shape which is dense at the
front and progressively thinner towards the tailing edge (Robards, 1994). The peak
tailing effect produces broader peaks which results in loss of resolution. The secondary
interaction sites are likely to be free silanol hydroxyl groups that are present in even the
most intensively derivitised reverse-phase columns where silica is used as the support
for the bonded phase. Compounding this problem is the fact that quinolones and
quinolines are notorious as a class of compounds for secondary interactions with
stationary phase silanol groups (Kim et al., 2002).
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A large number ofHPLC runs were carried out using a wide array of conditions in
which both stationary, mobile phase and run temperature were varied in an attempt to
reduce this effect. For convenience only a small selection of separations are represented
here. Over the course of this optimisation process several HPLC methods yielding
upright peaks with near baseline separation and minimal peak tailing were developed.
For each of these methods the phase extracted sample was run several times at overload
conditions to prepare sufficient quantities of compounds for analysis by NMR. Unless
stated otherwise the flow rate was always set at 1.5ml/minute and the injection volume
was 5pl. The detector wavelength was set at 280nm with optical density read as detector
mV output and the column temperature was left as ambient. In some HPLC runs the
anti-oxidant p-mercapto ethanol was included in the mobile phase as a precaution
against oxidation of active principle(s).
To begin with, the phase extracted sample was run with standard reverse-phase
























Optical density 280nm (mV)
% solvent B (MeCN)
Figure 4.21 Separation on a Thermohypersil beta basic C-18 5p 4.6mm x 150mm column with solvent A
5mM P-mercaptoethanol and solvent B 5mM p-mercaptoethanol MeCN.
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The standard conditions yielded crowded peaks with some peak tailing and
progressively shallower gradients failed to improve the resolution. Peak tailing is often
caused by interactions between free (un-capped) silanol groups in the non-bonded phase
of the column and positive charges on analyte molecules so a polymeric non-silica
column was used to see if this would reduce the peak tailing.
% solvent B (MeOH)
— Optical density 280nm
Figure 4.22 Separation on a Polymeric TPR-100 4.6mm xl50mm column with solvent A H20 and solvent
B Methanol.
The polymeric column gave little improvement over the C-18 column suggesting the
peak tailing effect may not be due to secondary interactions with the stationary phase.
Next, a range of ion suppression mobile phases each buffered to a different pH were
used to determine if suppression of analyte positive charge could result in an improved
separation. The use of strongly basic mobile phases was only possible with the
polymeric stationary phase so this column was used throughout.
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Minutes
— % solvent B (MeOH)
— Optical density 280nm
Figure 4.23 Separation on a polymeric TPR-100 4.6mm xl50mm column

















Figure 4.24 Separation on a Polymeric TPR-100 4.6mm xl50mm column with solvent A as lOmM citrate




— % solvent B (MeOH)
Figure 4.25 Separation on a Polymeric TPR-100 4.6mm xl50mm column with solvent A as lOmM citrate
pH 5.0 and solvent B Methanol
Minutes
— % solvent B (MeOH)
—
Optical density 280nm
Figure 4.26 Separation on a Polymeric TPR-100 4.6mm xl50mm column with solvent A as lOmM HC1





% solvent B (MeOH)
Optical density 280nm
Figure 4.27 Separation on a Polymeric TPR-100 4.6mm xl50mm column with solvent A as lOmM HC1










Figure 4.28 Separation on a Polymeric TPR-100 4.6mm xl50mm column with solvent A aslOmM
Na2C03/NaHC03 buffer pH 10.6 and solvent B as methanol.
The results show that increasing the pH of the mobile phase increases the retention times
of the analytes presumably due to ion suppression. Thus at pH 10.6 the polarity of the
analytes is reduced compared to pH 1 (resulting in increased affinity for the stationary
phase). The resolution of the separations are still poor however with broad peaks and
with some peaks not resolved at all.
Further separations were carried out with basic mobile phases using a C-18 bonded silica
column to see if the same peak tailing would occur. The mobile phases were not
buffered as the column would not tolerate strongly basic mobile phases.
— Optical density 280nm
0.1% Triethylamine 5mM BME MeCN
Figure 4.29 Separation on a Thermohypersil beta basic C-184.6mm x 150mm with solvent A as 0.1%
triethylamine 5mM BME and solvent B as 0.1% triethylamine 5mM BME MeCN.
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100 I
— Optical density 280nm
0.2% Ammonia 5mM BME 90% MeCN
Figure 4.30 Separation on a Thermohypersil beta basic C-l 84.6mm x 150mm with solvent A as 0.2%
ammonia 5mM BME and solvent B as 0.2% ammonia 5mM BME 90% MeCN
The results show that increasing mobile phase pH results in more pronounced peak
tailing than that seen with the polymeric column. Therefore basic mobile phases were
not used in future separations. Since the CM52 ion exchange experiments indicate that
lunacridine is positively charged, a negatively charged ion pair heptane sulphonic acid
was used to see if this would interact with the positive charge and allow a purely
reverse-phase separation without any secondary interactions.
Figure 4.31 Separation on a Thermohypersil beta basic C-l 84.6mm x 150mm column with solvent A as
5mM heptane sulphonic acid and solvent B as 5mM heptane sulphonic acid 70% MeCN.
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The peaks are two closely grouped to allow them to be collected easily and changes in
the gradient did not improve the resolution.
Lunacridine is a quinoline and is therefore structurally related to the quinolone
antibiotics. Numerous methods exist for the detection of antibacterial quinolones from
blood plasma and the predominant feature of such methods is the use of phosphate
mobile phases (Gertz, 1990). Various phosphate based mobile phases were therefore
tested to see if they would produce the desired improvement in peak shape.
— Optical density 280nm







Figure 4.32 Separation on a Thermohypersil beta basic C-l84.6mm x 150mm with solvent A as lOmM pH
9 potassium phosphate and solvent B as lOmM pH 9 potassium phosphate 70% MeOH.
The run was repeated at pH 8 with a shallower gradient of 40% to 60% solvent B
resulting in a marked improvement in the quality of the separation.
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Figure 4.33 Separation on a Thermohypersil beta basic C-184.6mm x 150mm with solvent A as lOmM pH
8 potassium phosphate and solvent B as lOmM pH 8 potassium phosphate 70% MeOH.
Next, a more acidic phosphate mobile phase using phosphoric acid was tried but this





















0.1 % H3PO4 70% MeOH
Figure 4.34 Separation on a Thermohypersil beta basic C-18 4.6mm x 150mm with solvent A as 0.1%
H3PO4 and solvent B 0.1% H3P04 70% MeOH
Increasing solvent B at 11minutes revealed the highly distorted peak eluting at 12
minutes to be composed of two separate peaks. The run was repeated again with a
sudden increase to 70% B to try and further resolve them.
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— Optical density 280nm
0.1 % H3PO4 70% MeOH
Figure 4.35 Separation on a Thermohypersil beta basic C-18 4.6mm x 150mm with solvent A as 0.1%
H3PO4 and solvent B 0.1% H3PO4 70% MeOH
The use of phosphate mobile phases improved the quality of the separation but it was
still far from being the baseline resolution that would allow a definitive analysis of the
active principles in the bark extract. A new column sold under the brand name
Hypercarb which is based on a porous graphite stationary phase was used to see if its
novel chemistry would mitigate the effects of peak tailing encountered with basic
analytes on a silica bonded phase. The graphite stationary phase sorbs polar analytes via
a polar retention effect but is equally capable of reverse phase interactions. It is also able
to withstand high temperatures which increase the partition rate of analytes between the
mobile and stationary phases (Knox, 1986). The column was eluted with a mobile phase


























1:1 IPA/0.1% TFA MeCN
Optical density 280nm
Figure 4.36 Separation on a Hypercarb 5p 4.6 x 50mm with solvent A as 0.1% TFA and solvent B B 1:1
IPA/0.1% TFA MeCN.

















1:1 I PA/0.1 TFA MeCN
Optical density 280nm
Figure 4.37 Separation on a Hypercarb 5p. 4.6x50mm with solvent A as 0.1% TFA and solvent B 1:1
IPA/0.1% TFA MeCN with a column temperature of 70°C.
Neither increase in column temperature or variation in solvent gradients were able to
give a satisfactory separation.
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Further research revealed the phenyl-hexyl stationary phase as a good candidate to try
next. The phenyl-hexyl phase is said to give increased selectivity for polar heterocycles;
the phenyl group promoting pi-pi interactions with aromatic analyte molecules and the
hexyl chain providing a reverse-phase character (Marchand et al., 2005). Standard
mobile phases containing methanol or acetonitrile failed to elute much material from the
column confirming the presence of a different mode of interaction from the columns
used so far. The H3PO4 mobile phase (below) provided improved peak relative to the C-
18 column but as with other runs the main peaks were merged and this was not
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— 0.1 % H3PO4 70% MeOH
Figure 4.38 Separation on a Phenyl-Hexyl 4.6mm x 150mm with solvent A as 0.1% H3P04 and solvent B
0.1% H3PO4 70% MeOH.
The phenyl/hexyl column was run with the mobile phase recommended for the
hypercarb column to see if the presence of isopropanol which is higher up the elutrophic
series than either methanol or acetonitrile would improve the resolution. The resolution
showed some improvement and by using a shallower gradient a chromatogram was
produced that showed basline resolution of seven peaks. Removing TFA from the
mobile phase was found to reduce the quality of the separation as was reducing the level
of isopropanol.
152
1:1 IPA/MeCN 0.1% TFA
Optical density 280nm
Figure 4.39 Separation on a Phenyl-Hexyl 4.6mm x 150mm column with solvent A as 0.1% TFA and
solvent as Bl:l IPA/0.1% TFA MeCN injecting 5pi of a 1/10 diluted sample. Column temperature set at
ambient. The combination ofTFA, isopropanol and a shallower solvent gradient result in a markedly
improved separation.
The run was repeated replacing TFA with different acidic mobile phase modifiers to
determine if other acids would give the same degree of resolution.
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— Optical density 280nm
Figure 4.40 Separation on a Phenyl-Hexyl 4.6mm x 150mm with solvent A as 0.1% H3PO4 and solvent as




— Optical density 280nm
Figure 4.41 Separation on a Phenyl-Hexyl 4.6mm x 150mm with solvent A as lOmM KH2P04 and solvent
as Bl:l EPA/ MeCN injecting 1 pi sample.
Both runs give a similar elution profile indicating that TFA is not necessary and that
other acidic mobile phase modifiers can be used to achieve the same effect. Thus the
conditions for improved separation appear to be the use of a phenyl/hexyl stationary
phase and an acidic mobile phase containing isopropanol. With this is mind a method
was developed to allow the use ofmineral acids whilst preventing precipitation of salts
in the column. The method uses a solvent gradient similar to above followed by a 5
minute wash with 75% water to remove salts before the high solvent B elution which
elutes remaining peaks and regenerates the column. In this way multiple preparative runs
could be carried out in succession.
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Figure 4.42 Separation on a Phenyl-Hexyl 4.6mm x 150mm column using a 4 part gradient with solvent A
as lOmM KH2P04, solvent B as IPA, solvent C MeCN and solvent D H20 injecting 50pl phase extracted
bark extract.
The run was repeated 10 times injecting a total of 0.5ml extract (equivalent to 14.9mg
phase extracted L. amara alkaloids or 72mg crude L. amara bark solids). Each peak was
collected into individual tubes and after removing organic solvent in a rotary evaporator
was made to >1M KC1, extracted into chloroform and back extracted into water to
remove traces of KC1 before ffeeze-drying and weighing. Each peak was taken up in
lOOpl H2O and assayed in wells. Zones of inhibition were as follows:








Table 4.16 Active peaks from lOmM KH2P04 phenyl/hexyl column separation.
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Active peak 5 consisted of 7.23mg white solid which was identified as lunacridine by 'H
NMR (see below). Peak 7 was also collected and treated in the same way providing
sufficient material for NMR identification as the related alkaloid lunacrine (see section
4.7 for NMR correlations). Next the same procedure was repeated replacing KH2PO4
with HC1, H2SO4 H3PO4TFA and CHOOH as the mobile phase modifier and in each
case collecting the same characteristically sail shaped peak (peak 5). All apart from
acetic acid gave good separation equivalent to the KFFPC^run shown above and this
was overcome by taking a slice from the centre of the lunacridine peak.
Finally a run was carried out using a 300mM KC1 mobile phase to see what effect high
salt concentration would have on the separation when using a standard C-18 column; it
was reasoned that since salt promoted the partition of L. amara alkaloids into
chloroform it might increase the interaction of the analytes with the stationary phase.
The mobile phase, which contained no acidic modifiers and was therefore highly inert,
gave base line resolution of the bark constituents. The improvement in separation was an
unexpected finding since there is no mention in the literature of the use of KC1 in
combination with a reverse phase stationary phase. It is possible that by somehow
increasing the interaction of the quinolines with the stationary phase in analogy to the
chloroform phase extraction, the peak tailing effect was overcome. Another possibility is
that the high salt concentration acted like a cation exchange mobile phase, overcoming
the electrostatic interactions with free silanol groups and so allowing the quinolines to
bind in a purely reverse-phase manner.
In an attempt to discern whether lunacridine was the sole anti-S. aureus constituent in
the bark, 5g fresh (un-dried) Lunasia bark was thoroughly extracted with 10ml ethanol,
evaporated to dryness and taken up in 1ml 10% ethanol. 25p,l were run with the KC1
method (Figure 4.43) and each peak collected and assayed in wells along with a control




— Optical density 280nm
Figure 4.43 Separation on a C-18 5p 4.6mm x 150mm column with solvent A as 300mM KC1 and solvent
B MeOH injecting 25pi non-phase extracted L. amara bark extract.
Figure 4.44 Each peak (1-15) was collected manually and dried down to 25pi and assayed in wells. A
positive control equivalent to the injected sample and a negative control of 1M KC1 (higher in KC1 than
the most concentrated sample) were included for reference.
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The plate (Figure 4.44) shows that peak 9 (lunacridine) is responsible for almost all of
the activity of the extract with a very small amount of activity surrounding peak 6.
The method was used as above to inject 50pl samples of extract in multiple runs to
prepare several mg of the lunacridine peak for NMR. See section 4.7 for proton NMR
spectra.
— MeOH
Figure 4.45 Separation on a C-18 5p 4.6mm x 150mm column with solvent A as 300mM KC1 and solvent
B methanol, injecting 50pl sample.
4.7 Identification of samples by NMR
Each of the samples were subjected to a proton NMR spectrum to confirm that the
sample was in fact lunacridine and to determine if any chemical modification such as
trifluoroacetylation and occurred. Shown below are the proton spectra for the samples.
For the sample prepared with TFA, trifluoroacetylation of the side chain hydroxyl has
occurred and so the sample is the same as the "TFA derivative" isolated previously.
Where TFA was replaced with acetic acid lunacridine appears as the corresponding
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formyl derivative. Samples prepared with phosphate containing mobile phases and

















8.2, 8.0 not fully resolved; appears as t
8.0, 0.8 small J not resolved
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* = assigned by analogy with spectrum of trifluoroacetyl derivative and so may be
interchanged






r C, 3 ,CR3
OH
HoC























9.0, 7.5, 6.7not fully resolved appear as q




d = doublet, dd = doublet of doublets, ddd = doublet of doublets of doublets, dt =
doublet of triplets, q = quartet, oc = octet, s = singlet, t = triplet
* = assigned by analogy with spectrum of trifluoroacetyl derivative and so may be
interchanged
Table 4.18 ]H NMR Spectral Data of 2'-0-Formyl-lunacridine prepared using 0.1% acetic acid mobile
phase.
Figure 4.47 2'-0-Formyl-lunacridine prepared using 0.1% acetic acid mobile phase.
Site 5h proton Jhh (Hz)
multiplicity
5 7.8 (d) 8.2
6 7.4 (t) 7.3, 8.2
7 7.3 (d) 7.3
r 5.0 (dt) 9.3,2x6.:
la 3.3 (dd) 14.9, 9.3
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IT) 3.0 (dd) 14.9, 6.
3' 2.1 (oc) 6.7
4' 1.0 (d) 6.8
5' 1.0 (d) 6.9
Table 4.19 'H NMR Spectral Data of Lunacrine prepared with KH2PO4 mobile phase
Figure 4.48 Structure of lunacrine prepared with KH2P04 mobile phase.
It was noticed that samples of native lunacridine lost their antibacterial activity after
several months even when stored at -20°C. lH spectra of both old and fresh lunacridine
prepared under identical conditions were recorded and these showed the presence of
increasing quantities of an impurity corresponding broadly with lunacrine (data not
shown) suggesting cyclisation of lunacridine occurs even at low temperatures. Loss of
activity was not observed with the formate and trifluoroacetyl derivatives (presumably
since capping of the side chain hydroxyl prevented cyclisation) and so for subsequent







MIC experiments were carried out with S. aureus NCTC 6571 and E. coli ATCC 10536
to gain a more quantitative measure of the antibacterial activity of the bark extracts and
the 2'-6>-Trifluoroacetyl-lunacridine compound (Table 5.1). For comparison, certain
related compounds (nalidixic acid, etoposide and chloroquine) were included. The agar
dilution technique described by (Andrews, 2001) was used for the bark extracts and
structurally related compounds but it was necessary to use the microdilution method
(Andrews, 2001) for the pure compound since only small quantities were available.
Aqueous and ethanolic extracts were prepared by thorough extraction of 5g finely
powdered bark with 100ml ethanol or water, filtering through Whatman No. 1 paper
followed by rotary evaporation or freeze-drying. This yielded 0.5515g and 0.7247g
solids respectively which were taken up in ethanol and water to make 1 Omg/ml solutions
before filtering through a 0.2g syringe tip (Sartorius) to sterilise.
Drug or extract MIC qg/ml S. aureus MIC [xg/ml E. coli ATCC
NCTC 6571 10536
Crude ethanolic extract 128 >256
Crude aqueous extract 256 >256
(freeze-dried)
Etoposide 32 >256
Chloroquine diphosphate >256 >256
TFA lunacridine 64 (by microplate dilution) >256
Nalidixic acid sodium salt 4 64
Table 5.1. MICs of aqueous and ethanolic L. amara bark extracts along with pure 2'-0-Trifluoroacetyl-
lunacridine and certain related compounds.
The MIC data show lunacridine to be inactive against E. coli and only weakly active
against S. aureus with an MIC of 64pg/ml. Such activity is well below that of clinically
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used antibiotics so it is unlikely lunacridine would show much potential in this area. It
was instead decided to look at lunacridine's mode of action and determine what other
activities it possessed.
Lunacridine bears structural similarities to the antibacterial quinolone class of
compounds epitomised by the founding member of the class nalidixic acid. This
similarity in structure led to the suspicion that lunacridine, like its quinolone relatives is
an inhibitor of bacterial topoisomerase(s). To test this theory lunacridine was assayed
against strains of the gram positive bacterium Streptococcus pneumoniae differing in
their sensitivity to penicillin, erythromycin and the quinolone antibiotic ciprofloxacin
(Table 5.2). The assay was carried out by Professor S. Amyes (Department of Medical
Microbiology, University of Edinburgh) who had obtained stocks of clinically acquired
strains with varying susceptibilities to the antibiotics. Disks containing 200ug
lunacridine were screened against the strains using the Kirby/ Bauer filter paper disk
diffusion assay. S. pneumoniae strains were cultured according to NCCLS guidelines at
37°C, 5% CO2, on Mueller-Hinton agar supplemented with 5% defibrinated horse blood.
Compound/Strain 25306 3018 SZ 27033 ATCC49619
Lunacridine ZOI 14 9 15 16
Penicillin MIC 8 0.015 1 sensitive
Erythromycin MIC 512 256 64 sensitive
Ciprofloxacin MIC 1 4 2 sensitive
Table 5.2 TFA lunacridine zones of inhibition (mm) on strains of S. pneumoniae with varying sensitivities
to penicillin, erythromycin and ciprofloxacin. MICs expressed as pg/ml.
The sensitive reference strain ATCC49619 gave the largest zone of inhibition whereas
strain 3018 which has a raised MIC towards both erythromycin and ciprofloxacin gave a
considerable decrease in the lunacridine zone size from 16mm down to just 9mm
showing that lunacridine's antibacterial potency is reduced with quinolone resistant
strains. Strain 25306 which has a raised MIC of 8 tig/ml for penicillin and a high MIC of
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256[ig/ml for erythromycin showed only a small decrease in the lunacridine zone size
from 16mm for the sensitive strain down to 14mm. Strain SZ 27033 had a raised MIC of
64|ig/ml for erythromycin and but much smaller increases in MIC towards penicillin and
ciprofloxacin but did not produce the same dramatic drop in zone size seen with 3018
thereby removing the possibility that macrolide resistance was responsible for the 9mm
zone size seen with quinolone resistant strain 3018. With strain ATCC 49619 numerous
colonies were seen around the rim of the zone of inhibition indicating the presence of
lunacridine resistant mutants.
5.2 DNA intercalation
The planar-cationic aromatic structure of lunacridine lead to the suggestion that it might
act as a DNA intercalator since such compounds are known for their ability to slot
between base pairs and complex with DNA (Lerman, 1961). The phenomenon was first
investigated with the acridine dyes by L.S Lerman in 1961 who postulated a mechanism
in which untwisting of the double helix provides sufficient space between the layers of
bases to allow intercalation. To test the idea, a DNA intercalation assay was set up using
the method described by Cain et al 1978 (Cain et al., 1978). The assay is based on a
ligand displacement type approach which makes use of the increased fluorescence of
complexed ethidium Br/DNA over free ethidium Br. In the assay the fluorescence of
intercalated ethidium Br DNA is decreased when displaced by a competing intercalator.
Care was taken to determine that compounds did not absorb at either the excitation or
emission wavelengths (546 and 595nm) at the highest concentration reached in the
assay.
To begin with, the known intercalating agents amsacrine and chloroquine were used and
both agents produced the anticipated decrease in fluorescence giving IC50 figures in
broad agreement with those obtained by Cain et al (Cain et al., 1978) although the figure
for amsacrine was slightly lower than expected (Figure 5.1). As predicted 2'-O-
trifluoroacetyl-lunacridine also caused a reduction in ethidium DNA fluorescence
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although this occurred at a markedly higher concentration than with amsacrine or
chloroquine. The experiment was also carried out using the prototype quinolone
nalidixic acid. Whilst quinolones such as nalidixic acid are known to bind to DNA
(Sandstrom et al., 2003) this does not occur through an intercalative type mechanism and
as expected high concentrations (0.7 mM) failed to illicit any decrease in fluorescence.
The effect was investigated further the by using DNA pre-incubated in 0.5mM nalidixic
acid and adding increasing concentrations of chloroquine. The resulting graph is near
identical to that obtained with chloroquine alone, indicating the nalidixic acid binding
site is located distal to the chloroquine site of intercalation.
Decreasing ethidium-DNA fluorescence with increasing





Drug concetration (micro molar)
Figure 5.1 Intercalation of chloroquine, chloroquine and 0.5mM nalidixic acid and amsacrine with calf
thymus and pBS plasmid DNA
Lunacridine intercalation data was also collected replacing calf thymus DNA with pBS
plasmid (Figure 5.2). As expected intercalation occurred less easily with the plasmid, its
closed circular structure acting to resist unwinding of the helix which is necessary for
















Change in ethidium DNA fluorescence with increasing TFA
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Figure 5.2 Intercalation ofTFA lunacridine with calf thymus DNA and pBS plasmid. Minimal and no
intercalation are seen with related compounds lunacrine and nalidixic acid respectively.
Samples prepared with each of the different HPLC mobile phase additives were assayed
to determine their relative activity (Figure 5.3). All of the samples prepared with salts
(KH2PO4, HC1, H2SO4 and KC1) are native lunacridine whereas those prepared with
TFA and CH3COOH were modified at the side chain hydroxyl to form ester derivatives.
The modified samples proved to be the most efficient intercalators whereas the samples
prepared with mineral acids showed varying degrees of intercalation despite
identification by NMR as highly pure lunacridine. This further supported the use of the
2'-0-Trifluoroacetyl derivative rather than the native compound which appeared to be
unstable.
168
Decrease in ethidium DNA fluorescence upon addition of lunacridine
prepared using different HPLC mobile phase additives









Figure 5.3 Comparison of intercalative ability ofvarious lunacridine samples prepared with different
HPLC mobile phase additives. The ester derivatives which lack a free hydroxyl group are the most active.
Compound Sample DNA IC50 intercalation (pM)
Amsacrine Calf thymus 4
Chloroquine Calf thymus 14
Chloroquine pBS plasmid 64.6
Chloroquine Calf thymus pre-treated
with 0.5mM Nalidixic acid
13.5
TFA Lunacridine Calf thymus 220




Lunacrine Calf thymus >1144
Nalidixic acid Calf thymus >660
Table 5.3 DNA intercalation IC50 of each compound with calf thymus linear DNA or pBS plasmid
(derived from previous graphs).
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5.3 Topoisomerase inhibition
A logical progression from the identification of lunacridine as a DNA intercalator was to
test the compound in a human topoisomerase II inhibition assay since there is a
relationship between DNA intercalation and inhibition of the decatenating enzyme
(Brana et al., 2001). Moreover, a planar cationic ring system along with an "interfering
side chain" are two important characteristics of the topoisomerase poison group of
inhibitors (Capranico and Binaschi, 1998). The topoisomerases are a family of enzymes
dedicated to controlling the degree of supercoiling present in the DNA of both
eukaryotic and prokaryotic cells (Sinha, 1995). Mammalian topoisomerase II belongs to
the ATP dependent type II group of enzymes and is able to perform a range of functions
including the decatenation of linked concatemers and the removal of both negative and
positive supercoils from DNA. Mammalian topoisomerase II has been shown to be vital
for a variety of cellular processes including replication, transcription, recombination and
chromosome segregation (Bromberg and Osheroff, 2001).
The possibility of an interaction with topoisomerase was supported by the experiments
with S. pneumoniae that showed antibacterial activity was reduced in bacteria that were
resistant to ciprofloxacin which is known to target type II bacterial topoisomerases
(Anderson et al., 1999). Although bacterial type II enzymes are distinct from their
mammalian counterparts certain drugs such as etoposide and novobiocin are inhibitors
of both enzymes. To test the theory a topoisomerase II assay kit was purchased from
TopoGEN Inc, Columbus, Ohio, USA along with recombinant human topoisomerase II
alpha (pl70). The assay is based on the ability of the enzyme to decatenate kinetoplast
DNA (kDNA) which is composed of numerous interlinking concatemers of closed
circular DNA. The kDNA is too large to migrate on an agarose gel so forms an intense
band adjacent to the leading edge of the well it is loaded into, but in the presence of
enzyme and ATP, the kDNA substrate is de-concatemerized into monomers that are
small enough to migrate down the gel. To test the kit, reactions were run for 1 hour at
37°C in the presence of varying concentrations of amsacrine which is a known
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topoisomerase II poison. The gel shows no inhibition at 0.5(iM demonstrated by the
presence of a decatenation product band but complete inhibition at 1 fxM where only the
immobile kDNA band is visible (Figure 5.4). This is in broad agreement with figures
reported for amsacrine cleavable complex formation (Nelson, 1983; Patel et al., 2000).
0.05|jM 0.1 |jM 0.5|JM 1.0|JM
Lanes 1-4 0.05 (iM to 1 |iM Amsacrine
Figure 5.4 Human topoisomerase II alpha incubated with amsacrine between 0.05uM and I uM. Complete
inhibition of decatenation occurs between 0.5 and lpM.
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The experiment was then repeated with TFA lunacridine at lOnm to 5|iM to look for
similar signs of inhibition to those seen with amsacrine. As can be seen in the gel below
there is a clear cut off between 1 and 5[xM with pronounced inhibition of decatenation
visable at 5fxM.
OjjIVS 10nM 100nM 1pM 5 |jM
Lane 1 no drug control, lanes 2-5 10nM to 5 |iM
TFA Lunacridine
Figure 5.5 Human topoisomerase II alpha incubated with TFA lunacridine between lOnM and 5|iM with
inhibition occurring between lpM and 5liM.
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The assay was repeated with a narrower range of concentrations. As can be seen from
the gel there is a sudden drop in topoisomerase II activity between 4uM and 5pM TFA
lunacridine (Figure 5.6). The experiment was repeated twice each giving the same result.
0|iM 1|jM 2qjM 3[M 4|jM 5|jM
Lane 1 no drug control, lanes 2-6 1 to 5 gM TFA Lunacridine
Figure 5.6 Human topoisomerase II alpha incubated with TFA lunacridine between 1 and 5pM with
inhibition occurring between 4pM and 5|iM. Experiment was repeated twice.
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Inhibitors of mammalian topoisomerase II may act as catalytic inhibitors by targeting the
enzyme itself (a mode of action typified by the coumarin class of drugs) or may act as a
topoisomerase poison and trap the enzyme on its DNA substrate e.g. amsacrine and
numerous other DNA intercalators (Jensen and Sehested, 1997). To investigate whether
lunacridine mediated inhibition occurred through direct binding to the enzyme or if
DNA was necessary for inhibition, both amsacrine and lunacridine were incubated with
enzyme alone for 10 minutes before addition of kDNA substrate and reaction buffer
which diluted the drugs to below the levels previously required for inhibition (Figure
5.7). The rest of the assay was then carried out as before. Inhibition of
deconcatermerisation did not occur despite both drugs being initially present at twice the
concentration previously required for inhibition.
The result shows that inhibition does not occur through direct covalent binding to the
enzyme, a more likely mode of action being topoisomerase poisoning in which enzyme,
DNA and drug are trapped together in a tripartite complex. Although certain DNA
intercalators such as aclarubicin are able to inhibit topoisomerase II by simply hindering
the interaction of enzyme and substrate (Larsen et ah, 2003) this would appear unlikely
in the case of lunacridine since complete enzyme inhibition occurs at concentrations
below which significant DNA binding takes place.
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Pre-incubation concentrations (without DNA)
OpM 10gM Lunacridine 2pM Amsacrine
Lane 1 No drug control, lanes 2 and 3
topoisomerase enzyme pre-incubated for 10
minutes at twice the concentration required
to inhibit decatenation (2 and 10 pM TFA
lunacridine and amsacrine respectively)
before addition of kDNA substrate.
Figure 5.7 Decatenation products after pre-incubation of enzyme with 2pM and lOpM amsacrine'and TFA
lunacridine respectively. kDNA and reaction buffer were then added to dilute the drugs below the lpM
and 5pM needed for inhibition and after 1 hours incubation at 37°C the reaction products were run on a
gel as before. Decatenation was able to take place despite initial inhibitor concentration being twice what
was required for inhibition in the presence of kDNA substrate.
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5.4 Potential anti-viral activities
Several lines of evidence suggested that lunacridine might posses some degree of anti¬
viral activity, either against certain members of the Herpesviridae which depend on
cellular topoisomerase II for replication (Bailly, 2000) or against retroviruses such as
HIV-1 since quinolones and certain DNA intercalators have been shown to inhibit the
reverse transcriptase (RT) (Tomita and Kuwata, 1976). Experiments were therefore
carried out with herpes simplex virus 2 (HSV-2) and HIV-1 reverse transcriptase to see
if this was indeed the case.
5.4.1 Reverse transcriptase inhibition activity
Certain quinolones such as nalidixic acid as well as some intercalators (Aoyama, 1991),
(Tomita and Kuwata, 1976) have been reported to act as inhibitors of the virally encoded
enzyme reverse transcriptase (RT). To establish if lunacridine possessed such activity a
RT assay kit was purchased from Roche Diagnostics Ltd, Lewes UK. The assay is based
on an ELISA format in which biotin and digoxigenin labelled nucleotides are
incorporated into DNA by RT working on a poly A x oligo (dT)i5 hybrid template
primer. The resulting DNA is bound to the surface of streptavidin coated wells. Bound
DNA is then detected with a peroxidase antibody conjugate (anti-DIG-POD) which
binds to the digoxigenin labelled nucleotides and produces a coloured reaction product
upon addition of 2,20 -azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid), diammonium
salt (ABTS) substrate. The kit was tested with chloroquine, nalidixic acid and TFA
lunacridine up to 20 mM (Figure 5.8) incubating each drug for at 37°C for one hour in
the presence of HIV-RT enzyme, template primer and a reaction buffer provided with
the kit (for more details see section 2.13). The reaction contents were then transferred to
the specially provided streptavidin-coated microplates and after repeated cycles of
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washing, antibody was added and the plates read colourmetrically. RT activity was
plotted as % no-drug control.
Inhibition of HIV-1 reverse transcriptase by Chloroquine, Nalidixic




5 10 15 20
Drug concentration (mM)
25
Figure 5.8 Inhibition ofFIIV-1 RT by TFA lunacridine, chloroquine diphosphate and nalidixic acid.
Results are expressed as a percentage of no-drug control carried out independently for each drug and are
an average of 4 data points for each drug concentration.
Reduction in HIV-1 reverse transcriptase activity with increasing
concentrations of TFA lunacridine
Drug concentration (mM)
Figure 5.9 Inhibition ofHIV-1 RT by TFA Lunacridine. Results are expressed as a percentage of no-drug
control carried out independently for each drug. Results are an average of 4 data points for each drug
concentration.
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The results show a clear inhibition of HIV-RT enzyme activity for all of the drugs,
lunacridine being the most potent of the three (IC50 1.25mM). The effect is clearly not
simply due to intercalation with the template primer since chloroquine which is a far
more efficient intercalator is less active than lunacridine.
5.4.2. Anti-herpes simplex virus activity
HSV-1 and HSV-2 replication is dependent on cellular topoisomerase II; the HSV-1
genome in particular contains numerous topoisomerase II recognitions sites which are
acted on late in the infective cycle (Erbert et al., 1990;1994). There is therefore some
interest in using topoisomerase II inhibitors such as those developed as cancer drugs as
inhibitors of the viruses (Bailly, 2000). A stock solution of TFA lunacridine was sent to
Dr M. Ogilvie at the Specialist Virology Centre, Edinburgh Royal Infirmary to asses its
potential as an anti-HSV-1 agent.
TFA lunacridine was evaluated using the virus yield reduction assay, which was chosen
instead of the more commonly used plaque reduction assay as it is a more sensitive
technique using a multiplicity of infection of 0.01 plaque forming units (PFU) per cell
compared with a multiplicity of infection of 1 or 2 PFU for the plaque reduction assay.
This allows the detection of antiviral activity more rapidly and over a wider range of
drug concentrations. Plates treated with acyclovir showed a 100% reduction in virus
yield as expected but TFA lunacridine showed no reduction relative to uninfected
controls even at 15.63gM the highest concentration used (data not shown). The drug
could not be used above this concentration due to cytotoxic effects so the study was not
taken any further.
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5.5 Cytotoxicity and induction of apoptosis in human cell lines
The low micro molar concentration required for inhibition of human topoisomerase II by
TFA lunacridine pointed towards a degree of cytotoxicity in human cell lines since
topoisomerase II inhibitors are widely employed as cytotoxic agents in cancer
chemotherapy (Sinha, 1995). Topoisomerase II poisons are known to cause double
strand breaks in cellular DNA (Jensen and Sehested, 1997) and if such breaks are not
repaired they may trigger the apoptotic pathways that lead to programmed cell death
(Kaina, 2003; Sordet et al., 2003). This activity is exploited by cancer drugs such as
amsacrine and etoposide which are able to produce selective killing of tumour cells
(Dolega, 1998). It is thought that such selective cytotoxicity is possible because cancer
cells divide more rapidly than healthy cells and so undergo replication more frequently
(Marchini et al., 2004); the increased topoisomerase II activity resulting in increased
DNA damage (De Beer et al., 2001; Holden, 2001; Lock and Ross, 1987). Since
topoisomerase II is an important cancer drug target, (Sinha, 1995) cytotoxicity assays
were carried out with different cell lines to determine if lunacridine showed any degree
of selective cytotoxicity towards carcinoma cells.
Three cell lines were selected namely ATCC MRC-5, NCI H226 and HELA. MRC-5 are
non-carcinoma lung cell fibroblasts derived from foetal lung tissue and reach senescence
in 42 to 48 doublings (Jacobs et al., 1970) whilst H226 are an immortal non-small cell
lung carcinoma line. HELA are epithelial cervical carcinoma cells (Scherer and
Hoogasian, 1954) and the fastest growing of the three cell lines. The cells were treated
with lunacridine and the known topoisomerase II poison etoposide at concentrations up
to lOOjiM and left for time varying time intervals ranging between 4 and 72 hours. After
exposure to the drugs, cell viability was measured using the Cell Titer 96 Aqueous One
solution cell proliferation reagent (Promega) which contains the tetrazolium compound
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS(a)] and an electron coupling reagent (phenazine ethosulfate;
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PES). Reduction of the reagent as a result of cellular metabolic activity results in the
production of a coloured formazan product whose absorption at 490nm is directly
proportional to the number of living cells. The cells were grown in optical 384 well
tissue culture treated microplates which were read colourmetrically at 490nm in a plate
reader. Cell viability was expressed as % of no drug controls after subtracting
background absorbance. The following graphs depict the decreasing cell viability of
each of the three cell lines with increasing exposure to the two drugs. Cell viability is
expressed as a percentage of no drug controls and each drug concentration was repeated
8 times. Only positive error bars (standard deviation) are shown for clarity.
Viability of MRC-5, H226 and HELA cells after 4 hours exposure to

















Figure 5.10 Viability ofMRC-5, H226 and HELA cells exposed to etoposide and TFA lunacridine for 4
hours. Cells were trypsinised and plated into transparent 384 well plates, allowed to attach overnight
before adding serially diluted drugs. The plate was then incubated for 4 hours before addition ofCell Titer
reagent and incubated for a further 2 hours before reading colourimetrically at 490nm.
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Viability of MRC-5, H226 and HELA cells after 12 hours exposure to
Etoposide and TFA Lunacridine









Figure 5.11 Viability ofMRC-5, H226 and HELA cells exposed to etoposide and TFA Lunacridine for 12
hours.
Viability of MRC-5, H226 and HB.A cells after 24 hours exposure to























Viability of MRC-5, H226 and HH.A cells after 48 hours exposure to








Figure 5.13 Viability ofMRC-5, H226 and HELA cells exposed to etoposide and TFA Lunacridine for 48
hours.
Viability of MRC-5, H226 and HB.A cells exposed to etoposide and TFA









Figure 5.14 Viability ofMRC-5, H226 and HELA cells exposed to etoposide and TFA Lunacridine for 72
hours.
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Viability of MRC-5, H226 and HELA cells with increasing exposure to
12.5uM etoposide and TFA lunacridine
14 24 34 44 54 64 74







Figure 5.15 Viability ofMRC-5, F1226 and HELA cells exposed to 12.5pM etoposide and TFA
Lunacridine between 4 and 72 hours (data derived from previous graphs).
The results clearly show a downwards progression in cell viability with increasing drug
concentration for lunacridine but unfortunately there is little difference between the
carcinoma cell lines (H226 and HELA) and non-carcinoma cell line MRC-5. This is not
the case with etoposide which as expected exhibits selective inhibition of the carcinoma
cell lines showing little inhibition of MRC-5 cells even after 72 hours exposure to
lOOpM concentration of the drug (Figure 5.14).
Despite this it was decided to repeat the experiment replacing the CellTiter reagent for a
caspase detecting reagent to ascertain if the reduced cell viability was due to a cell
necrosis type mechanism or, as is the case with other topoisomerase II poisons an
apoptotic cell death mechanism (Figure 5.16) (Kiechle and Zhang, 2002).
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Apoptosis is the programmed cell death of damaged cells and is distinct from cellular
necrosis in that it represents a specific and programmed biochemical process which is
dependent on key effectors in the apoptotic pathway and therefore takes time to
complete; necrosis on the other hand occurs rapidly after the initial insult (Philchenkov,
2004). Caspases (cysteinyl aspartate-specific proteases) are key effector molecules in the
apoptotic pathway that become activated in response to DNA damage such as
topoisomerase II poison induced double strand breaks (Philchenkov, 2004). Caspases
can be divided into two groups based around their role in the complex apoptotic
pathways either as initiators (caspases 2, 8, 9 and 10) or effector caspases (3, 6 and 7)
(Philchenkov, 2004). Effector caspases are activated by initiator caspases and once
active are able to cleave a wide range of substrates which include crucial structural and
regulatory proteins thereby "disassembling" the cell (Philchenkov, 2004).
The Apo-1 reagent consists of a lysis buffer which allow release of cellular caspases and
a profluorescent caspase-3/7 consensus substrate, bis-(N-CBZ-L-aspartyl-L-glutamyl-L-
valyl-aspartic acid amide) rhodamine 110 (Z-DEVD-R110). Upon cleavage on the C-
terminal side of the aspartate residue in the DEVD peptide substrate sequence by
caspase-3/7 enzymes, the rhodamine moiety is released and able to fluoresce at 521nm
when exited at 498nm. Since caspases exhibit substrate specificity for a 4 residue
aspartic acid containing sequence in their substrate proteins the reagent is selectively
activated by caspases 3 and 7 (Smolewski et al., 2002).
Before carrying out the assay, microplates were set up containing 100pM etoposide and
TFA lunacridine (the highest concentration used in the assay) to check that neither drug
fluoresced or absorbed at the specified wavelengths. The reagent was made up according
to manufacturer's instructions by diluting the rhodamine substrate 1:100 with the lysis
buffer and warmed to 37C° in a water bath. After addition of the Apo-1 reagent the
plates were shaken using the Wallac Victor 1420 multi label counter and then incubated
for 7 hours on a bench top with the lid on before reading fluorimetrically at 498nm
excitation and 521nm. Graphs were then plotted as % increase in fluorescence over no
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drug controls. Because of the expense of the reagent the experiment was first carried out
at a fixed concentration (lOOpM) to find out which cell lines/drugs increased caspase
activity and at what time interval. As with previous experiments each data point (well)
was replicated eight fold.
Activation of caspase-3/7 in MRC-5, H226 and HELA cells exposed to




























Figure 5.16 Activation of caspase-3/7 activity in H226, MRC-5 and HELA cells with increasing exposure
to TFA Lunacridine and Etoposide. Cells were trypsinised and plated into opaque white 384 well plates
and allowed to attach overnight before adding drugs. The plate was then incubated for the prescribed time
intervals before addition ofApo-1 reagent and shaking for lminute. The plate was then incubated at room
temperature for a further 7 hours before reading fluorimetrically in a plate reader Ex 498 Em 521.
The results show a marked increase in caspase 3/7 activity with the H226 cells for both
lunacridine and etoposide between 24 hours and 48 hours. There is also a gradual
increase in caspase 3/7 activity with time suggesting that as the cells become serum
starved and/or confluent they naturally undergo apoptosis. To further investigate the
effects of the two drugs on H226 cells the experiment was repeated at increasing drugs
concentrations from 12.5 to 100pM (Figure 5.17).
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Increase in Caspase-3/7 activity in H226 cells incubated for 48 hours



























Figure 5.17 Activation of caspase-3/7 activity in H226 cells with increasing concentrations ofTFA
Lunacridine and Etoposide after 48 hours exposure. Activity is expressed as % increase over no drug
controls. Cells were trypsinised and plated into opaque white 384 well plates and allowed to attach
overnight before adding drugs. The plate was then incubated for 48 hours before addition ofApo-1
reagent and shaking for 1minute. The plate was incubated at room temperature for a further 7 hours before
reading fluorimetrically in a plate reader Ex 498 Em 521. Cell viability is expressed as a percentage of a






The ethnobotanical survey provided a list of over 200 plant species many of which were
used in an antiseptic type-role but despite this only three species exhibited clear
antibacterial activity against E. coli and S. aureus in the field screening process. Several
different factors are likely to have contributed to this, ranging from selective
antibacterial activity, non-antibacterial modes of actions (such as wound healing
activity/adhesion inhibition mechanisms) and variations in the levels of active plant
constituents.
An inherent limitation of the field screening approach was that only non-fastidious, non¬
pathogenic organisms would suit the rapid testing requirements of the assay kit. Thus
plants that exhibited a broad spectrum of antibacterial activity stood the best chance of
detection. This is unfortunate since a narrow spectrum of activity may be indicative of a
highly specific mode of action, something often lacking with plant-derived compounds.
High molecular weight molecules such as polyphenolics and tannins that lack drug-like
properties are notorious for giving positive results in assays by virtue of their ability to
bind covalently to proteins via their numerous hydroxyl groups (Cowan, 1999). The
assay could therefore be improved by including a wider range of strains representing
several bacterial genera to increase the likelihood of detecting the more selective
antibacterial plants.
A second factor that was likely to have reduced the number of hits from the screening
process is the presence of plants with non-antibacterial mode of actions. Inhibition of
bacterial cell adhesion has been shown to be an effective means of suppressing infection
(Sharon and Ofek, 2002) since adherence of gram-positive species such as S. aureus to
endothelial cells is a prerequisite for the tissue-invasive stage of bacterial infection
(Fischetti, 2000; Kuusela, 1978) whilst agents that inactivate bacterial toxins and
promote the host immune response have also shown promise (Cazzola et al., 2004).
Plants whose active constituents worked through either of these mechanisms would of
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course not have been detected with the field assay. The role of insect vectors in
infections such as the tropical ulcer must be considered too. The tropical ulcers
described by informants in the field were observed to be attractive to flies which would
attempt to feed on the ulcerative tissue. Spirochaete bacteria are known to be transmitted
by the fly Hippelates pallipes and remain motile in its pharynx and oesophageal
diverticula for up to several hours whilst Hippelates flies have been observed feeding on
purulent skin lesions in Panama (Allen and Taplin, 1974). The use of insect repellent
plants is well documented in the ethnobotanical literature (Seyoum et al., 2002; Waka et
al., 2004) so it is plausible that their application to partially healed tropical ulcers, would
reduce the chances of re-infection with Spirochaete bacteria.
Finally, variations in the levels of antibacterial plant metabolites present in individual
plants, is likely to have had some impact on the efficacy of the screening process.
Phytoalexins are defence compounds produced by the host plant in response to attack
from plant pathogens (Baker et al., 1997) and many phytoalexins play a role in
defending plants from pathogenic bacteria (Lugtenberg et al., 2002). Upon infection
with plant pathogens, the plant detects the presence of the bacteria and activates specific
host elicitor pathways, triggering their synthesis and greatly increasing their
concentration in the affected plant tissue (Montesano, 2003). Another strategy employed
by plants is to vary the concentration of defence compounds from leaf to leaf or between
plants to make themselves an unpredictable food source. Studies with the neotropical
tree Cecropia peltata reveal tannin levels may vary between trees by as much as 13mg
to 58mg per gram of dry weight matter; it is thought that the presence of high tannin
trees benefits neighbouring low tannin trees by making the population an unpredictable
food source (Coley, 1986). Thus plants that displayed no antibacterial activity might
have produced clear zones of inhibition had they been tested after undergoing some form
of stress, or had been sampled from more than one plant.
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6.2 Lunacridine's antibacterial activity
The baseline resolution HPLC separation of the Lunasia amara crude extract using a
300mM KC1 mobile phase showed lunacridine to be almost entirely responsible for the
anti-S. aureus activity of the bark extract with a very minimal contribution from peak 3
which was not identified (Figure 4.43). Since the bark extract was not subjected to any
preliminary cleanup step, the HPLC running conditions were mild and the extract
prepared from a specially non-dried sample it is unlikely that active principles were lost
or chemically inactivated. Lunacridine is the major bark alkaloid comprising some 10%
of the extractable aqueous bark solids or approximately 0.014% of the overall bark in
disagreement with Johnstone et al 1958 who reported lunacrine as the major component
(0.5-1%) (Johnstone, 1958). Johnstone et al were working with samples of the
Australian variety however, (referred to as L. quercifolia) and assuming the alkaloidal
composition of the species were to reflect the extreme variation in vegetative features
reported by Hartley (1967) such a difference should be expected (Hartley, 1967).
Overall, the antibacterial activity of lunacridine was disappointing; with an MIC for
Staphylococcus aureus NCTC 6571 of 64pg/ml it is considerably less active than
clinically used antibiotics most of which exhibit MICs for their target organism of less
than 1 ug/ml. Furthermore, considering its activity against human cells it is unlikely the
compound could be considered a potential lead for antibiotic development. Based on
lunacridine's topoisomerase II inhibition activity prokaryotic homologues of the enzyme
such as DNA Gyrase or topoisomerase IV seemed potential targets of the drug in
bacteria. To test this theory the compound was assayed on disks against several strains
of Streptococcus pneumoniae (Table 5.2). The resulting zones of inhibition showed a
clear pattern of activity which correlated with resistance to the quinolone antibiotic
ciprofloxacin. Thus there was a decrease in the lunacridine zone of inhibition with strain
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3018 which displays a raised MIC value against the quinolone antibiotic ciprofloxacin.
The zones size did not alter accordingly for the other two strains (25306, SZ 27033)
even though their MICs against erythromycin and penicillin were considerably greater
than 3018 for ciprofloxacin. This demonstrates that both ciprofloxacin and lunacridine
anti- S. pneumoniae activity are affected by the same drug resistance mechanisms thus
raising the possibility of a shared mode of action between the two drugs.
Other mammalian topoisomerase II poisons and intercalators were tested for
antibacterial activity to see if there is a general pattern of cross over between the
eukaryotic and prokaryotic topoisomerase targeting drugs (Table 5.1). The clinically
used anti-tumour compound etoposide showed a similar pattern of activity to
lunacridine, with weak activity for S. aureus (32pg/ml) but no activity for E. coli. This is
in line with reports of a related topoisomerase poison mode of action between the two
drugs in bacteria (Sioud and Forterre, 1989). Chloroquine however which is a highly
efficient DNA intercalator did not show any antibacterial activity. It is unclear why
lunacridine and etoposide inhibit S. aureus but not E. coli whilst nalidixic acid, which
shares some characteristics with lunacridine is far more active against E. coli than S.
aureus. A possible clue however can be gained from the mode of action of the
fluoroquinolones which exhibit a 1000 fold increase in potency towards certain gram
positive bacteria over non-fluoronated quinolones such as nalidixic acid (Anderson et
al., 1999). In gram positive bacteria topoisomerase IV is the primary target of
fluoroquinolones as opposed to Gram negative species where Gyrase is more important
(Ferrero et al., 1994; Maxwell, 1997). Whilst both enzymes are type II topoisomerases,
bacterial topoisomerase IV is more analogous to its mammalian counterpart in that it is
able to deconcatermerise chromosomes and resolve knots in DNA as opposed to DNA
gyrase whose role is more centred on controlling superhelical density (Anderson et al.,
1999). Thus it is possible that lunacridine and etoposide selectively target topoisomerase
IV of gram positive bacteria. The lack of activity of chloroquine is less surprising since
DNA intercalation is not by itself sufficient to produce cytotoxicity.
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6.3 Lunacridine and its DNA intercalation activity
Upon identifying lunacridine as the active ingredient in the bark extract it was clear that
it shared some structural similarities to certain quinolone and quinoline drugs. The
quinolines and quinolones are both bicyclic nitrogen containing compounds but in the
quinolones a carbonyl group is directly opposite the ring nitrogen at position 4 and a
carboxylic acid side chain directly adjacent to the carbonyl group at position 3 (Figure
6.1) (Park et al., 2002). Both are extremely important pharmacaphores which form the
basis of numerous anti-infective agents such as antibiotics (Domagala, 1994),
antimalarials (Chong and Sullivan, 2003), anti-virals (Richter et ah, 2004) as well as
cytotoxic tumour drugs (Chu et al., 1994). What they share in common is an ability to
interact with DNA and so inhibit the activity of certain DNA associated enzymes. In the
case of the quinolones the DNA interaction occurs through non-specific groove binding
(Park et al., 2002) whereas the quinolines tend to intercalate between base pairs by
virtue of their planar structure (Yin et al., 2003).
Quinoline Quinolone
Figure 6.1. Quinoline and quinolone pharmacaphores.
As a planar quinoline is seemed likely lunacridine would act as a DNA intercalator and
the results of the ethidium bromide DNA fluorescence assay confirm this. TFA
lunacridine intercalates with an IC50 of approximately 0.2mM; somewhat less active than
chloroquine and amsacrine but more so than nalidixic acid which did not show any
intercalation activity.
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DNA intercalators are molecules that insert themselves between base pairs in the DNA
double helix (Brana et al., 2001). The phenomenon was first investigated with the
acridine dyes by L.S Lerman (Lerman, 1961) who postulated a mechanism in which
untwisting of the double helix would provide sufficient space between the layers of
bases to provide access to small planar heterocycles (Figure 6.2). The presence of a
positively charged ring nitrogen increases the affinity for DNA (Snyder and Arnone,
2002). In the common B-form of DNA the bases are in close Van der Waals contact so
intercalation is not possible but by unwinding the double helix slightly, spaces of
suitable depth are opened up between the layers of bases whilst leaving hydrogen
bonding between the bases undisturbed (Lerman, 1961). In this way DNA intercalators
are able to slot themselves between base pairs and by virtue of their aromatic structure
participate in the base stacking k-tz interactions thereby adding stability to the structure
(Haq, 2002).
Figure 6.2. The Lerman model of DNA intercalation; changes in B-DNA structure upon intercalation of a
planar cation between base pairs. To accommodate the intruding molecule the helix must unwind slightly
causing a localised distortion of the phosphate-sugar back bone. (Adapted from Lerman et al (Lerman,
1961)).
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Lunacridine exhibited mild intercalation activity compared with known intercalators
such as the anti-neoplastic drug amsacrine and the antimalarial chloroquine which were
approximately 20 to 40 times more active respectively (Figure 5.2). The prototype
quinolone antibiotic nalidixic acid, did not exhibit any intercalating activity at all
however, despite its apparent similarity in structure to lunacridine. It has been shown
that DNA is a target of quinolone antibiotics such as nalidixic acid but the mode of
interaction is not intercalative; the interaction being greater with single stranded than
duplex DNA (Shen and Pernet, 1985). Studies with other quinolones such as norfloxacin
suggest the drugs may partially intercalate into CpG steps as well as participating in
non-specific groove binding, (Sandstrom et al., 2003) but this it seems is insufficient to
displace intercalated ethidium Br.
Intercalation of both chloroquine and TFA lunacridine was considerably more efficient
with calf thymus DNA than with the plasmid pBS. pBS like other plasmids is negatively
supercoiled in its native state, and so intercalation of small molecules will result in a
gradual relaxation of negative supercoiling with a concomitant reduction in superhelical
writhe (Wang, 1974). Thus the lower IC50 for linear DNA than closed circular DNA
could therefore be explained by differences in the forces that must be overcome to allow
helix unwinding; plasmid unwinding being less energetically favourable due to the
presence of higher torsional forces.
Intercalation of lunacrine was far less pronounced (Figure 5.2) and this can be attributed
to the presence of the bulky furan ring on the alkaloid which disrupts the planar surface
of the quinoline pharmacaphore. Samples prepared using KC1 and mineral acids all
displayed a lower efficiency of intercalation than those prepared with TFA and acetic
acid; a phenomenon which can be explained by their propensity to cyclise whilst in
storage. Reaction of the side chain hydroxyl to the ring carbonyl would produce a
derivative identical to lunacrine except for a carbonyl group in the place of the methoxy
group at position 4. This would create a furan ring and disrupt the planar structure of the
alkaloid. Supporting this is the fact that proton NMR spectra recorded with underivitised
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lunacridine samples showed an increase in impurities corresponding to lunacrine peaks
after being stored at -20°C for several months (personal communication Dr I. Sadler).
6.4 Lunacridine and its topoisomerase II inhibition activity
It is well established that DNA intercalation, whilst not a prerequisite for eukaryotic
topoisomerase II inhibition is nonetheless a related activity, since numerous DNA
intercalators act as inhibitors of the enzyme (Brana et al., 2001). As suspected, TFA
lunacridine proved to be an effective inhibitor with a mode of action that most likely
falls within the topoisomerase poison category of inhibitors. Surprisingly however,
complete inhibition of the enzyme occurred at 5pM (Table 6.1), well below that required
for significant DNA intercalation, whereas by comparison the DNA tumour drug
amsacrine gave complete inhibition at lpM; a figure somewhat higher than its
intercalative activity would have suggested.
Inhibitor IC50 DNA Complete inhibition Topo II inhibition/
intercalation of Topoisomerase II intercalation
(pM) (pM)
Amsacrine 4 1 0.250
TFA lunacridine 220 5 0.023
Table 6.1 IC5o concentrations for intercalation of amsacrine and TFA lunacridine with calf thymus DNA
and concentrations at which topoisomerase II decatenation activity was inhibited.
6.4.1 Topoisomerase structure and function
Topoisomerase II is a highly conserved enzyme which is essential for normal cellular
function (Roca, 1995). There are two mammalian isoforms of topoisomerase II, termed
alpha and beta. The gene for topoisomerase II a is located on chromosome 17q21-22
and encodes a 170 kDa protein whereas the topoisomerase II B gene encodes a 180 kDa
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protein and is located on chromosome 3q24 (Kellner et al., 2002). They both have
similar primary structures and exhibit virtually identical catalytic properties in vitro.
Numerous lines of evidence suggest the alpha isoform to be the enzyme most involved
with mitotic processes whereas the role of the beta isoform is more obscure (Sakaguchi
and Kikuchi, 2004). In both isoforms, dimerisation of the gene product is required for
topoisomerase activity.
The extreme length of genomic DNA poses several problems of access to nuclear
proteins. As is the case with any string-like structures there is a natural tendency to form
knots as well as to undergo torsional stress which if not overcome results in
supercoiling, otherwise known as toroidal writhe (White and Bauer, 1986). This
phenomenon is exploited by both prokaryotic and eukaryotic cells as a means of
packaging genomic DNA but needs to be overcome to allow the myriad of DNA
associated proteins such as polymerases to traverse the double helix. This role is in part
carried out by the two isoforms of topoisomerase II which are able to untangle knotted
DNA and relieve toroidal writhe. They do this by making double strand breaks in DNA
and passing a segment of an adjacent DNA helix through the resulting gate before
resealing and releasing the two segments (Kellner et al., 2002).
The precise mechanism by which topoisomerase II does this has been extensively
studied and Topoisomerase II is the only enzyme capable of both cleaving and ligating
double stranded DNA (Kellner et al., 2002). The enzyme is composed of two
homodimers which when dimerised together form a DNA binding/ligation site along
with gates to mediate the translocation of individual strands of DNA (Figure 6.3). The
middle section is where double strand break formation and ligation occur while either
side of this are the two gates formed from paring of the N and C-terminal portions of
each dimer. A length of DNA termed the G-segment is cut in the middle section of the
enzyme through interaction with two tyrosine residues on each monomer (Tyr-805 in
human topoisomerase II alpha) (Jensen et al., 1996). A second piece ofDNA termed the
T-segment is then passed through the "gate" formed from the gap in the G-segment via
opening and closing of the two N and C-terminal-formed gates. Where the G and T
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segments are from different "links" in a concatemer, the enzyme cycle will mediate de-
concatemerisation (Roca, 1995). The process can be summarised as follows:
1. The helix to be cleaved termed the G-segment is bound to the enzyme at a
species dependent consensus sequence (Spitzner and Muller, 1988) where it
undergoes nucleophilic attack at two different locations 4 base pairs apart
producing a double strand break. The resulting 5'-phosphoryl groups at each side
of the cut are held in place by covalent linking to two tyrosine residues on the
enzyme. At this point a second DNA duplex termed the T-segment is free to pass
in and out of the gate formed by the break in the G-segment.
2. Upon binding ofATP to the outermost section formed from the two N-terminal
domains, the gate closes locking translocated T-segment on the opposite side of
the enzyme.
3. The T-segment then exits the enzyme via a gate formed from the two C-terminal
domains which then close behind it. The G-segment is then re-ligated, and upon
hydrolysis of the bound ATP (which reopens the N-terminal gate) is released
from the enzyme.
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Figure 6.3. Mode of action ofmammalian topoisomerase II. Adapted from (Roca, 1995).
6.4.2 Mode of action of topoisomerase II inhibitors
Inhibitors of type II topoisomerases may be divided into two classes namely catalytic
topoisomerase inhibitors and topoisomerase poisons (Jensen and Sehested, 1997). The
topoisomerase poisons act to stabilise the so called cleavable complex formed between
the enzyme, drug and the transiently bound G-segment DNA (Larsen et al., 2003); drugs
such as the epodophylotoxins (etoposide), the DNA intercalators such as amsacrine and
the antibacterial quinolones all inhibit the enzyme via this mechanism. The catalytic
inhibitors are typified by agents such as novobiocin and the coumermycins and act on
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other steps in the catalytic cycle such as ATP binding (novobiocin), stabilise non-
covalent DNA enzyme complexes (merbarone) or intercalate with DNA to prevent DNA
enzyme interaction (aclarubicin) (Larsen et al., 2003). Despite the extreme variation in
structure between antibacterial quinolones and eukaryotic topoisomerase II poisons
(Huff and Kreuzer, 1990) and the limited sequence homology of their respective enzyme
targets, (Wyckoff et al., 1989) there is still a degree of overlap in activities (Huff and
Kreuzer, 1990; Yamashita et al., 1992). Indeed mapping of the drug interaction domain
ofDrosophila topoisomerase II demonstrates overlap in the enzyme drug binding site
for structurally disparate inhibitors (Elsea et al., 1997). This is further exemplified by the
antibacterial assays with etoposide and TFA lunacridine where both displayed anti-S.
aureus activity.
TFA lunacridine and the clinically used topoisomerase poison amsacrine were studied
using a topoisomerase II kDNA decatenation assay. The assay showed clear inhibition
between 4pM-5pM TFA lunacridine and for amsacrine the effect occurred between 0.5
and I |iM in agreement with published figures. Thus despite amsacrine being
approximately 100 fold more efficient a DNA intercalator the drug was merely 5-10 fold
more potent an inhibitor of topoisomerase II. This phenomenon is mirrored by other
topoisomerase poisons. Whilst some intercalators such as the acridine carboxamides
(Figure 6.4) show a relationship between increased DNA affinity and topoisomerase II
inhibition/cytotoxicity (Adams et al., 2000), the general consensus is that intercalation
does not guarantee enzyme inhibition by itself.
Figure 6.4. Acridine carboxamide compound 9-amino-DACA. The side chain is critical to its
topoisomerase II inhibition activity.
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Moreover, a side chain, capable of making contacts with the enzyme is required for
activity. This is reflected in the acridine carboxamides structure activity relationship in
which the side chain, which must be in the acridine 4 position and posses an
unsubstituted NH group, twomethylene groups and a terminal protonated N,N-
dimethylamino group is a crucial feature (Adams et al., 2000). Thus it is the side chain
which modifies the activity of the drug either by contacting the enzyme itself or making
contacts with DNA that stabilise the cleavable complex (Capranico and Binaschi,
1998). A more dramatic example is provided by the two acridine based drugs m-AMSA
(amsacrine) and o-AMSA which differ only in the position of a methoxy group (Figure
6.5). Whilst m-AMSA is a potent intercalator and topoisomerase II inhibitor o-AMSA
displays only weak topoisomerase II inhibition activity and thus no cytotoxic activity









Figure 6.5. Structures of o-AMSA and m-AMSA which differ only in the position of a methoxy group.
Unlike m-AMSA, o-AMSA does not posses topoisomerase II inhibition activity despite being the more
efficient DNA intercalator of the two compounds.
Various models have been put forward to describe the formation of the cleavable
complex and these differ between the eukaryotic and prokaryotic forms of the enzyme.
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Since crystal structures are not available for trapped topoisomerase II or gyrase,
inferences on the position ofDNA, drug and enzyme in the complex are predominantly
based on mutation mapping studies carried out in bacteria, yeast and mammalian cell
lines (Macinga et al., 2003). For the antibacterial quinolones the interaction with DNA is
thought to be afforded either by a by a Mg2+ bridge which mediates binding of the drugs
to DNA phosphate (Palumbo et al., 1993) or intercalation at the site of the cleaved
phosphodiester bond (Freudenreich and Kreuzer, 1993). Structure-activity relationships
suggest that position 6 of the quinoline pharmacaphore is involved with recognition of
the gyrase enzyme pocket (Sissi et al., 1998) whilst numerous quinolone-resistance
mutation mapping studies reveal locations near the N-terminal DNA binding domain
such as Ser 83 ofGyrA (gyrase) and corresponding residues of ParC (topoisomerase
IV) as the likely location for contact between enzyme and drug (Ferrero et al., 1994;
Yoshida et al., 1988).
With eukaryotic topoisomerase II poisons such as amsacrine, intercalation with DNA
occurs via the acridine portion of the molecule (Rene et al., 1996) whilst contacts with
the enzyme occur through the substituent at position 1' on the anilino ring (Rene et al.,
1997). Analysis of human and yeast topoisomerase II mutants reveal residues in the a4
helix of the enzyme as possible sites for drug interaction; intriguingly, one common
yeast mutation Ser-740 is homologous with Ser 83 of prokaryotic DNA gyrase
suggesting a similar mode of interaction to the quinolones with gyrase. (Strumberg et al.,
1999). Molecular modelling of the amsacrine cleavable complex carried out using
crystal co-ordinates from a large fragment of yeast topoisomerase II (Berger et al., 1996)
suggests a model in which the acridine chromophore is intercalated at the site of the cut
G-segment with two of the methyl hydrogens from the NHSO2CH3 group of the anilino
ring forming hydrogen bonds with Thr 744 and Gly 747, both of which are adjacent to
Ser 740 in the DNA binding domain of the enzyme (Moro et al., 2004). Thus for o-
AMSA the configuration of the side chain does not support contacts with these residues,
so explaining its inability to stabilise the cleavable complex.
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It is therefore possible that the lunacridine side chain performs a similar role and
accounts for the unexpectedly potent topoisomerase inhibitory activity of the drug
relative to its intercalative ability. Assuming the molecule were to form a cleavable
complex analogous to that described for amsacrine (Moro et al., 2004) a perplexing
result is that trifluoroacetylation of the side chain does not eliminate topoisomerase II
inhibition activity suggesting the side chain hydroxyl is not involved with enzyme
interaction. It is tempting to postulate a model in which lunacridine intercalates at the
site of strand cleavage and contacts residues in the vicinity of those involved with
amsacrine binding via its T-butyl methyl hydrogens or those of the methoxy groups.
Several quinolones bearing structural similarities to those of Lunasia amara have been
purified from the bark of a related species Sarcomelicope megistophylla Hartley
(Rutaceae). Megistoquinone II (Figure 6.6) has a similar bicyclic structure to lunacridine
with a side chain at position 3 whilst megistoquinone II is analogous to lunacrine in that
the side chain is used to close a furan ring with the carbonyl at position 2.
Megistoquinone II has an MIC of 0.75mg/ml for S. aureus ATCC 25923 compared with
2.35mg/ml for megistoquinone I. Thus whilst both compounds are only weakly active,
megistoquinone II with its planar structure and side chain is the more active compound
further exemplifying the importance of such features (Fokialakis et al., 2001).
O QMe O OMe
Megistoquinone 1 Megistoquinone
Figure 6.6. Structures of megistoquinones I and II from Sarcomelicope megistophylla (Rutaceae)
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Once topoisomerase II had been established as the target of lunacridine, a further
experiment was carried out to probe the mode of enzyme inhibition. Amsacrine and
lunacridine were pre-incubated with the enzyme at twice the concentration required for
total inhibition of decatenation (2uM and lOpM respectively) (Figure 5.7). kDNA and
reaction buffer were not included so DNA intercalation and ATP binding could not
occur. After incubation at 37°C for 10 minutes, water, reaction buffer and kDNA
substrate were added diluting the drug 10 fold to a concentration below that required for
inhibition to occur. After further incubation for 1 hour at 37°C the reaction products
were analysed revealing no inhibition to have taken place. The result suggests DNA
must be present for enzyme inhibition to occur and precludes a covalent enzyme binding
mode of action for both drugs. This is consistent with amsacrine's established mode of
action as a topoisomerase poison. A catalytic inhibitor mode of action for lunacridine
cannot be ruled out however since drugs such as the anthracycline aclarubicin act as
catalytic inhibitors by intercalation alone and without stabilising a cleavable complex
(Larsen et al., 2003). This would appear unlikely for lunacridine however, since
topoisomerase II inhibition occurred at concentrations below those required for
significant DNA intercalation.
6.5 Tumour cell inhibitory activity and Caspase 3/7 activation
The interaction of lunacridine with DNA and its low micromolar inhibition of
topoisomerase II made it likely it would show some degree of cytotoxicity towards
human cells. Although this did not relate directly to the ethnobotanical use of Lunasia
amara, such a pattern of activity is in keeping with drugs like novobiocin and etoposide
which inhibit both bacteria and mammalian cells due to concomitant
prokarytotic/eukayotic type II enzyme inhibition activity (Larsen et al., 2003; Sioud and
Forterre, 1989).
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Topoisomerase II poisons are known to cause double strand breaks in cellular DNA
(Jensen and Sehested, 1997) and if such breaks are not repaired they may trigger
apoptosis (Kaina, 2003; Sordet et al., 2003). This activity is exploited by cytotoxic
cancer drugs such as amsacrine and etoposide which are able to produce selective killing
of tumour cells (Dolega, 1998). It is thought that such selective cytotoxicity is possible
because cancer cells divide more rapidly than healthy cells and so undergo replication
more frequently (Marchini et al., 2004); the high topoisomerase II activity of tumour
cells resulting in increased DNA damage (De Beer et al., 2001; Holden, 2001; Lock and
Ross, 1987)
Apoptosis is distinct from cellular necrosis in that it represents a programmed
biochemical process which takes time to complete whereas necrosis on the other hand
occurs rapidly after the initial insult and is not a programmed event (Philchenkov, 2004).
Caspases (cysteinyl aspartate-specific proteases) are key effector molecules in the
apoptotic pathway and are divided into two groups namely effector and initiator
caspases, 12 of which have been identified so far (Philchenkov, 2004). Initiator caspases
which include caspases 2, 8, 9, 10 and probably 11 activate the effector caspases 3, 6
and 7 (Wolf and Green, 1999). Initiator step pathways are grouped around key
organelles such as mitochondria, golgi apparatus, the nucleus as well as cell membrane
receptor activated pathways (Ferri and Kroemer, 2001). Once activated the effector
caspases are able to cleave a wide range of substrates which include crucial structural
and regulatory proteins thereby destroying the cell (Liu et al., 2005). DNA damaging
agents may activate both the membrane death receptor pathways (Beck et al., 2001) and
the endogenous mitochondrial damage pathway through upstream events that occur in
the nucleus as a result of DNA lesions (Kaina, 2003).
The cascade of events that lead to topoisomerase II poison induced apoptosis begins
with the formation of the cleavable complex which consists of drug, DNA and
topoisomerase enzyme trapped mid way through its catalytic cycle (Larsen et al., 2003).
Topoisomerase II is covalently attached to cleaved DNA and unable to complete its
204
catalytic cycle due to the presence of the topoisomerase poison which contacts both the
DNA and enzyme (Binaschi et al., 1995). The cleavable complex is not lethal in itself
but is converted into DNA double strand breaks during replication and transcription
when enzymes such as helicase collide with it, dissociating topoisomerase II to reveal a
double strand break (D'Arpa et al., 1990; Howard et al., 1994).
Detector protein kinases DNA-PK, ATM and ATR bind preferentially to DNA breaks
and activate downstream kinases such as c-Abl and the checkpoint protein Chk2 which
induce apoptosis by activating cell death pathways such as SAPK, p53 and p73 as well
as inhibiting certain cell survival pathways (Kaufmann, 1998; Sordet et al., 2003). P53 is
a key agent in the activation of apoptosis in that it may send a cell into cell cycle arrest
to allow repair of genetic lesions since it possesses 3'-5' exonuclease function as well as
an ability to detect and prevent erroneous homologous recombination (Clifford et al.,
2003; Valkov and Sullivan, 2003). If repair of the lesion is not carried out correctly it
activates a wide range of pro-apoptotic signalling molecules (Valkov and Sullivan,
2003). Further evidence for p53's role in DNA damage induced apopotosis comes from
tumour cells expressing defective p53 which are resistant to topoisomerase II inhibitors
such as etoposide (Valkov and Sullivan, 2003).
There is a high degree of cross-talk between topoisomerase II and p53 which both binds
and stimulates the catalytic activity of the enzyme as well as controlling its expression
(topoisomerase II a only) by binding to a promoter upstream on its gene (Valkov and
Sullivan, 2003). Recent evidence suggests DNA damage may also result in caspase-2
being recruited to a complex termed the PIDDosome which contains the death domain
protein PIDD and the adaptor protein RAIDD (Tinel and Tschopp, 2004). Caspase-2 is a
key initiator of the mitochondrial death pathway which it activates by stimulating the
release of cytochrome C (Philchenkov, 2004). Thus once DNA double strand breaks
reach a critical level, and are beyond repair, a set of events is set into motion which lead
to the induction of apoptosis and eventual cell death.
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The gradual decline in cell viability seen with the Cell Titer reagent was both time and
concentration dependent in line with what would be expected from topoisomerase II
induced apoptosis. At 4 and 12 hours there is very little difference between the cell types
but at 24 hours (Figure 5.12)TFA Lunacridine starts to show marked inhibition of both
H226 and MRC-5 fibroblasts. H226 is the more inhibited of the two between 25 and 50
[iM but MRC-5 more so at concentrations over lOOpM. This is in contrast to etoposide
which shows little inhibition of any cell line at 24 hours. At 48 hours (Figure 5.13)
MRC-5 is inhibited more than other cell lines by lunacridine whereas it is unaffected by
etoposide which starts to show selectivity for H226. At 72 hours (Figure 5.14) etoposide
shows selective inhibition for FI226 and HELA inhibiting the faster growing HELA cells
slightly more than H226 whilst the less proliferative MRC-5 is completely uninhibited
and indeed shows a marked increase in cell viability in response to increasing etoposide
concentrations. This selectivity is not matched by lunacridine which shows only slightly
more inhibition of H226 and HELA than MRC-5 especially at the lower concentration
ranges. Of the two compounds TFA lunacridine was the more active with 50% inhibition
at 72 hours occurring at less than 12.5pM as opposed to etoposide which failed to reach
50% inhibition. The overall lack of selectivity of lunacridine between the tumour cell
lines (H226 and HELA) and the non-carcinoma MRC-5 fibroblasts is shown by the plot
of cell viability at 12.5pM over time (Figure 5.15) in which there is little difference in
cell viability between the three cell types over the full 72 hour time course. This
compares unfavourably with etoposide which shows an approximate 40% to 60%
difference in cell viability between H226/MRC-5 and HELA/MRC-5 respectively. Thus
on the basis of the cell viability experiments alone, TFA lunacridine does not posses
sufficient selectivity to merit its development as an antitumour compound. The structural
basis for the selectivity of compounds such as etoposide remains unclear but it is thought
that sequence specific binding may play a role (Palumbo et al., 2002). Thus it is possible
that the right structural modifications to the lunacridine pharmacaphore might impart
selectivity for carcinoma cell lines.
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At both 48 and 72 hours there is a surprisingly non-linear relationship between drug
concentration and cell viability which is exemplified by lunacridine with HELA cells but
is also seen with etoposide. The cell viability curve shows an initial sharp decrease
between 0 and 12.5pM after which point cell viability increases with lunacridine
concentration so that at lOOpM cell viability is 60% despite being nearly 20% at
12.5pM. Such a non-linear dose response curve is characteristic of topoisomerase
poisons such as the antrhacyclines and ellipticines whose ability to promote DNA strand
breakage follows a bell shape curve starting with increasing activity and then declining
with increasing drug concentration (Koo et al., 1999; Pommier Y, 1996). It is thought
that at high drug concentrations, intercalated drug occupies so many DNA binding sites
that it obscures the topoisomerase binding site (Liu, 1989). Such "template blockage"
prevents the stabilisation of the cleavable complex and therefore the formation of DNA
strand breaks and the induction of apoptosis. Thus lunacridine acts as an inhibitor of its
own cytotoxic activity at high concentrations. This distortion of the expected monotonic
curve further supports a topoisomerase poison mode of action for lunacridine.
The caspase 3/7 experiments indicated caspase activation in H226 cells with both of the
drugs between 24 and 48 hours exposure (Figure 5.16). Lunacridine is the more effective
of the two with more than four fold increase in caspase activity at 24 hours. This
coincides with the decrease in H226 viability seen at 24 and 48 hours. Thus on the basis
of caspase 3/7 activity alone, TFA lunacridine is a highly selective inducer, more so
even than etoposide showing almost no induction of caspase 3/7 with MRC-5 at any of
the time intervals. Perplexingly, neither agent displayed any such activity towards
HELA cells but this may be due to the narrow window of activation of caspases which
may have been missed by the choice of time intervals. Activation of caspase 3 and 7 in
H226 cells was repeated with varying drug concentrations (Figure 5.17) achieving a
similar result but with etoposide the more effective inducer at lower concentrations. At
48 and 72 hours there is marked increase in caspase 3/7 activity of all the cell lines
including the controls suggesting that serum depletion of the cells had induced
apoptosis.
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6.6 Anti HSV-1 and reverse transcriptase inhibitory activity
6.6.1 Anti HSV-1 activity
Various lines of evidence pointed towards a potential anti herpes simplex virus (HSV)
activity for lunacridine. Firstly, ethnobotanical data on the use of L. amara describe its
use in the Philippines to treat inflamed eyes (Hartley, 1967), a description that closely
resembles conjunctivitis one of the causative agents of which being HSV-1 (Stumpf et
al., 2002). Secondly, HSV-1 replication has been shown to be dependent on cellular
topoisomerase II (Bailly, 2000) (HSV-1 does not encode its own copy of the enzyme)
and inhibition of topoisomerase II using classical anti-tumour compounds such as
amsacrine and etoposide has been shown to inhibit the replication of cytomegalovirus
(another member of the Herpesviridae)(Benson and Huang, 1988).
The TFA lunacridine sample was used in a virus yield reduction assay against a strain of
HSV-1 (SC16) but failed to show any degree of inhibition. This was unexpected
considering recent reports in the literature of the potential for topoisomerase II inhibitors
as anti-HSV agents (Bailly, 2000). Crosslinking studies have shown that the alpha
isoform (pl70) associates with the viral DNA (Ebert et al., 1994) and since lunacridine
was shown to inhibit this isoform it should be expected to also inhibit viral replication. It
is not certain however that inhibition of topoisomerase II is responsible for the antiviral
action of amsacrine and etoposide and the possibility remains that their antiviral action
occurs through interaction with a second target that is distinct from cellular
topoisomerase II. Evidence to support this idea comes from the 7-substitueted-l,3-
dihydroxyacridones which were originally synthesised as DNA intercalating
topoisomerase II inhibitors and subsequently screened for anti-HSV activity, revealing
the 7-chloro derivative to be highly active. But more recent work on this class
demonstrates that topoisomerase II is unlikely to be the target of the drugs
(Akanitapichat et al., 2000) and that inhibition of HSV-1 DNA polymerase is more
likely to be responsible for their antiviral activity (Bailly, 2000).
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6.6.2 Reverse transcriptase inhibition activity
Various quinolines and quinolones have been shown to be active against retroviruses
including chloroquine which has recently emerged as a potent HIV-1 inhibitor (Boelaert
et al., 2001). Other intercalators such as doxorubicin are known to inhibit mouse
leukaemia virus reverse-transcriptase (Tomita and Kuwata, 1976) whilst nalidixic acid is
an inhibitor of avian myeloblastosis virus reverse-transcriptase, all be it at relatively high
concentrations (Aoyama, 1991). Furthermore, studies with the DNA intercalating
benzo[c]phenanthridine alkaloid fagaronine isolated from the roots of another species of
Rutaceae has demonstrated its activity against a number of reverse transcriptases from
different sources (Fleury et al., 2000).
An ELISA based assay was used to determine the reverse transcriptase inhibitory
activity of TFA lunacridine along with nalidixic acid and chloroquine. The results place
lunacridine as the most active of the three compounds with an IC50 of approximately
1.25mM (Table 6.2). Nalidixic acid was the least active with an IC50 of 17mM whilst
chloroquine's IC50 was approximately 2mM. Thus as was the case for topoisomerase II
inhibition the efficiency of DNA intercalation does not correlate with enzyme inhibition
activity. This would seem to rule out a mechanism in which the compounds inhibit
reverse transcriptase simply as a result of their intercalation with DNA since if this were
the case chloroquine would be significantly more active than lunacridine. Unfortunately
ICso's are far higher than the level at which cytotoxicity was detected in human cell lines
so lunacridine could not be assayed against HIV-1 in vivo.
Inhibitor IC50 DNA IC50 RT inhibition RT inhibition /
intercalation (uM) mM Intercalation
Chloroquine 14 1.4 0.1
Nalidixic acid >660 17.2 <0.03
TFA lunacridine 220 1.3 0.006
Table 6.2 Comparison ofRT inhibition activity and calf thymus DNA intercalation activity between
chloroquine, nalidixic acid and TFA lunacridine.
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6.7 Conclusion, Lunasia amara as a plant medicine
The results of the various assays can be interpreted to determine the efficacy of the plant
medicine in terms of its intended use i.e. the treatment of tropical ulcers. The plant was
prepared by scrapping small amounts of material from the surface of the bark so as to
produce fine shavings which were then applied directly to the tropical ulcer. The fresh
bark was moist and this presumably aided the transfer of lunacridine to the site of
infection. Since un-concentrated aqueous extracts of the bark give sizeable zones of
inhibition with S. aureus (which is thought to be involved with the ulcerative process),
(Braun-Falco, 1991) it would seem likely that the bark would have a therapeutic effect.
This would occur despite the relatively high MIC of lunacridine for S. aureus (64 [xg/ml)
since the bark appears to be particularly rich in the alkaloid. The hydrophilic nature of
lunacridine would also aid its transfer and solubility in the aqueous environment of the
ulcer. Thus the efficacy of a plant derived ethnomedicine such as Lunasia amara bark
cannot be determined solely by the activity of purified active constituents but would be
better described in terms of the activity of the whole bark as it exists in the field.
Furthermore, as has been seen through the numerous attempts at purification, the pure
alkaloid is not stable in its pure form but when applied direct from the tree bark it would
easily reach the site of infection intact.
A potential problem with using a DNA intercalating topoisomerase II inhibitor such as
lunacridine as a topical antibacterial agent is that it provides little selectivity for the
bacteria in the wound over the cells in the infected tissue. It is not possible to determine
the concentration of lunacridine that would reach the site of infection since the alkaloidal
content would vary from tree to tree but since the MIC for S. aureus is greater than the
IC5o for MRC-5 human cell viability (< 5ug/ml after 72 hours incubation) the bark
preparation would be expected to impart a certain degree of toxicity to the infected
tissue.
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DNA intercalators such as lunacridine are potentially mutagenic since by inserting
between bases there is a tendency for polymerases to recognise them as a purine base
and by inserting a corresponding pyrimidine give rise to a frame shift mutation
(Hoffmann et al., 2003). Secondly, topoisomerase inhibition which results in double
strand breaks i.e. topoisomerase poisoning is a potentially mutagenic event (Boos and
Stopper, 2000) since repair of the double strand breaks or action of exonucleases on the
exposed ends ofDNA may result in deleterious repair and loss function mutations.
There is even evidence to suggest that etoposide induces chromosomal recombination
during meiosis since re-ligation of double strand breaks may result in rejoining of the
original un-crossed strands (Russell et al., 2000). Mutagenic effects arising from the
application of L. amara bark to tropical ulcers would most likely go unnoticed however
since any carcinogenic effect would occur long after the event.
Despite this, in evaluating the use of the plant preparation it is necessary to way the cost
of leaving an infected wound untreated against the likely impact of possible side effects.
Since tropical ulcers have the potential to develop into chronic infections which may
ultimately result in amputation or septicaemia (MacDonald, 2003), and antibiotics are
not readily available to the inhabitants of the Whiteman Range in Papua New Guinea;
the use of L. amara bark may well represent a worthwhile risk.
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